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ABSTRACT 
Colorectal cancer (CRC) is a major health problem in the Western world. CRC is treatable with surgery 
and often curable when the disease is diagnosed at an early stage. With improved surgery and adjuvant 
chemotherapy treatment, the disease-free-survival (DFS) rate for colon cancer is approximately 80% for 
stage II and for stage III close to 65%. There is a continual need for the established risk stratification of 
CRC based on the tumor, node, metastasis (TNM) staging to evolve.  
The overall aim of this thesis was to detect new potential prognostic and predictive factors for 
molecular and clinical responses in primary CRC. One specific aim was to establish whether thymidylate 
synthase (TS) expression in a large group of patients with stage II and stage III CRC is a prognostic 
and/or predictive factor alone or in combination with mismatch repair (MMR) status in the colon cancer 
subgroup. Another aim was to explore in primary CRC the potential association between tumor budding 
and MMR status and the impact of tumor budding as a factor of tumor recurrence and development of 
distant metastases. The last aim was to investigate the prognostic and predictive value of tumor budding, 
tumor border configuration and T-cell infiltration in primary colon cancer with known MMR status. 
Tumor material for the studies was derived from the adjuvant Nordic trials which randomized from 1991 
to 1997, 2224 patients with stage II or stage III CRC to surgery alone or surgery plus adjuvant 5-FU-
based chemotherapy. Immunohistochemistry (IHC) was used to detect and evaluate TS expression, 
MMR-status, tumor budding and infiltration of CD3+ and CD8+ T-cells. 
Paper I. TS expression was assessed in tumors from 1,389 patients with stage II and III CRC. TS 
expression with the classification of TS grade 0-1 versus 2-3 as well as TS 1-2 versus TS 3 was 
prognostic in the surgery alone group. A high TS expression was associated with a shorter overall 
survival (OS). Among patients with TS grade 3, the subgroup treated with adjuvant chemotherapy had a 
significant longer OS compared with the group treated with surgery alone.  
Paper II. Primary colon cancer with a deficient MMR status (dMMR) is associated with an improved 
prognosis. Data indicates that colon cancer with a proficient MMR status (pMMR) and with high TS 
expression has an improved response to adjuvant 5-FU-based chemotherapy. This study evaluated if a 
combined analysis of MMR status and TS expression in 716 colon cancer patients added prognostic value 
and better predicted response to adjuvant 5-FU-based chemotherapy. In the group of patients treated with 
surgery alone, patients with dMMR tumors and low TS grade had a trend to a better OS compared to 
patients with pMMR tumors and high TS grade. In stage III, patients with pMMR tumors and high TS 
grade who received adjuvant 5-FU-based chemotherapy had a significantly improved OS compared to 
patients treated with surgery alone. No relationship was found between MMR status and TS expression. 
Paper III. A pMMR status compared to a dMMR status and tumor budding are considered adverse 
prognostic factors in primary CRC. This exploratory study included 134 patients with primary CRC. It 
assessed tumor budding grade in tumors with pMMR status compared to dMMR status to see if it 
differed as to whether local recurrence or metastases did or did not develop. The 29 available dMMR 
cases which developed recurrence or distant metastases (met+) were matched with a dMMR group with 
no recurrence or metastases (met-), and the pMMR/met+ group with pMMR/met- cases. A significantly 
higher percentage of high-grade tumor budding was only found in the dMMR/met+ group compared to 
the pMMR/met+ group. 
Paper IV. Tumor budding is correlated to the development of local and distant metastases in CRC while 
high density of tumor infiltrating immune cells is associated with an improved prognosis. In this study, 
tumors from 478 patients with stage II-III colon cancer and known MMR status were examined to 
determine the prognostic value of tumor budding, tumor border configuration and CD3+ / CD8+ T-cell 
infiltration. An association was found between high grade tumor budding and more advanced stage, 
higher N-stage, pMMR status, an infiltrating tumor border configuration and lower levels of high score 
CD3+ and CD8+ T-cells. High grade tumor budding was correlated to worse OS in univariate analysis 
but not in multivariate. In the entire study population, an infiltrative tumor border configuration was an 
adverse prognostic factor for OS and a dense infiltration of CD8+ T-cells was independently associated 
with a better OS. 
In conclusion, TS is a prognostic factor in CRC patients treated with surgery alone and patients with the 
highest level of TS expression had an improved clinical outcome following adjuvant 5-FU-based 
chemotherapy. In stage III colon cancer, a combined rather than a single marker analysis of MMR-status 
and TS expression, can improve the prediction of response to 5-FU-based chemotherapy. Whether tumor 
budding can provide prognostic information for patients with primary CRC and a dMMR status should be 
further explored in larger studies. An independent prognostic impact was found for CD8+ T cell 
infiltration and tumor border configuration as well as an association between them and tumor budding. 
Our study supports the inclusion of tumor border configuration, tumor budding, CD8+ T cell infiltration 
in the risk assessment for stage II-III colon cancer patients. 
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Populärvetenskaplig sammanfattning 
Cancer i tjock- och ändtarm (kolorektalcancer) är den tredje vanligaste tumörsjukdomen i 
Sverige och ett stort hälsoproblem i hela västvärlden. Oftast är kolorektalcancer botbar med 
kirurgi om den diagnostiseras i ett tidigt stadium. Med modern kirurgi och postoperativ 
cytostatikabehandling är sjukdomsfri överlevnad för koloncancer stadium II (tumören 
begränsad till tarmväggen) cirka 80 % och för stadium III (spridning till lymfkörtlar i 
närheten av tumören) cirka 65%. Risk för återfall beror till stor del på tumörens stadium vid 
diagnos. Ändå behövs kompletterande riskmarkörer för återfall. Det övergripande målet 
med avhandlingen var att studera nya sådana potentiella riskmarkörer som kan förutse dels 
risk för återfall i cancer och dels svar på behandling. Sådana markörer kallas prognostiska 
respektive prediktiva faktorer. 
 
Tumörmaterialet för delarbete I-IV kommer från en nordisk studie som pågick under 1991–
1997. Där randomiserades 2224 patienter med kolorektalcancer i stadium II-III till endast 
kirurgi alternativt kirurgi följt av postoperativ kemoterapi med 5-fluorouracil (5-FU). 
 
I delarbete I studeras uttrycket av enzymet thymidylat syntetas (TS) i tumörmaterial från 
1389 patienter med kolorektalcancer. TS är viktig för DNA-syntes och celltillväxt och 
blockeras av cytostatikabehandlingen med 5-fluorouracil (5-FU) vilket är en basbehandling 
vid kolorektalcancer.  
 
Kroppen har flera sätt att reparera skador på DNA. Ett av dem är mismatch repair systemet 
(MMR). Defekter i MMR proteiner (dMMR) eller hög-mikrosatellitinstabilitet (MSI-H) 
leder till felaktig DNA-reparation. Detta uppstår i cirka 15% av kolorektalcancer. Patienter 
med kolorektalcancer som uppvisar dMMR har en bättre prognos jämfört med dem som 
har en MMR-stabil tumör (pMMR), men svarar sämre på adjuvant 5-FU terapi.  
Studier har visat att patienter vars tumör uppvisar högt TS har kortare överlevnad men att 
de tenderar att svara bäst på 5-FU-baserad kemoterapi. 
 
I delarbete II undersöks om en kombinerad analys av TS-uttryck och MMR-status har ett 
utökat prognostiskt- och prediktivt värde i ett material med 716 patienter med koloncancer i 
stadium II–III. 
 
Tumor budding, som definieras som 1–5 isolerade tumörceller som lämnar tumörens 
invasionsfront, är associerad med utveckling av lokal- och fjärrmetastasering.  
 
I delarbete III undersöks den potentiella associationen mellan tumor budding och MMR-
status som en faktor för lokalrecidiv respektive fjärrmetastasering i en grupp om 134 
patienter.  
 
Utseendet av tumörens invasionsfront har betydelse för prognos. Förekomst av 
immunceller, till exempel CD3+ och CD8+ T-celler, i tumörvävnad är associerat till en 
bättre prognos.  
 
I delarbete IV utforskas det prognostiska värdet av tumor budding, utseende av tumörens 
invasionsfront och T-cell infiltration (CD3+ och CD8+) i en grupp bestående av 478 
patienter med koloncancer. 
 
För att påvisa TS uttryck, MMR och förekomsten av tumor budding samt T-lymfocyt 
infiltration av CD3+ och CD8+ T-celler användes immunohistokemi. 
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Resultat i delararbete I-IV 
Delarbete I: Studien visade att TS-uttryck var prognostiskt i den grupp av patienter som 
endast fick kirurgi som behandling. Högt TS-uttryck var associerat med en sämre prognos. 
I gruppen med högt uttryck av TS, hade patienter som fått kemoterapi en signifikant längre 
överlevnad jämfört med patienter med endast kirurgisk behandling. 
Delarbete II: Ingen korrelation noterades mellan TS-uttryck och MMR-status. I gruppen 
med pMMR och högt TS-uttryck fanns hos stadium III patienter en signifikant förlängd 
överlevnad i gruppen som fått kemoterapi jämfört med gruppen som endast behandlades 
kirurgiskt. 
Delarbete III: Studien visade att gruppen med dMMR/MSI-H som utvecklade lokalt 
recidiv alternativt fjärrmetastaser hade en hög frekvens tumor budding i sina tumörer. 
Delarbete IV: En koppling hittades mellan hög buddingfrekvens och en infiltrerande 
invasionsfront, ett mer avancerat stadium, pMMR-status och lägre infiltration av CD3+ och 
CD8+ T-celler. Invasionsfrontens utseende och CD8+ T-cell infiltration var oberoende 
prognostiska faktorer. En infiltrerande invasionsfront var associerat med sämre prognos 
medan hög infiltration av CD8+ T-celler var associerat med förbättrad prognos. 
 
Sammanfattning 
TS är en prognostisk faktor för patienter med kolorektalcancer som behandlas endast med 
kirurgi. Med en kombinerad analys av både MMR och TS bör man bättre kunna förutse 
svar på cytostatikabehandling efter kirurgi. Större studier bör genomföras för att se om 
tumor budding kan ge kompletterande prognostisk information till patienter vars 
koloncancer uppvisar dMMR. Vår studie stödjer inkludering av analys av tumörens 
invasionsfront, tumor budding och framförallt CD8+ T-cell infiltration i riskvärdering och 
riskanalys för kolorektalpatienter i stadium II–III. 
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1. BACKGROUND 
1.1 Epidemiology and Etiology 
Cancer of the colon or rectum is a major health problem. Worldwide it is considered the 
third most common cancer accounting for approximately 880 792 deaths per year, an 
estimated 1.8 million new cases and 1.2 million deaths in the coming ten years [1, 2]. 
Approximately two thirds of the cases are colon cancers and the rest are rectal cancers [3]. 
Colorectal cancer (CRC) ranks second worldwide with regard to mortality [2]. In Sweden 
the incidence rate of colorectal cancer (CRC) in 2017 was 69/100 000 [4] (Table 1). There is 
a higher incidence of CRC, about two thirds, in developed countries compared to 
developing countries which is attributed to a western lifestyle [3].  
 
Table 1. Colorectal cancer incidence (total number) in Sweden 2017 
Tumor site Male Female Total 
Colon 2324 2313 4637 
Rectum 1383 992 2375 
Total 3707 3305 7012 
 
CRC occurs relatively seldom (<5%) in persons younger than 40 and increases thereafter 
[5]. A stabilizing or decreasing trend in incidence and mortality of CRC has been identified 
in highly developed countries which is most likely due to early detection of the tumor, 
improved surgical techniques as well as oncological treatment [1, 3]. 
 
Screening programs for early detection of CRC based on fecal occult blood testing and 
colonoscopy are currently underway in most European countries, Canada, North America 
[6]. Analyses of the first five years of the CRC screening program established in Stockholm, 
Sweden 2008 for men and women age 60-69 showed that 1.8% were examined with 
colonoscopy and 0.1% were diagnosed with CRC [7]. There is some more recent data 
indicating a CRC incidence increase in left-sided tumors, especially rectal cancer, in 
younger adults, under the age of 50 [3, 8]. These younger patients tend to present with a more 
advanced stage at diagnosis and a worse outcome [9]. The cause of the increase in young 
adult CRC is unknown but it is estimated that 35% are associated with known hereditary 
CRC syndromes [8, 10, 11]. An estimate was done in a retrospective cohort study of the 
Surveillance, Epidemiology, and End Results Reporting (SEER) CRC registry predicting 
an increase of incidence rates by 2030 in colon and rectal cancer for patients age 20 to 34 
years to 90.0% and 124.2%, respectively [12]. 
In general, an interesting shift has been observed internationally with a greater increase 
in right-sided colon tumors, especially cecal ones [13, 14]. This is thought to be due in part to 
colonoscopy being a better diagnostic tool for left-sided tumors due to anatomical reasons, 
differing tumor biology of the right-sided tumors (flatter tumors such as serrated adenomas) 
as well a true increase in incidence of right-sided tumors [15].  
The development of CRC of which more than 90% are adenocarcinomas is a 
multifactorial process with its cause encompassing genetic predispositions, environmental 
exposures and inflammatory conditions of the digestive tract [16]. 
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1.2 Risk Factors 
Influencing screening recommendations 
Increasing age is a known risk factor for sporadic CRC as mentioned above. Individuals 
with a long-standing inflammatory bowel disease, ulcerative colitis or Crohn’s disease have 
an increased risk of developing colorectal cancer and are included in special programs for 
screening and follow-up [17]. 
1.2.1 Genetic risk and family history 
CRC is considered in most cases (75-80%) a sporadic disease. Approximately 2-8% of 
CRC is caused by genetic predisposition, due to pathogenic germline variants in genes 
associated with high cancer risk [18, 19]. Lifetime risks for CRC can approach 50-80% for 
mutation carriers in the absence of endoscopic and/or surgical intervention. [20]. 
1.2.2 Polyposis syndromes 
Familial adenomatous polyposis (FAP) is a rare inherited autosomal dominant condition 
that is characterized by the presence of hundreds to thousands of polyps in the colon and 
rectum [21]. It is characterized by a germline mutation in the adenomatous polyposis coli 
(APC) gene, a tumor suppressor gene (linked or located on chromosome 5q21). It is an 
early mutation in the development of colorectal cancer and is the initiating event in the 
chromosomal instability (CIN) pathway to colorectal tumorigenesis. The CIN (APC) 
pathway is also a common molecular pathway for sporadic CRC. Approximately 1% of all 
CRC is caused by FAP and if untreated it inevitably leads to cancer [21]. Tumors are mostly 
located in the distal colon and rectum. FAP patients are screened regularly for CRC 
beginning at around the age of 10 to 12 with colonoscopies and colectomy is performed 
electively in the late teens/early twenties or earlier depending on symptoms or with 
suspected/verified CRC [22].  
Another polyposis associated syndrome is the MUTYH-associated polyposis (MAP) 
which is as autosomal recessive disease due to germline mutation to the base excision 
repair gene MUTYH1. There is a carrier frequency of 1% in the European ancestry 
population and it is associated with a moderate 1.5-2 fold increased risk for CRC, 
especially if there is a first degree relative with CRC [23]. 
Syndromes which also have a greater risk for CRC are Peutz-Jeghers syndrome (PJS), 
Juvenile polyposis syndrome (JPS) and the phosphatase and tensin homologue deleted on 
chromosome 10 (PTEN)-hamartoma tumor syndrome (PHTS) [24]. 
1.2.3 Non-polyposis syndrome 
Lynch Syndrome, previously referred to as Hereditary Nonpolyposis Colorectal Cancer 
(HNPCC), is an autosomal dominant cancer predisposition syndrome caused by a germline 
mutation in one of the four mismatch repair (MMR) genes (MLH1, PMS2, MSH2, MSH6) 
or within the epithelial cell adhesion molecule (EPCAM) gene adjacent to the MMR gene, 
MSH2 [25, 26].  
In contrast, deficiency in MMR for sporadic CRC which is present in 15-20% of all 
colon cancer, is mainly due to an epigenetic inactivation by the biallelic methylation of the 
MLH1 gene promoter [27]. Defective MMR (dMMR) leads to failure to repair errors during 
replication of small repetitive DNA sequences, microsatellites, and thus induces 
microsatellite instability (MSI) [28].  
Background 3 
 
MLH1 and MSH2 gene mutation carriers have a higher lifetime risk, between 30-74%, 
of CRC compared to gene mutation carriers of MSH6 and PMS2 that have a risk range of 
10-20% [25]. Male mutation carriers have a higher lifetime risk for CRC than females. In 
Lynch syndrome 60-80% of the tumors are located in the proximal colon (proximal to the 
splenic flexure) [29]. 
About 3% of newly diagnosed cases of CRC are caused by Lynch syndrome. It is 
considered a multi-tumor syndrome in which the most common malignancy is CRC and the 
second most common is endometrial cancer while other tumor sites such as stomach, 
biliary tract, ovaries and brain are less common [30]. There is a 70-90% lifetime risk for 
cancer in mutation carriers with development of cancer at a mean age of about 45 years and 
a risk of multiple synchronous and metachronous tumors [31]. The Amsterdam criteria as 
well as the Bethesda guidelines have been developed to identify and classify families with 
the Lynch syndrome [32]. High risk individuals should undergo colonoscopy with (1)-2 year 
intervals from the age 20-25 years and upon a CRC diagnosis a subtotal colectomy may be 
recommended due to the high-risk for metachronous tumors [30, 31].  
Although germline mutation analysis on blood samples is the gold standard in Lynch 
syndrome diagnostics it is not feasible as a universal screening method due to cost and 
time-consumption. In tumors with immunohistochemical loss of MLH1/PMS2 further 
BRAF mutation analysis may aid in distinguishing somatic alterations from germline 
defects. Lynch syndrome CRCs can present with KRAS mutations but not BRAF 
mutations while BRAF mutations (mostly in V6000 codon) occur exclusively in sporadic 
dMMR tumors or MSI-high (MSI-H) tumors [33].  
Proficient MMR (pMMR) hereditary nonpolyposis CRC has been detected in half of 
the CRC families meeting the Amsterdam criteria. No identifiable germline mutations have 
been found in the MMR genes. The lifetime risk for CRC is lower for this group and no 
increase in extracolonic tumors has been seen [34]. 
1.2.4 Familial syndromes 
Excluding the FAP and Lynch syndrome, carcinomas and adenomas aggregate in families 
in which the specific genes have not been found. There is an approximate two-fold risk of 
developing CRC for an individual with a first-degree relative with CRC and four-fold risk 
with at least two affected relatives [35, 36]. About 10 to 30% of CRC cases are thought to be 
attributed to this syndrome. 
1.2.5 Other potential risk factors (modifiable) 
Extensive research has been done in order to determine the importance of environmental 
factors in the development of CRC.  
Obesity has been found to be a risk factor for CRC [37]. A link was found between 
diabetes and the risk of developing CRC in a meta-analysis of 14 studies [38]. A theory of 
the mechanism behind is that high levels of insulin-like-growth factor (IGF-1) and IGF 
binding protein-3 (IGFBP-3) stimulate colonic tumor cells [39]. 
The use of tobacco has been associated, especially in rectal cancer, with increased 
incidence and mortality from CRC [40]. 
An excessive alcohol consumption is also considered a risk factor for CRC [41]. This 
could be due to a decreased folate intake caused by alcohol interfering with folate 
absorption but the role of folate as a protective agent against CRC is controversial [42]. 
4 Background 
 
Long-term consumption of red meat or processed meat has been implicated with a 
higher risk for CRC, in particular left-sided tumors [43].  
There is data suggesting an association between diet and the development of CRC 
mediated by a decreased diversity of the gut bacterial microbiome and increased 
colonization of the gut by strains of Fusobacterium or E. coli [44]. 
1.2.6 Factors that can reduce risk 
The intake of a diet high in fiber, fruits and vegetables has been shown in some 
epidemiologic studies to decrease the risk for developing CRC [45].  
An active lifestyle was shown in a study to decrease the risk of colon cancer but not for 
rectal cancer [46]. 
Long-term use of aspirin or nonsteroidal anti-inflammatory drugs (NSAID) protect 
against CRC, particularly proximal colon tumors [47]. Studies have shown that aspirin 
impairs tumor cell growth by inhibition of cyclooxygenase-2 (COX-2) and increased 
apoptosis [48]. This protective effect was also seen in a study in Lynch syndrome patients 
[49].  
COX-2 is an enzyme encoding for prostaglandins which in turn control inflammation 
processes and are known to promote cellular proliferation, migration, invasiveness, 
angiogenesis. COX-2 overexpression is associated with decreased survival in CRC patients 
which ties into the concept of cancer-related inflammation being a hallmark of cancer. 
Epidemiological studies noted that benefit of aspirin after CRC diagnosis was limited to 
patients with PIK3CA-mutated tumors [50]. About 15-20% of CRC patients harbor 
mutations in PI3KCA [51]. Upon mutation of the PIK3CA gene which encodes PI3K kinase, 
a constitutive activation occurs of the PI3K-AKT-mTOR pathway which plays a role in 
stimulating carcinogenesis. This also results in COX-2 upregulation [50]. 
A randomized, double-blinded, placebo controlled study (ALASCCA) on stage I-III 
CRC, is currently ongoing in Sweden and studies the post-operative protective effect of 
daily low dose aspirin versus placebo in patients with mutated PI3KCA tumors [52]. 
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2 MOLECULAR PATHOGENESIS OF COLORECTAL 
CANCER 
2.1 Adenoma to Carcinoma Progression Sequence 
The majority of CRCs are believed to develop from adenomas (adenomatous polyps) that 
evolve to carcinomas over 10 to 15 years. Removal of polyps is confirmed in controlled 
trials to decrease the incidence of CRC [53]. The adenoma-carcinoma sequence was 
described by Fearon and Vogelstein in 1990 as a genetic multistep model for colorectal 
carcinogenesis which encompasses the accumulation of mutations in the adenomas, with 
mutation in the tumor suppressor gene, APC, occurring early, followed by mutation of the 
oncogene KRAS and inactivation of the tumor suppressor gene p53 occurring late [54]. 
In the original model it was proposed that only tubular and tubulovillous adenomas had 
the potential to progress to invasive adenocarcinoma. It is now known that even serrated 
polyps can become malignant via an alternative pathway, the CIMP pathway, which differs 
from the APC tumor-suppressor gene pathway associated with the conventional tubular 
adenomas [55]. Colorectal cancer is considered a heterogeneous disease in which the 
different pathways to malignancy can be distinguished at the molecular level by the 
genomic and epigenomic instability. In addition to point mutations, other genetic changes 
occur such as altered DNA methylation (epigenetic), gene rearrangements, amplifications, 
overexpression and deletions. It includes the activation of oncogenes, genes that partake in 
cell growth pathways and cell cycle regulation and deactivation of tumor suppressor genes, 
genes that suppress the cell cycle [56].  
The three most common pathways leading to CRC are: the chromosomal instability 
(CIN), microsatellite instability (MSI) and the CpG island methylator phenotype (CIMP) 
pathways [57]. Figure 1 illustrates these pathways, including the molecular pathogenesis, 
leading to the development of CRC [54]. 
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Figure 1. Pathways leading to CRC. (Reprinted, with permission, from East et al. Gut 2017)  
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2.2 Chromosomal Instability (CIN) Pathway 
The CIN pathway accounts for the development of as many as 85% of the sporadic CRCs 
[58]. CIN is believed to increase clonal diversity in tumor cells thus stimulating cancer 
progression. 
Typical for the CRC CIN phenotype is a distal tumor location, a well-differentiated 
(low-grade) tumor, a higher tendency to local lymph node and distant metastases as well as 
a low or no peritumoral lymphocyte infiltrate. 
2.2.1 APC 
The earliest event in the CIN pathway is the genetic disruption of the APC gene, located on 
chromosome 5q. As mentioned previously, germline mutations in APC are responsible for 
FAP while somatic mutations in APC are observed in the sporadic CRCs. Other than APC, 
there are several deregulated genes in CIN that affect chromosome segregation, telomere 
regulation and DNA damage response.  
The APC gene product is a protein involved in functions such as regulation of 
differentiation, adhesion, polarity, migration, development, apoptosis and chromosomal 
segregation [59]. In its normal state the APC protein interacting with glycogen synthase 
kinase-3β (GSK-β), casein kinase 1α/ε (CK1α/ε) and β-catenin provide suppression of the 
Wnt signal. A genetic disruption of APC is the first event which in turn constitutively 
activates the Wingless/Wnt signaling pathway. The mutant APC gene product cannot bind 
to β-catenin, a protein encoded by the CTNNB1 gene, which leads to increased cytoplasmic 
levels of β-catenin allowing it to translocate to the nucleus and activate transcription of 
multiple genes involved in tumor growth and invasion, see Figure 2 [59]. 
 
 
 
Figure 2. The Wnt Signaling pathway in the “OFF” and “ON” states. (Reprinted, with permission, from 
Pino et al. Gastroenterology 2010) 
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“OFF”: in the absence of a Wnt signal, the destruction complex containing adenomatous polyposis coli 
(APC), glycogen synthase kinase 3β (GSK-3β) and casein kinase 1α/ε (CK1α/ε) on an axin-conducting 
scaffold targets the degradation of cytoplasmic β-catenin in a proteasome-dependent manner. In the 
nucleus, Wnt target genes are also kept silent by the repressor Groucho interacting with DNA-bound T 
cell factor (TCF). 
“ON”: in the presence of a Wnt ligand, occupancy of the receptors Frizzled (Frz) and coreceptor low-
density lipoprotein receptor-related protein (LRP) triggers the phosphorylation of the cytoplasmic tail of 
LRP by CK1 and GSK-3β as well as the disheveled (Dsh)-dependent recruitment of axin on 
phosphorylated LRP. Phosphorylation of β-catenin no longer occurs, and the increased cytoplasmic levels 
of β-catenin translocate to the nucleus, where the transcription of multiple genes is initiated through 
displacement of Groucho and the interaction of β-catenin with the T-cell factor (TCF)/lymphoid enhancer 
factor (LEF) family of transcription factors. 
2.2.2 P53 
The p53 gene, a key tumor suppressor gene, is located on chromosome 17p and is 
considered the ‘guardian of the genome’ [60]. It is a stress-inducible transcription factor 
regulating many different downstream genes that have a regulative function in several 
signaling processes. Stress stimuli such as DNA-damage response, dysfunctional 
telomeres, oncogene activation and oxidative stress, trigger p53 to induce cell cycle arrest, 
apoptosis or senescence [61]. p53 is the most commonly mutated gene in human cancers [62]. 
In sporadic CRC p53 mutation occurs in approximately 40-50% with a higher frequency in 
distal tumors compared to proximal tumors [63]. The loss of p53 function is a late event and 
is believed to play a critical role in the adenoma-carcinoma transition. 
CRC patients with a mutant p53 seem to be more chemo-resistant and have poorer 
prognosis compared to patients with non-mutated/wild-type p53 CRC [64]. The p53 tumor 
suppressor function is in part due to its inhibition of the Wnt pathway and epithelial 
mesenchymal transition (EMT) through miR-34. Thus, loss of this inhibition by disruption 
of p53 could activate proliferation and tissue invasion by CRC cells [65]. 
2.2.3 Other CIN events 
Typical for CIN pathway CRCs is a widespread imbalance in chromosome number 
(aneuploidy), loss of heterozygosity (LOH) with the majority (as many as 70%) of losses 
on chromosome 18 which contain the tumor suppressor genes DCC, SMAD4 and SMAD2 
[66]. The loss of DCC expression has been associated with worse prognosis in stage II CRC 
[66].  
Somatic mutations in SMAD4 have been found in some CRC patients [67]. Patients 
with juvenile polyposis syndrome have germline mutations in SMAD4 and have an 
increased risk of CRC [68]. The SMAD4 gene protein product is necessary for the function 
of the signaling pathway of the transforming growth factor-beta (TGF-β) which has a 
suppressive effect on cancer cells. Interference with TGF-β signaling allows cancer cells to 
escape this inhibition [69]. 
There is evidence that the erosion of telomeres plays a role in CIN. Telomeres are 
DNA-protein complexes of hexameric repeats (TTAGGG) that protect the ends of 
eukaryotic chromosomes during chromosome segregation. A theory is that telomere 
shortening stimulates CIN in early carcinogenesis while in later stages activation of 
telomerase, the enzyme complex that elongates telomeres, contributes to the immortality of 
tumor cells [70]. 
Research focuses on identifying mutations in key genes (e.g. APC, CTNNB1, BRAF, 
KRAS) and their signaling pathways contributing to progression of cancer. The signaling 
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pathway involved in tumorigenesis such as the Ras-Raf-MEK-ERK signaling pathway will 
be discussed later on in section 7.1 and in the CRC oncological treatment section (6.2.4) 
with regard to KRAS and BRAF and their clinical implications. The PI3K/Akt/mTOR 
pathway (section 6.7.1) and the Wnt/β-catenin signalling (section 2.2.1 and 7.4.1) will also 
be discussed later on. 
2.3 Microsatellite Instability (MSI) Pathway 
DNA repair mechanisms are essential for a cell’s genetic stability and function. The 
damage on one of the DNA strands can be correctly repaired by excision and then replaced 
by synthesizing new DNA using the complementary strand as a template. Three main 
excision methods used are base excision repair (BER), nucleotide excision repair and 
mismatch repair (MMR) [71]. MMR genes include: MLH1 (mutL homolog 1), PMS1 
(postmeiotic segregation 1), PMS2 (postmeiotic segregation 1), MSH6 (mutS homolog 6) 
and MSH2 (mutS homolog2).  
In humans, the protein products of these genes function as two heterodimers, 
MutS and MutL. Specifically the MutSα complex is formed by MSH2/MSH6 and the 
MutSβ by MSH2/MSH3 while the MutLα complex consists of MLH1/PMS2 and the 
MutLγ of MLH1/MLH3. MutSα has the ability to recognize single base-pair mismatches as 
well as single-base insertion/deletion loops (IDLs) and the MutSβ recognizes larger IDLs 
(2 to 8 nucleotides). A known interaction that enables the DNA damage correction process 
is the binding of MutSα to MutLα. The function of the interaction of MutSβ to MutLγ is 
unclear. Once the MutSα complex recognizes the single base pair mismatch it slides as a 
clamp around the DNA strand and recruits MutLα. Upon reaching the DNA polymerase 
complex, it becomes a large complex by further interaction with exonuclease I and 
proliferating cell nuclear antigen (PCNA) and can thus excise nucleotides in the daughter 
strand back to the mismatch. Thereafter, the sliding complex disassociates leaving the DNA 
strand available for DNA resynthesis [72]. Figure 3 illustrates the steps involved in MMR 
[72]. 
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Figure 3. DNA MMR system. (Reprinted, with permission, from Boland et al. Gastroenterology 2010) 
Step (A): MSH2-MSH6 (MutSα) recognizes single base-pair mismatches (i.e. DNA polymerase has 
matched the wrong base G with the T on the template) and creates a sliding clamp around the DNA. This 
requires the exchange of adenosine triphosphate (ATP) for adenosine diphosphate (ADP) (by MSH2, but 
neither MSH6 nor MSH3). The complex diffuses away from the mismatch site and is then bound by the 
MLH1-PMS2 (MutLα) complex. This larger (MutSα/MutLα)-complex (sliding clamp) moves along the 
new DNA chain until it encounters the DNA polymerase complex.  
Step (B): The DNA MMR protein sliding clamp interacts with exonuclease-1, proliferation nuclear 
antigen (PCNA), and DNA polymerase. Excision then occurs of the daughter strand back to the site of the 
mismatch and eventually the complex falls off the DNA and resynthesis occurs, correcting the error. 
Step (C): Variations on the DNA MMR interaction: MSH2-MSH6 recognizes single pair mismatches and 
small insertion-deletion loops (IDLs). MSH2-MSH3 (MutSβ) recognizes larger IDLs. MLH1 can 
dimerize with PMS2, PMS1, or MLH3. MSH2-MSH3 (MutSβ) prefers to interact with MLH1-MLH3 
(MutLγ) but other heterodimers exist and are not entirely understood. 
 
Microsatellites are defined as short tandem repeats of DNA sequences (binucleotide 
repeats) located throughout the genome and are distinctive and consistent in length in every 
tissue in each person [72]. The inactivation of the MMR genes results in a deficient MMR 
(dMMR) which then causes failure in the correction of insertion or deletion of the repeating 
units (microsatellites) during DNA replication. MSI leads to frame-shift mutations and 
premature stop codons and inactivation of genes involved not only in DNA repair (e.g. 
MMR genes) but even in cell proliferation (e.g. IGFR2, TGF-β) and in cell cycle/apoptosis 
(e.g. BAX, PTEN). This mutational signature is used to identify tumors with MSI [72]. 
MSI in colorectal cancer is observed in approximately 15% of cases where 3% of the 
cases are due to Lynch syndrome caused by germline mutations in one of MMR genes as 
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mentioned previously and 12% are sporadic cases [72]. Contrary to CIN tumors, also 
referred to as microsatellite stable (MSS) tumors, MSI tumors exhibit a diploid karyotype 
and the gene mutations differ from those observed in CIN CRCs. There seems to be a 
subgroup of CRCs that display both CIN and MSI [73]. 
The majority of tumors that are MSI-H have deficient MMR while most MSI-low 
(MSI-L) tumors have no MMR defect. Downregulation of MSH3 occurring 
heterogeneously throughout the tumor is believed to induce MSI-L [72].  
Most sporadic MSI-H CRC is not due to a mutation in a MMR gene but to the loss of 
MMR activity due to the epigenetic event of hypermethylation of a gene promoter for a 
MMR gene (often the MLH1 gene) in patients with the CpG island methylator phenotype 
[74]. Epigenetics involves modifications in the phenotype or gene expression and does not 
indicate changes of DNA sequence but rather transcriptional silencing of gene expression.  
Sporadic MSI CRC has been found to be associated with the serrated neoplasia 
pathway and often have BRAFv600E mutations differing from Lynch tumors which do not 
have BRAF mutations and present only with KRAS mutations [75]. 
Contrary to CIN tumors, MSI CRC are frequently located in the right colon, tend to be 
mucinous with signet ring cell morphology, poorly differentiated (high-grade), have strong 
lymphocyte infiltration and a pushing border configuration. 
2.3.1 Methods to detect MSI-high (MSI-H) 
A technique used widely to measure MSI is polymerase chain reaction (PCR) which creates 
thousands to millions of copies of a particular segment of DNA. The amplification of 
amount of the particular DNA sequence aids in its detection [76]. Of the several 
microsatellite loci that could be used for MSI analysis a National Cancer Institute (NCI) 
workshop recommended in 1997 a reference panel (Bethesda panel) consisting of 5 
markers (2 mononucleotide: BAT-225 and BAT-26 and 3 dinucleotide: D2S123, D5S346, 
D17S250) [77]. In their guidelines for MSI classification MSI-H is defined as instability in 2 
or more of these markers while microsatellite stable (MSS) and MSI-L as instability in only 
one of the markers. Currently many laboratories use a panel of 5 mononucleotide markers 
(BAT-25, BAT-26, NR-21, NR-24 and MONO-27) that have high sensitivity and 
specificity for recognizing defective DNA in the MMR genes and don’t require 
corresponding normal tissue [78].  
In the clinical setting, immunohistochemistry (IHC) which is equivalent to MSI 
analysis in specificity and sensitivity, is often more available to identify the absence of 
expression of MMR proteins and thus identify the specific MMR gene that should be 
sequenced [79]. More detailed information on IHC analysis is given in section 9.2. 
2.4 CpG Island Methylator Phenotype (CIMP) / Serrated Pathway 
DNA methylation has an essential role in the alteration of gene expression seen in 
carcinogenesis and is extensively researched as biomarkers of CRC [80].  
Epigenetic instability in CRC is exhibited as hypermethylation of loci containing CpG 
islands and as global hypomethylation. A subgroup of CRCs, 10-20%, have a very high 
proportion of methylated CpG loci and are considered CIMP+ tumors [81]. It is unclear 
which mechanisms cause CIMP. The aging process which causes an epigenetic drift could 
contribute to an increased aberrant DNA methylation inactivating a tumor suppressor gene 
resulting in the development of CRC [82].  
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The CIMP+ defect in colorectal tumors often results in hypermethylation of CpG 
islands in the promoter region of the MMR gene, MLH1, silencing its gene expression thus 
resulting in the dMMR/MSI-H phenotype seen in sporadic CRC [83]. Epigenetic alteration 
can inactivate several cellular pathways including not only DNA repair system (MLH1 and 
also MGMT) but also apoptosis (DAPK), angiogenesis inhibition (THBS1), metastasis 
suppression (TIMP3), cell cycle regulation (p14 ARF, p15 INK 4b, p16 INK4a) and cell 
adherence (CDH1, CDH13) [84].  
The criteria for determining CIMP is increased methylation in at least three foci from a 
selected panel of five gene-associated CpG islands. Subclasses of CIMP are suggested in 
which CIMP low has <2/5 markers and CIMP high has >3/5 markers [85].  
There is a correlation between CIMP-high CRC, deriving most likely from sessile 
serrated polyps, and right colon cancer, MSI-H and a high rate of BRAFV600E mutations but 
no KRAS mutation. CIMP-low is associated with MSS and carries mutant KRAS [86].  
2.5 Summary Genetic and Epigenetic Events in CRC Development 
In summary there are several genetic and epigenetic events involved in the development of 
CRC. A summary of the genes involved and molecular alterations is in Table 2 [59]. 
 
Table 2. Genetic and epigenetic events in the development of CRC 
Tumor Suppressor Genes Proto-Oncogenes Other Molecular Alterations 
APC(a) BRAF Chromosome instability 
ARID1A ERBB2 CpG island methylator phenotype 
CTNNB1 (b) GNAS Microsatellite instability 
DCC (c) IGF2 Mismatch-repair genes 
FAM123B KRAS (f) SEPT9 
FBXW7 MYC VIM, NDRG4, BMP3 
PTEN NRAS POLE/POLD1 
RET PIK3CA (g)  
SMAD4(d) RSPO2/RSPO3  
TGFBR2 SOX9  
TP53(e) TCF7L2  
Genetic mutations in CIN-positive CRC: 
(a) *5q21; **30-70%, ***inhibition of Wingless/Wnt signaling, cytoskeletal regulation 
(b) *3p22; **~4-15% (~50^), ***regulation of Wnt pathway target genes that promote tumor growth and invasion 
(c) *18q21; **~6%; ***cell surface receptor for netrin-1 
(d) *18q21; **~10-20%; ***intracellular mediators of the TGF-β pathway 
(e) *17p13; **~40-50%; ***cell cycle arrest, apoptosis induction 
(f) *12p12; **~30-50%; ***cell proliferation, survival and transformation 
(g) *3q26; **~20%; ***cell proliferation and survival 
*=chromosomal location 
**=prevalence of mutation 
***=function of gene product 
^=identified in 50% without APC mutations 
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3 PRESENTATION AND MORPHOLOGY OF CRC 
The majority of patients developing colorectal cancer will eventually present with 
symptoms. Main symptoms include persistent rectal bleeding, often with no anal 
symptoms, as well as change in bowel habit that persists over six weeks or more (tenesmus, 
frequent defecation or looser stools or both), abdominal pain and weight loss. Iron 
deficiency anemia caused by the bleeding from the tumor and signs of intestinal obstruction 
are secondary effects [87].  
Symptoms can vary depending on the tumor site. Right-sided colon tumors often 
present late and have more general symptoms of fatigue, fever, weight loss, anemia and in 
23% of cases have a palpable mass. Left-sided tumors tend to have more of cramping 
abdominal pain while fresh rectal bleeding and increased tenesmus is more common in 
rectal tumors [88].  
It is important that primary care physicians who most often first see these patients do a 
physical examination including a digital rectal one as well as doing an occult fecal blood 
test and a full blood count to control for anemia. Rapid referral is then indicated to a 
suitable clinic that will continue the investigation with colonoscopy/rectoscopy, rigid 
proctoscopy and biopsy of the tumor. 
Standard investigation for CRC also includes a Magnetic Resonance Imaging (MRI) of 
the pelvic area for rectal tumors, and for both colon and rectal tumors a computed 
tomography (CT)-scan of the thorax and abdomen. These are required for the radiological 
staging of the tumor to assess locally advanced disease and metastatic disease [87]. 
A full biochemical workup is done that includes besides blood count even liver- and 
kidney function tests as well as the tumor marker tests (CEA, CA 19-9, CA-125). Deranged 
levels of liver enzymes, high alkaline phosphatase (ALP) and lactase dehydrogenase 
(LDH) and low serum albumin imply advanced disease where the three latter tests also 
indicate poor prognosis. Elevated carcino-embryonic antigen (CEA), a specific CRC 
marker, is observed in approximately two-thirds of CRC cases and is used mainly with 
monitoring response to treatment and indicative of relapse [89]. Elevation of tumor markers 
CA 19-9, a marker of upper gastro-intestinal tumors and CA-125, a gynecological tumor 
marker and indicative of peritoneal metastases, can be seen in CRC but are not specific for 
it.  
After the work-up is done the patients case is presented at a pre-therapeutic Multi-
Disciplinary Team (MDT) conference. As part of the work-up before the MDT conference, 
information should be available if the patient has any comorbidity and if there is a family 
history of cancer. 
The MDT-conference was established in clinics to discuss the individual patients case 
and recommend the best treatment option available for the patient. They occur weekly and 
are attended by oncologists, surgeons, radiologists, pathologists and contact-nurses. MDT 
conferences began primarily for rectal cancer cases but has now grown to a routine practice 
for all CRC cases as well as other malignancies. Although there are no randomized studies 
done to investigate the benefit of MDT conferences to the patient, reports have shown 
better results in rectal cancer outcome for patients whose cases were discussed at a MDT 
conference [90]. 
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3.1 Primary Tumor Location and Pattern of Metastasis 
About 20% of CRC develops in the cecum, 25% in the sigmoid colon, 10% in the 
rectosigmoid junction and 20% in the rectum [91].  
Spreading of CRC can occur by lymphatic and hematogenous dissemination as well as 
contiguously and transperitoneally. Distant metastases are most often seen in liver, lungs, 
lymph nodes and peritoneum. For colon tumors and proximal rectal tumors, hematogenous 
dissemination is via the venous drainage of the intestinal tract to the portal system, and then 
to the liver, lungs, skeleton and at times other sites such as the brain. The venous drainage 
for the distal rectal tumors is through the inferior rectal vein into the inferior vena cava 
instead of the portal system which results in initial metastasis to the lungs. 
3.2 Staging 
The international tumor, node, metastasis (TNM) staging system introduced in 1959 is used 
for staging CRC and is continually updated by the American Joint Committee on Cancer 
(AJCC) and the International Union Against Cancer (UICC). The most recent revision, is 
the eighth edition from 2017 [92]. 
The (T) in TNM stands for the invasiveness of the primary tumor, (N) is the number of 
regional lymph node metastases and (M) is the presence of distant metastases. 
Updates in the latest TNM edition include a more clarified definition of pT4a, tumor 
deposit and distant metastasis. Factors which are important in treatment decisions but not 
yet incorporated into formal staging criteria are preoperative serum CEA, tumor regression 
score, lymphovascular and perineural invasion, microsatellite instability (MSI) and 
mutation status of KRAS, NRAS and BRAF. 
The sixth edition of the AJCC staging system was used in study I-II [93], and the 
seventh edition in study III-IV [94]. The earlier pathological classification of CRC, Dukes 
staging system, can be translated to the current TNM staging system. See Table 3 for the 
different versions. 
 
Table 3. TNM classification according to the 8th edition of the AJCC Cancer Staging Manual. 
 TNM Stage *8th and 7th Edition  TNM Stage 5th and6th Edition Duke’s 
Stage T N M Stage T N M  
0 Tis N0 M0 0 Tis N0 M0 – 
I T1-2 N0 M0 I T1-2 N0 M0 A 
IIA T3 N0 M0 IIA T3 N0 M0 B 
IIB T4a N0 M0 IIB T4 N0 M0 B 
IIC T4b N0 M0     B 
IIIA T1-2 
T1 
N1/N1c 
N2a 
M0 
M0 
IIIA T1-2 N1 M0 C 
C 
IIIB T3-T4a 
T2-T3 
T1-T2 
N1/N1c 
N2a 
N2b 
M0 
M0 
M0 
IIIB T3-4 N1 M0 C 
C 
C 
IIIC T4a 
T3-T4a 
T4b 
N2a 
N2b 
N1-N2 
M0 
M0 
M0 
IIIC Any T N2 M0 C 
C 
C 
IVA Any T Any N M1a IV Any T Any N M1 D 
IVB Any T Any N M1b     D 
*IVC Any T Any N M1b      
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Tumor-Node-Metastasis Classification 
 AJCC 8th and 7th Edition AJCC 5th and 6th Edition 
  T (primary tumor) 
TX Primary tumor cannot be assessed Primary tumor cannot be assessed 
T0 No evidence of primary tumor No evidence of primary tumor 
Tis Carcinoma in situ: intra epithelial or 
Invasion of lamina propria 
Carcinoma in situ: intra epithelial or 
Invasion of lamina propria 
T1 Tumor invades submucosa Tumor invades submucosa 
T2 Tumor invades muscularis propria Tumor invades muscularis propria 
T3 Tumor invades through the muscularis propria into 
pericolorectal tissues 
Tumor invades through the muscularis propria into 
pericolorectal tissues 
T4 Tumor directly invades other organs or structures 
and/or perforates visceral peritoneum 
Tumor directly invades other organs or structures and/or 
perforates visceral peritoneum 
T4a Tumor penetrates to the surface of the visceral 
peritoneum 
  
Reprinted with 
permission from 
CancerBro: 
https://cancerbro.com 
T4b Tumor directly invades or is adherent to other 
organs or structures 
  
  
 
 N (Regional lymphnodes) 
NX Regional lymph nodes cannot be assessed Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastases No regional lymph node metastases 
N1 Metastases in 1 to 3 regional lymph nodes Metastases in 1 to 3 regional lymph nodes 
N1a Metastases in one regional lymph node  
N1b Metastases in 2 to 3 regional lymph node  
N1c Tumor deposit(s) in the subserosea, mesentery, or 
non peritonealized pericolic or perirectal tissues 
without regional nodal metastases 
 
N2 Metastases in 4 or more regional lymph nodes Metastases in 4 or more regional lymph nodes 
N2a Metastases in 4-6 regional lymph nodes  
N2b Metastases in 7 or more regional lymph nodes  
 
 M (Distant metastases) 
MX Distant metastases cannot be assessed Distant metastases cannot be assessed 
M0 No distant metastases No distant metastases 
M1 Distant metastases Distant metastases 
M1a Metastases combined to one organ or site (for 
example lung, liver, ovary, non-regional node) 
 
M1b Metastases in more than one organ/site or the 
peritoneum 
 
 
Radiological imaging establishes if there is distant spread or metastasis and the 
histopathological staging which is made after surgical resection of the colorectal tumor 
determines any local and regional spread. 
Other than the invasiveness of the primary tumor (T), the number of regional lymph 
node metastases (N) and the presence of distant metastases (M) the TNM staging system 
recommends other factors for routine assessment that aid in prognosis such as the presence 
of extratumoral tumor deposits, lymphovascular and perineural invasion, histologic grade 
of differentiation, preoperative level of CEA, MSI, RAS and BRAF mutations. 
TNM is used in different settings where cTNM (c stands for clinical) refers to clinical 
findings and radiology, yTNM is used in assessing preoperative radiotherapy (RT) or 
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chemotherapy and pTNM (p stands for pathology) is the combined clinical, radiological 
and pathological assessment of the resected tumor. 
An increase in T substage is correlated to a negative prognosis [95]. 
So as to not understage the tumor it is recommended by the AJCC and the College of 
American Pathologists that at least 12 lymph nodes are examined in the resected tumor 
specimen [92, 96]. The impact of lymph node status was supported by the large study done by 
the SEER database that found a 20% decrease in mortality when more than 15 lymph nodes 
were examined [97]. The higher the number of involved nodes, independent of the T 
category, correlates with a worse prognosis in stage III [97]. 
Residual tumor, defined as local residual disease after the completion of therapy, is an 
adverse prognostic factor [98]. 
Tumor deposits are defined as nodules of tumor within the pericolic, perirectal fat or in 
adjacent mesentery. They are often linked to extramural venous invasion and are equivalent 
to nodal metastases with their adverse prognostic influence [99]. 
3.3 Prognosis 
Stage, which embodies the combination of TNM, is still considered the most significant 
determinant of the prognosis of the CRC as well as the management of it [100].  
At diagnosis approximately 39% of CRC cases are localized or confined to the primary 
site, 35% have spread to regional lymph nodes, 22% have distant metastases and 4% have 
an unknown stage [101]. 
Generally, a more advanced stage correlates to a worse overall survival (OS), see Table 
4 [102]. Figure 4 displays the relative overall survival curves for colon cancer and rectal 
cancer according to TNM stage as reported by the Swedish colorectal cancer registry [103]. 
 
Table 4. 5-year relative survival rates for colon cancer and rectal cancer based on people  
diagnosed between 2009 and 2015 
Stage Colon Cancer Rectal Cancer 
Localized  90.4% 88.9% 
Regional  71.3% 71.1% 
Distant 13.8% 15.1% 
All Stages combined 63.4% 66.7% 
Unstaged/Unknown 26.2% 50.4% 
*Based on data from the website of the National Cancer Institute (https://www.cancer.gov), accessed 
August 2019.  
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Figure 4. Relative Overall Survival in colon cancer and rectal cancer in Sweden 2012-2018. 
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4 COLON CANCER - CURATIVE TREATMENT 
Guidelines from the American Society of Clinical Oncology (ASCO), National 
Comprehensive Cancer Network (NCCN), European Society for Medical Oncology 
(ESMO) and National Swedish Guidelines aid in the recommendation of a suitable 
treatment for the patient which is then discussed with the individual patient. 
4.1 Surgery 
For localized colon cancer (stage I-III) surgery is the only curative modality. A successful 
surgical resection of the tumor involves complete removal of the tumor as well as of the 
major vascular pedicle and the regional lymphatic drainage basin. Depending on the site of 
the tumor surgical options are as follows: right hemicolectomy for tumors in the right 
colon; extended right hemicolectomy for tumors in the transverse colon; left 
hemicolectomy for tumors in the left colon and sigmoid colectomy for sigmoid colon 
tumors. A total abdominal colectomy with ileorectal anastomosis is reserved for selected 
patients with Lynch, FAP or metachronous tumors.  
4.2 Chemotherapy Agents in Adjuvant Setting 
Background on adjuvant chemotherapy 
The goal of adjuvant (postoperative) chemotherapy is to eradicate micrometastases and 
thus reduce the risk of disease recurrence and increase the cure rate. The two chemotherapy 
agents used in the adjuvant setting are 5-Fluorouracil (5-FU), given intravenously 
combined leucovorin or as an oral pro-drug (Capecitabine), and Oxaliplatin. They are also 
used in metastatic CRC (mCRC) treatment. 
4.2.1 5-Fluorouracil (5-FU) 
5-FU, a fluoropyrimidine, is an antimetabolite drug developed in the 1950s, and is 
considered a cornerstone of both adjuvant and mCRC treatment. It causes cytotoxicity by 
misincorporation of fluoronucleotides into RNA and DNA as well as the inhibition of 
thymidylate synthase (TS), a nucleotide synthetic enzyme. More detailed information on 
thymidylate synthase is provided in section 7.3. 
As 5-FU is an analog to uracil with a fluorine atom instead of hydrogen at the C-5 position, 
it can ‘quickly’ enter the cell where it is then intracellularly converted to the active 
metabolites: fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine 
triphosphate (FdUTP) and fluorouridine triphosphate (FUTP). FUTP is cytotoxic by 
damaging the normal RNA processing through its incorporation into RNA thus leading to 
faulty translation as well as obstructing synthesis of other forms of RNA (e.g. rRNA, 
tRNA, pre-mRNA). A major effect of 5-FU is by inhibition of TS by its metabolite 
FdUMP. FdUMP binds to TS instead of its usual substrate, dUMP [104]. 
The function of the enzyme TS is to convert deoxyuridine monophosphate (dUMP) to 
deoxythymidine monophosphate (dTMP) using the reduced folate 5,10-
methylenetetrahydrofolate (CH2THF). This important process supplies the only de novo 
source of thymidylate, one of the nucleotides necessary for DNA replication and repair. 
Lethal DNA damage by TS inhibition is then due to a depletion of dTMP and consequently 
of deoxythymidine triphosphate (dTTP). A further consequence of TS inhibiton by 5-FU is 
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the accumulation of dUMP leading in turn to increased levels of deoxyuridine triphosphate 
(dUTP). Both the 5-FU metabolite , FdUTP and dUTP can be misincorporated into DNA 
causing damage [105]. The enzyme thymidine kinase (TK) can salvage dTMP from 
thymidine thus providing a possible explanation of 5-FU resistance [104]. The mechanism of 
5-FU is pictured in Figure 5 [104]. 
 
 
Figure 5. Modulation of 5-fluorouracil activity. (Reprinted, with permission, from Longley et al. Nat Rev 
Cancer 2003) 
 
Leucovorin (LV) increases the intracellular pool of 5-10-methylene tetrahydrofolate (CH2THF), thus 
enhancing thymidylate synthase (TS) inhibition by fluorodeoxyuridine monophosphate (FdUMP). 
Eniluracil and uracil inhibit DPD-mediated degradation of 5-FU. Methotrexate (MTX) is thought to 
increase 5-FU activation by increasing phosphoribosyl pyrophosphate (PRRP) levels. Interferons (IFNs) 
have been reported to enhance thymidine phosphorylase (TP) activity, abrogate acute TS induction 
caused by 5-FU treatment and enhance 5-FU-mediated DNA damage. Capecitabine is a 5-FU pro-drug 
that is converted to 5´-deoxy-5-fluorouridiine (5’DFUR) in the liver by the sequential action of 
carboxylesterase and cytidine deaminase. 5’DFUR is converted to 5-FU by TP. 
 
In an effort to improve the effect of 5-FU, different modulators have been developed. 
Leucovorin (LV) is an established modulator of 5-FU. Its function is to increase the 
intracellular concentration of CH2THF as well as stabilizing the ternary complex with TS 
and FdUMP thus in turn increasing 5-FU toxicity. Although it did not improve OS in 
mCRC, a meta-analys showed that the combination of 5-FU/LV had a better response rate 
(23%) compared to single 5-FU (11%) [106]. 
The oral fluoropyrimidine, the 5-FU prodrug Capecitabine, was designed to avoid 
dehydropyrimidine dehydrogenase (DPD)-mediated degradation in the liver. After 
absorption through the gastrointestinal wall it is converted in the liver to 5’deoxy-5-
fluorouridine (5’DFUR) by carboxylesterase and cytidine deaminase. The enzyme 
thymidine phosphorylase (TP) that then converts 5’DFUR to 5-FU is more active in tumor 
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cells than normal cells which may contribute in clinical trials to capecitabine having a 
higher response rate (28.4%) than 5-FU/LV (15.5%), though survival was the same [107]. 
Another oral agent not commonly used in Europe and Sweden is UFT which combines 
uracil, a competitive inhibitor of DPD with tegafur, a 5-FU prodrug which is converted to 
5-FU in the liver by the cytochrome P-450 enzyme. 
4.2.1.1 Dehydropyrimidine dehydrogenase (DPD) 
DPD, is the rate-limiting enzyme involved in 5-FU catabolism both in normal cells as in 
tumor cells. It is a rapid process and up to 80% of the degradation occurs in the liver [108]. 
The gene coding for DPD, DPYD, is located on chromosome 1, containing 23 exons in a 
single copy. A prevalence of 0.5% for partial or 5% for total deficiency of DPD has been 
identified as an autosomal recessive trait [109]. 
Approximately 30% of fluoropyrimidine treated patients will experience 
fluoropyrimidine-associated toxicity and 0.5-1% of them with fatal outcome [110]. It is 
estimated that 60-70% of cases of 5-FU toxicity are due to decreased levels of DPD. The 
most common allele variant associated with loss of DPD activity is DPYD*2A 
(c.1905+1G>A; rs3918290). It accounts for 25% of DPD-deficient patients. Genotype 
approaches to evaluate DPD deficiency vary from single nucleotide polymorphism (SNP) 
genotyping for evaluation of solely DPYD*2A or four validated DPYD variants or a full 
nucleotide analysis [111]. 
It has been shown in a clinical trial of >2000 patients that analysis of DPYD*2A and 5-
FU dose reduction to approximately 50% for variant carriers, reduced grade 3 or higher 
toxicity from 73% to 28%, a rate similar to the *2A noncarriers. A disadvantage in the trial 
is that other DPYD polymorphisms were not identified. The analysis identified 18 as 
carriers of *2A and showed their screening process to be cost-efficient [112]. 
Other than SNP genotyping other methods used for measuring DPD deficiency are: 
measuring clearance of [2-13C]-labeled uracil in breath or serum level of uracil after an 
oral dose and enzymatic DPD activity in peripheral blood mononuclear cells [113]. 
ESMO guidelines have recommended DPD testing before 5-FU administration to be 
an option but is not routinely recommended [114]. The goal in the future is to increase patient 
safety as well as the clinical benefit by DPYD genotype-guided dosing. 
4.2.2 Oxaliplatin 
Oxaliplatin is a third generation platinum compound and has synergistic effects with 5-FU. 
It causes DNA damage by crosslinking the DNA double helix thus hindering DNA 
replication and transcription [115]. 
4.3 Adjuvant Chemotherapy Stage III 
Stage III colon cancer patients are generally recommended adjuvant chemotherapy if no 
contraindications exist such as a significant level of co-morbidity and a poor performance 
status. After surgical resection the 5-year survival for stage III varies from approximately 
30% to 60% [116].  
The accepted timing for initiation of adjuvant chemotherapy within six to eight weeks 
after resection was adopted from the adjuvant colon cancer trials and supported by two 
meta-analysis [117]. Trials have shown benefit of adjuvant chemotherapy for the stage III 
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(node positive) colon cancer patients with a relative reduction of about 30% in risk of 
recurrence and 22 to 32% in mortality. 
The backbone of adjuvant chemotherapy is 5-FU with the modulator, leucovorin (LV) 
[118]. The immodulatory drug, levamisole, is no longer used as a modulator to 5-FU due to 
its toxicity to the central nervous system.  
Addition of Oxaliplatin to 5-FU/LV was shown in five randomized trials including the 
MOSAIC trial to increase the survival benefit but has the disadvantage of cumulative and 
dose-limiting peripheral neuropathy [119]. 
There are several studies, though no prospective randomized trials, indicating that 
dMMR or MSI-H colon cancers are resistant to 5-FU (fluoropyrimidine) chemotherapy [120-
122].  
Especially in stage III colon cancer patients with dMMR/MSI-H oxaliplatin retained a 
positive effect [123, 124]. 
4.3.1 Value of other oncological agents? 
Three trials (CALGB 89803, PETACC-3 and ACCORD) have been negative regarding the 
value of adjuvant irinotecan-containing chemotherapy for resected colon cancer [125-127]. 
Targeted therapies with vascular endothelial growth factor (VEGF)-inhibition and 
epidermal growth factor receptor (EGFR)-inhibition have shown improved survival in the 
metastatic setting. They have however not shown benefit in the adjuvant situation. This 
may be due to the absence of a tumor burden in a micrometastatic setting and thus a 
difference in molecular biology. There is a need of predictive biomarkers for the adjuvant 
setting, especially in selecting patients which could benefit of targeted therapy. 
The use of adjuvant bevacizumab (Avastin®), a monoclonal antibody inhibiting the 
vascular endothelial growth factor (VEGF), in addition to a 5-FU/LV adjuvant regimen did 
not improve the outcome of colon cancer patients in three large trials (NSABP C-08, 
AVANT trial, QUASAR2 trial) [128-130].  
Lack of benefit in the adjuvant setting for colon cancer patients was also seen with the 
addition of an EGFR-inhibitor, cetuximab, to 5-FU/LV plus an oxaliplatin regimen 
(FOLFOX) in 2 trials (N1074 and European PETACC8 trial) [131, 132]. 
4.3.2 Duration of adjuvant treatment 
Six-months of oxaliplatin-based chemotherapy is standard of care for the majority of 
patients with stage III colon cancer [133]. For adults older than 70 years, there is some 
evidence that there is little benefit to the addition of Oxaliplatin to 5-FU/LV [134]. 
There has been interest to shorten the duration of adjuvant chemotherapy. This is in 
part due to the cumulative and dose-limiting neuropathy of Oxaliplatin. In order to establish 
if shortening the adjuvant treatment would compromise the outcome, six trials have 
randomized between six versus three months of oxaliplatin-based adjuvant therapy. The 
trials results were summarized in a recent publication by the International Duration 
Evaluation of Adjuvant Chemotherapy (IDEA) Collaboration [135]. 
A suggestion is made from the results that high-risk cancers (T4 or N2) remain with 
the standard of a six-month treatment. However, due to only a small loss of absolute 
disease-free survival benefit (0.2% absolute difference at three years) and significantly 
lower Oxaliplatin neuropathy, they recommend a three-month treatment for low-risk 
disease (T1-3, N1). 
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4.4 Adjuvant Chemotherapy Stage II 
The value of adjuvant chemotherapy for stage II (node-negative) colon cancer patients is 
controversial. Although surgery usually cures most stage II colon cancer patients, about 20-
30% of patients will develop tumor recurrence and eventually die of metastatic disease [136].  
No benefit of fluoropyrimidine-based adjuvant chemotherapy was seen for stage II colon 
cancer in four large trials [137-140]. In the largest of these trials, the QUASAR trial, 2146 
stage II patients were randomized to adjuvant fluorouracil/LV with or without levamisole 
versus observation where they found a trend for better OS (Hazard Ratio (HR) 0.86, 95% 
Confidence Interval (CI) 0.54-1.19, five-year OS 83.9% versus 81.5%)) [138]. Three large 
trials (MOSAIC, NSABP C-07 and ACCENT) did not show any OS benefit with the 
addition of oxaliplatin to adjuvant fluorouracil/LV for stage II colon cancer patients [119, 141, 
142]. Of interest, the MOSAIC trial found a sizeable trend towards a better disease-free 
survival (DFS) in high-risk (e.g. T4) stage II colon cancer patients who received an 
oxaliplatin plus short-term infusional 5-FU and LV (FOLFOX) [141]. 
Clinicopathologic features which are considered to contribute to the risk of disease 
recurrence in stage II colon cancer are: fewer than 12 nodes analyzed, T4 substage, 
perforated or obstructed tumor, poorly differentiated tumor, lymphatic, vascular or 
perineural invasion and MMR-status [116]. Adjuvant chemotherapy in stage II colon cancer 
is considered in the presence of one or more high-risk features. 
In order for the patient to make an informed decision, the oncologist should discuss 
with the patient the relative risk of recurrence with or with adjuvant treatment as well as 
inform the patient of the expected side effects of chemotherapy.  
Treatment guidelines require that MMR-status be analyzed for stage II CRC before 
treatment decision [143].  
Studies have shown that MMR-status is a prognostic factor in Stage II colon cancer 
patients in which a dMMR or MSI-H status is correlated with a favorable prognosis [121]. 
Adjuvant chemotherapy is not recommended to patients with stage II CRC with no high-
risk features and a dMMR/MSI-H tumor. 
Although strong evidence is lacking, adjuvant therapy should be considered to patients 
with pMMR/MSS tumors and high-risk features. It is unclear what the best option is for 
patients with stage II dMMR/MSI-H and high-risk features. A reasonable option for these 
patients could be to give an oxaliplatin-containing regimen instead of fluoropyrimidene 
alone. 
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5 RECTAL CANCER – CURATIVE TREATMENT 
An essential step for a correct assessment and treatment decision at the MDT-conference 
for a newly diagnosed rectal cancer patient is the pelvic MRI which provides the local 
radiological staging of the tumor. 
5.1 Surgery 
For the majority of stage I-III rectal cancer patients, radical surgical resection of the 
tumor is still the cornerstone of curative therapy. Advances in surgical techniques, 
especially the total mesorectal excision (TME) technique for low and mid rectum 
tumors, have decreased the local recurrence rate and overall survival of rectal cancer. 
With the earlier surgical technique of abdominoperineal excision (APE) local 
recurrence rates were close to 30% [144].  
TME involves mobilization of the rectum, dissection in the avascular plane created by 
the mesorectal fascia (MRF) and removal of the tumor along with an intact mesorectum as 
well as less risk of tumor involvement in the lateral tumor margins. With TME-surgery 
local recurrence decreased to less than 10% [145, 146]. 
Patients that are fecal continent and have a rectal tumor in the low or mid rectum with 
no sphincter involvement most often undergo a low anterior resection (LAR) with the 
TME-dissection and bowel continuity. The abdominoperineal resection (APR) or 
abdominoperineal excision (APE) is subdivided into four options (intersphincteric, 
conventional, extra levator – ELAPE, and ischioanal) and is done in patients with lower-
third rectal cancers in which there is involvement of the sphincters or pelvic fixation [147]. 
5.2 Radiotherapy (RT) 
The role of RT with or without chemotherapy is established in the treatment of rectal 
cancer. Although the choice of oncological treatment for a rectal cancer regarding pre- or 
postoperative RT or chemoradiotherapy (CRT) and the benefit of chemotherapy has been 
controversial and differs between Europe and America.  
Besides the radiological TNM staging, the location of the tumor determines the choice 
of treatment. The definition of a low tumor is up to 5 cm from the anal verge, middle from 
>5 to 10 cm, high from >10 up to 15 cm. The MRI can determine if there is any extramural 
vascular invasion (EMVI), the T substage and whether the mesorectal fascia (mrf) (equates 
to circumferential resection margin (crm)) is threatened and thus help predict which 
patients are at risk of local recurrence and distant metastases. This aids the mdt team define 
the necessary preoperative treatment and extent of surgery. Assessment of radiological 
lymph node staging is not always accurate. Upper rectal cancers (>12 cm from the anal 
verge, above the peritoneal reflection) are treated more like colon cancers. 
A general categorization of the tumors can be done according to the Blomqvist and 
Glimelius recommendations in which ‘good’ tumors don’t require preoperative (C)RT and 
can go directly to surgery, ‘bad’ tumors generally require short-course RT (5Gy x5) and 
‘ugly’ tumors require CRT [148], see Table 5. Guidelines [87] for preoperative treatment of 
rectal cancers are not absolute criteria for treatment. Treatment is also, for example, 
adjusted according to tumor location (anterior or posterior) and if tumor growth is <1mm to 
levator ani muscles. 
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Table 5. Categorization of rectal tumors based on radiological TNM staging. 
Good Bad* Ugly 
Low tumor: T1-2, N0, mrf- 
High tumor: T1-T3b, N0, mrf- 
Low tumor: T3, N1-2, mrf- 
High tumor: T3c-d, N1-2, mrf- 
T4, T3 mrf+ 
Lateral nodes (N+) 
Mrf, mesorectal fascia; mrf-, unaffected mesorectal fascia; mrf+, affected mesorectal fascia.  
Cut-off between a low and a high rectal tumor is around 8 (6-10) cm where the upper rectum is above the peritoneal 
reflection and the middle and lower rectum lies below it. 
*if the tumor has signs of extramural vascular invasion (EMVI+) it is considered at least Bad 
 
Contrary to colon cancer in which recurrence is mostly with distant metastases, rectal 
cancer’s recurrence is equally distributed locally and in distant organs. RT of the rectum is 
more feasible and associated with less toxicity compared to the colon which is close to 
radiosensitive organs. The goal of RT is to lower local recurrence rate and aid in the 
improvement of survival together with a curative resection as well as to downsize and 
downstage locally advanced tumors allowing a radical (R0) resection. After different 
treatment schedules have been tried, the optimal RT dose for best effect has been set at 45-
50 Gray (Gy) in 4-5 weeks (i.e. long course RT 1.8 Gy daily up to 28 fractions) or an 
equivalent dose using another schedule, such as short course RT, 5 Gy daily up to 5 
fractions. 
A Swedish trial in the late 1990s demonstrated a significant increased overall survival 
in rectal cancer patients that were randomized to preoperative RT (58%) versus direct 
surgery (48%), p=0.004 [149]. Other trials with the same randomization have shown a better 
decrease in local recurrence for those in the preoperative RT arm [150, 151]. 
With the improved TME surgery which in turn lead to a better prognosis of rectal 
cancer patients, preoperative (C)RT has shown in later studies to have an effect on local 
control but less impact on overall survival [151, 152]. 
The addition of chemotherapy to RT acts as a radio-sensitizer and is mainly used in 
locally advanced rectal cancers, i.e. long course RT 1.8 Gy to 28 fractions combined often 
with the oral fluoropyrimidine, Capecitabine. It is also theorized that the added 
chemotherapy may have an eventual early effect on occult metastases. Two randomized 
phase III trials comparing CRT to RT on locally advanced tumors (T3-4, N1-2) showed 
however only a decrease in local recurrence rate (11% to 5%) but no survival difference 
[153]. 
Three meta-analyses studies show that neo-adjuvant treatment (RT or CRT) is superior 
to adjuvant treatment (RT or CRT or chemotherapy) regarding reduction in local failure 
rates and cancer specific survival (CSS) [154-156]. Based on this evidence preoperative long-
course CRT (total dose 50.4Gy with 1.8 Gy fractions concomitant with bolus 5-FU or 
Capecitabine) with a 6-8 week delay before surgery became a standard treatment for rectal 
cancer in Europe and Sweden [157].  
The addition of 5-FU based chemotherapy to the postoperative RT showed in two trials 
a 10% significant increase in survival [158, 159]. 
Traditionally in North America, the decision for postoperative CRT was made after 
histopathological staging. Nowadays the NCCN guidelines recommend neoadjuvant CRT 
for transmural (T3/4) or node-positive tumors, especially for low rectal tumors [160]. 
Advantages of neoadjuvant treatment are: a better effect due to tumor proliferation being 
greater before surgery, increased tumor radiosensitivity, decreased tumor seeding and less 
toxicity which leads to eventually a better compliance. The disadvantage of risk of 
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overtreatment in patients with early stage disease has decreased due to better MRI imaging, 
a more correct radiological staging. 
Several trials have explored whether neoadjuvant long course (C)RT versus short 
course RT on rectal tumors have similar effects on local recurrence survival, OS and 
toxicity. No significant difference between the two regimes was found regarding these 
endpoints in two trials, TTRAG trial and the Polish Colorectal Study group trial, which 
randomized T3 and T3/4 rectal tumors [161, 162].  
RT technique has developed throughout the years leading to a more accurate treatment 
of the target, less radiation to risk organs and thereby decreased toxicity. 
A complete pathologic response (pCR) of the resected rectal tumor is associated with a 
significantly lower recurrence rate and a better prognosis than with residual tumor, 
especially than with residual nodal disease [163].  
5.2.1 Tumor regression grading system 
Tumor regression grading (TRG) systems have been originally developed to categorize the 
amount of regressive changes in the histopathologic evaluation after (C)RT. Dworak et al 
demonstrated that the 5-year DFS rate was significantly correlated with the histopathologic 
tumor regression grade [164]. Dworaks TRG system as well as other TRG systems are 
illustrated in Table 6 [165]. The MRI-assessed tumor response (mrTRG) after (C)RT 
treatment in rectal cancer (Table 6) is also standard clinical practice as it is predictive of 
DFS and OS and provides prognostic information concerning the risk of local recurrence 
[166]. A mrTRG of complete tumor response is strongly correlated with a histopathologic 
complete response pCR [167]. 
 
Table 6. Tumor regression systems for rectal cancer 
 Dworak AJCC mrTRG 
Complete 
regression 
No tumor cells 
(TRG 4) 
No viable cancer 
cells (TRG 0) 
Absence of any tumor signal 
(mrTRG1) 
Near complete 
regression 
Very few tumor 
cells (TRG 3) 
Single or small 
groups of tumor 
cells (TRG 1: 
moderate response) 
Small amounts of residual tumor 
visible but with a predominant 
fibrotic area of low signal intensity 
(mrTRG2) 
Moderate 
regression 
Dominantly fibrotic 
changes with few 
tumor cells or 
groups (TRG 2) 
Residual cancer 
outgrown by 
fibrosis (TRG 2: 
minimal response) 
Mixed areas of low-signal-
intensity fibrosis and intermediate 
signal intensity present but with 
our predominance of tumor 
(mrTRG3) 
Minimal regression Dominant tumor 
mass with obvious 
fibrosis (TRG 1) 
Minimal or no 
tumor cells killed 
(TRG 3: poor 
response) 
Predominantly tumor signal 
intensity remaining, with minimal 
fibrotic low signal intensity 
(mrTRG4) 
No regression No regression 
(TRG 0) 
 No fibrosis evident, only tumor 
signal intensity visible (mrTRG5) 
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5.2.2 Complete response after neoadjuvant (C)RT 
A meta-analysis showed an increase in pCR, 13.7% to 19.5%, and no significant 
complications when surgery was delayed more than the norm of 6-8 weeks after (C)RT 
treatment [168]. The finding that pCR seemed to increase if surgery was delayed after (C)RT 
lead to trials to explore whether timing of surgery was of importance.  
One Swedish trial (Stockholm III trial) randomized rectal cancer patients: to short-
course RT with immediate surgery, short-course RT with a 4-8 week delay before surgery 
and a long-course RT with 4-8 week delay before surgery [169]. They found that in 
comparing the short-course arms, delayed surgery patients had a higher rate of pCR (=TRG 
4) compared to the immediate surgery patients, 11.8% vs 1.7%, p<0.001. Comparison of 
all arms showed no differences in rates of local recurrence, distant metastasis or OS.  
The Stockholm III trial as well as others have led to a standard in Sweden of short-
course RT with delay for the majority of rectal cancers and long-course CRT with delay for 
the locally advanced tumors. To avoid overtreating patients with RT and subjecting them to 
unnecessary side-effects from RT, the Swedish Guidelines for which rectal tumors should 
receive preoperative (C)RT are currently been revised. 
If neoadjuvant therapy (C)RT achieves clinical and radiological complete response in 
localized rectal cancer, the approach of “watch-and-wait”, thus achieving organ 
preservation and avoiding surgery, is showing to have safe and promising outcomes in 
several studies [170]. Close monitoring of these patients is required and further larger studies 
are needed before clinical implementation. 
5.3 Adjuvant Chemotherapy 
Evidence for adjuvant chemotherapy has not been as convincing for rectal cancers as it is 
for colon cancer. This is in part due to fewer rectal cancer patients participating in adjuvant 
trials to avoid the confounding factor of preoperative (C)RT that affects the tumor 
specimen histopathological assessment, ypTNM. Downgrading of the tumor stage by 
preoperative (C)RT is considered more of a prognostic marker than a predictive marker for 
response to postoperative adjuvant treatment. 
Meta-analyses have shown some advantage of adjuvant 5-FU-based chemotherapy in 
DFS and OS but the analyses did not exclude studies that did not perform TME-surgery or 
use preoperative (C)RT [138, 171]. 
In a meta-analyses that included randomised trials of adjuvant 5-FU/LV proceeding 
(C)RT and surgery, no survival advantage was observed for adjuvant 5-FU [172]. 
Combining oxaliplatin to 5-FU/LV as adjuvant therapy for rectal cancer has not shown 
conclusive results on OS [173].  
A better ‘relapse-free survival’ and OS was seen in high-risk rectal cancer patients 
receiving oxaliplatin plus 5-FU/LV that had no downstaging effect of preoperative CRT 
[174]. 
According to ESMO guidelines the oncologist should contemplate adjuvant 
chemotherapy in rectal cancer patients with yp stage III and high-risk yp stage II and have a 
risk-balanced discussion with the individual patient with regards to long-term effects of 
toxicity and risk for relapse [175]. 
In an effort to further establish whether rectal cancer patients would benefit with longer 
survival, a decreased risk for distant metastasis, a Swedish study (Rapido study) was done 
that tested neoadjuvant short-course RT followed by chemotherapy (6 cycles of 
capecitabine plus oxaliplatin, CAPOX) and then surgery compared to the standard arm of 
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long-course CRT followed by surgery followed by adjuvant chemotherapy [176]. The study 
has recently stopped including patients and the results are not yet published. Pending these 
results many clinics in Sweden have implemented the neoadjuvant concept of short course 
RT followed by chemotherapy (4 cycles CAPOX) as a study, LARCT-US (Locally 
Advanced Rectal Cancer Trial – Uppsala Style), that patients can be included into [177]. 
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6 METASTATIC CRC  
The mdt conference is of critical importance when establishing the potential goal of the 
treatment as well as the choice of a suitable type of treatment and its timing for a patient 
with metastatic CRC (mCRC), synchronous and/or oligometastatic (limited disease with 
few metastatic sites and lesions). Patients with metastatic disease are categorized into 
clearly resectable disease, initially unresectable disease but with conversion potential and 
unresectable disease.  
6.1 Oligometastatic Scenario 
In the stage IV, oligometastatic (OMD) scenario some patients, especially those with liver-
limited disease can be surgically cured of their disease. Common metastatic sites include 
the liver, lung, peritoneum, lymph nodes and ovary. Metastases to the brain/central nervous 
system (CNS) or bones are correlated to poor prognosis and are usually not included into 
the OMD classification. Treatment strategy for OMD patients is a radical surgical resection 
of both the primary tumor and metastases. If surgery isn’t possible, local ablative treatment 
(LAT) of the metastases can be an option. 
In Sweden a common LAT for liver metastastases is the use of microwave ablation. 
Other forms of LAT are stereotactic ablative body radiotherapy (SBRT), a good option for 
lungmetastases, radiofrequency ablation (RFA), radioembolization (selective internal 
radiation therapy, SIRT) and external radiotherapy. A long-term survival has been observed 
in 20-50% of CRC patients with OMD that underwent R0 surgical resection of their 
metastases [178].  
CRC patients with metastatic sites to the liver and especially the lung appear to have an 
improved prognosis, a longer survival time despite metastatic disease [179]. 
With radical surgical resection of lung metastases, 25-35% of selected patients reached 
a 5-year overall survival [180].  
Although there is no international consensus and no prospective studies regarding the 
strategy for CRC patients with liver metastatases, ESMO guidelines has published 
recommendations [180]. They include the following 3 categories: 
(1) Refers to patients with easily resectable liver metastases with excellent oncological 
prognostic criteria (e.g. limited number of liver lesions, long-term metachronous disease) 
where direct surgery is recommended. No perioperative chemotherapy is recommended 
here due to the negative results of the European Organization for Research and Treatment 
of Cancer (EPOC) trial with no 5-year OS advantage for the perioperative CT group 
compared to surgery-only group. 
The benefit of adjuvant chemotherapy in this category is debated in which some 
evidence indicates benefit for patients with adverse prognostic factors and where ESMO 
recommends adjuvant FOLFOX or CAPOX if the patient has not recently (<6-12 months) 
received adjuvant chemotherapy. 
(2) Recommends perioperative chemotherapy with 3 months preoperative (neoadjuvant) 
and 3 months postoperative FOLFOX or CAPOX regime, for easily resectable liver 
metastatases but only ‘good’ oncological prognostic criteria. Time duration and choice of 
chemotherapy regime is mainly derived from the EPOC trial. 
(3) For easily resectable but ‘bad’ oncological prognostic criteria preoperative FOLFOX 
regime is recommended. 
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The use of bevacizumab, VEGF-targeting antibody, in category (1) and (2) is not 
recommended due to lack of data and no addition of EGFR-inhibitor is recommended for 
categories (1) and (3) based on data from the New EPOC trial [181]. 
In the third (3) category, addition of a monoclonal antibody would be accepted or triple 
chemotherapy, 5-FU/LV combined with oxaliplatin and irinotecan (FOLFOXIRI), plus or 
minus bevacizumab.  
Synchronous metastases are seen in about 20-30% of newly diagnosed mCRC. In the 
cases with synchronous liver metastases the patient is usually recommended perioperative 
chemotherapy as in category (2) or (3), plus preoperative (C)RT for primary rectal cancer if 
needed, even if the liver metastatases is easily resectable and the patient has excellent or 
good oncologic criteria. Surgery is most often done in a two-stage resection with the 
resection of liver metastatases as the first stage and primary tumor resection as the second. 
The liver surgeons present at the mdt conference have guidelines on what liver 
metastases are considered technically R0 resectable, a criteria also being at least a 30% 
future liver remnant must be maintained after resection [182]. 
The goal of conversion treatment with systemic therapy is to induce response in 
unresectable metastatic disease, often liver metastases, aiming to render them resectable. 
An increase in survival duration has been observed in patients who are then able to undergo 
resection compared to patients treated with CT alone. This, in spite the 75% rate of relapse 
later on, most often a hepatic recurrence [180]. 
There are several trials with different chemotherapy regimens that have been used in a 
conversion approach with liver-limited disease but few randomized, controlled trials to help 
identify the most effective regimen [183-189]. 
Based on these trials as well as other trials, ESMO guidelines and Swedish guidelines 
recommend as conversion therapy in RAS wild-type tumors a cytotoxic doublet plus an 
anti-EGFR antibody and in RAS-mutant disease a cytotoxic doublet plus bevacizumab or 
FOLFOXIRI plus bevacizumab [87, 114]. 
The majority of patients who respond to conversion therapy are thought to reach a 
maximal response to the treatment after 12-16 weeks and should thus be evaluated in time. 
Upon response, total therapy duration (pre- and post- surgery) is recommended to be no 
longer than 6 months. 
The procedure of cytoreductive surgery and hyperthermic intraperitoneal 
chemotherapy (HIPEC) is done in CRC patients at specialized centers that have low-
volume peritoneal metastasis, with a peritoneal cancer index (PCI) less than 20, and no or 
limited signs of systemic disease. Standard in Sweden for most of these cases is no 
preoperative chemotherapy but direct cytoreductive surgery, resection of the primary tumor 
as well as resection of peritoneal metastases and affected local ‘organs/ structures’ followed 
by intravenous bolus 5-FU/LV and then heated intraperitoneal oxaliplatin chemotherapy 
[87]. Post-operative adjuvant chemotherapy is based on the histopathological assessment, 
ypTNM and is often recommended if the patient is in good general condition. 
6.2 Palliative Scenario 
Palliative chemotherapy is applied when a patient with stage IV CRC is considered to have 
non-resectable disease. The majority (61%) of patients diagnosed with mCRC are in this 
category. The purpose of palliative chemotherapy is to prolong survival, alleviate 
symptoms and improve quality of life. There are several types of active drugs that are used 
in the treatment of mCRC. 
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6.2.1 Treatment drugs available 
A major component in the treatment of mCRC is chemotherapy with fluoropyrimidines, 
parental (5-FU/LV) and oral (e.g. capecitabine), alone or in combination with oxaliplatin 
or/and irinotecan. Fluoropyrimidines and oxaliplatin are also used in the adjuvant setting as 
mentioned previously.  
Irinotecan which is used in the metastatic setting is a topoisomerase I inhibitor and is 
usually used in combination with 5-FU/LV but also has effect as a single agent in mCRC 
[190, 191]. 
An oral agent, TAS-102 is also available. It contains a combination of active 
ingredients, trifluridine and tipiracil hydrochloride. Trifluridine is a nucleoside analog that 
acts as an antimetabolite that inhibits the enzyme thymidylate synthase as well as after 
modification in the tumor cell causes DNA strand breaks through incorporation into DNA. 
Tiparicil is antiangiogenic and a strong thymidine phosphorylase inhibitor thus inhibiting 
trifluridine metabolism. 
Therapies targeting angiogenesis are: 
• Bevacizumab (a humanized monoclonal antibody inhibiting the vascular 
endothelial growth factor (VEGF). Most commonly used clinically and for which 
there is substantial evidence for its use in first line treatment combination with 
chemotherapy and even in second line treatment. 
Less commonly used in the clinical setting for refractory mCRC: 
• Aflibercept, a fully-humanized recombinant fusion protein with VEGF binding 
parts from the human VEGF receptors 1 and 2 fused to the Fc part of human 
immunoglobulin G1.  
• Ramucirumab (a humanized monoclonal antibody inhibiting the vascular 
endothelial growth factor receptor (VEGFR)). 
Both, aflibercept and ramucirumab, can be used only in combination with FOLFIRI and 
can be considered in patients after progressing on an oxaliplatin-containing regimen and 
who received bevacizumab in the first-line treatment.  
• Regorafenib is an oral active inhibitor of VEGF receptors 1 and 3 as well as 
stromal and oncogenic kinases.  
TAS-102 and regorafenib can be considered for patients with refractory mCRC who still 
remain in a relatively good general condition and have been pre-treated with the available 
cytotoxics, anti-angiogenic, EGFR-antibodies. Both treatments have shown survival benefit 
where TAS-102 is less toxic while regorafenib requires dose adjustment and close 
monitoring due to its toxicity [192-195]. 
Therapies targeting the epidermal growth factor receptor are cetuximab and 
panitumumab. Cetuximab was first developed and is a chimeric human-murine monoclonal 
antibody which binds to the ligand-binding site of the epidermal growth factor receptor 
(EGFR) [196]. Panitumumab which entered the clinical setting in 2006, is an entirely human 
monoclonal antibody that also targets the EGFR but is much less associated with allergic 
and anaphylactic reactions compared to cetuximab. Both are main agents used in the clinic 
in mCRC patients whose tumors are RAS- and BRAF-status wildtype. They are considered 
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equally active as single agents and are used with chemotherapy-doublets, in combination 
with Irinotecan or as single agents [114]. 
Recently immunotherapies, nivolumab and pembrolizumab, which inhibit programmed 
death 1 (PD1) receptors have been presented as a possible treatment for dMMR/MSI-H 
mCRC . 
6.2.2 Oncological treatment  
Although the optimal manner to combine and sequence the agents has not been fully 
established, guidelines are continually evolving based on results of multiple trials and 
clinical experience. Generally, it is considered that the patient gets the best survival benefit 
if exposed to all agents during their treatment period rather than a specific sequence of 
administration. There are however factors to consider when choosing the first line 
treatment and beyond based on the patient’s clinical condition (including age, performance 
status, co-morbidities), tumor burden, tumor location, tumor biology characteristics (RAS, 
BRAF and MMR-status) and treatment characteristics such as toxicity profile, flexibility.  
The OS of mCRC patients receiving no palliative treatment, just best supportive care (BSC) 
is approximately 5-6 months.  
Studies have shown that systemic fluorouracil (FU)-based chemotherapy alone 
improves progression-free survival (PFS) and OS compared to BSC alone [106, 197, 198].  
Although there are no trials comparing BSC to combination chemotherapy of FU with 
oxaliplatin or with irinotecan, the increased survival of over 2 years has been proven in 
clinical trials using these combinations [198]. 
With the advent of biologic agents and the concept of an mdt-managed continuum of 
care, mCRC patients can attain a survival of approximately 30 months. 
An mdt-managed continuum of care entails a 4-6 month 1st line induction therapy, 
upon response followed by possibly maintenance therapy and re-introduction of 1st line is 
possible upon progression or second-line treatment. 3rd line therapy is given upon 
progression of 2nd line and at times even a fourth line treatment thereafter or reintroduction 
of the 1st line therapy depending on the tumor biology and the patient’s general condition. 
6.2.3 First-line therapy 
The choice of a first-line therapy (induction therapy) is individualized where patients that 
are symptomatic, have a large tumor burden and are in need of more aggressive therapy, 
receive at least a doublet plus a biologic or even a triplet if the patient is of younger age and 
fit. The aim is to hinder the rapid tumor progression. Most patients are asymptomatic where 
the aim is to have disease control and prolong survival. 
As first-line FOLFOX, CAPOX or FOLFIRI are considered treatment regimens to 
have similar efficacy [199-204]. If the patient recently completed adjuvant chemotherapy with 
FOLFOX and was then diagnosed with unresectable mCRC the first-line therapy FOLFIRI 
is usually preferred. The combination of capecitabine and irinotecan (CAPIRI) is not used 
clinically due to its low level of evidence [205-207]. 
The triplet cytotoxic combination of FOLFOXIRI (5-FU/LV, oxaliplatin, irinotecan) 
has a superior effect to doublet chemotherapy but due to its increased toxicity is reserved 
predominantly for the younger patients with a good performance status and in need of 
tumor downstaging [203]. 
A known complication of oxaliplatin-based treatment is the cumulative neurotoxicity 
for which no antidote, as of yet, has been found. According to some studies, the majority of 
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patients that discontinue oxaliplatin-based treatment do so due to toxicity rather than 
progressive disease [208, 209]. 
The benefit of adding an antiangiogenic agents, e.g. bevacizumab to chemotherapy is 
greater when it’s given up to tumor progression [208]. 
6.2.4 Epidermal growth factor receptor (EGFR)-inhibitor therapy 
A review and meta-analysis of randomized, controlled trials involving EGFR antibody 
therapy found that mCRC patients with RAS wild type tumors had a significantly better OS 
compared to patients with RAS mutant tumors [210]. A negative prognostic effect was first 
demonstrated for the patients whose tumors harbored a mutation in the KRAS exon 2 
(codons 12/13). Analysis of two mCRC trials with EGFR-inhibition, the PRIME study with 
FOLFOX4 +/- panitumumab and the CRYSTAL study with FOLFIRI +/- cetuximab, as 
well as other clinical similar trials found that mutations in KRAS exon 3 and 4 as well as 
NRAS exons 2, 3, 4 also predicted a negative response to EGFR-inhibition, especially 
when combined with a chemotherapy-doublet containing oxaliplatin [211, 212]. 
Even a BRAF analysis is a prerequisite before considering EGFR-inhibitors. A meta-
analysis found that mCRC patients with BRAF mutant + RAS wild-type tumors had no 
significant added effect of EGFR-inhibition compared to standard chemotherapy alone [213]. 
Thus, a RAS mutation is considered a negative predictive marker in treatment with 
EGFR-inhibition and an expanded RAS analyses, plus BRAF analysis, is a requisite before 
considering this treatment in mCRC patients. 
6.2.5 Treatment breaks 
Trials exploring treatment breaks of palliative chemotherapy in mCRC patients have had 
varying results. A meta-analysis of eight randomized trials between continuous versus 
intermittent treatment, where 4 trials did not use maintenance therapy and 4 employed 
different types of maintenance therapy (fluoropyrimidine alone or with a biologic agent, 
two trials with biologic agent alone), did not show any disadvantage in OS or quality of life 
between the two arms, regardless of maintenance therapy [214]. 
A common guideline is that treatment breaks should not compromise outcome and 
must be individualized where the tolerance and response to the chemotherapy, tumor 
burden, symptomatology and tumor biology are taken into account. Tumors with a BRAF 
mutation have a worse prognosis, more aggressive disease in which treatment breaks are 
less appropriate. 
6.2.6 Tumor location 
Tumor location and its prognostic impact has been investigated in several trials. The right 
colon, extending from the cecum to the distal transverse colon, originates from the midgut 
while the left colon originates from the hindgut and consists of distal transverse colon to the 
rectum [215]. In the majority of studies, left-sided tumors are defined as tumors from the 
splenic flexure to the rectum and right-sided tumors as ones proximal to the splenic flexure 
[216]. About 65% of tumors occur on the left side and 35% on the right side [217]. 
Patient characteristics differ in that right-sided tumors are often more advanced tumors, 
poorly differentiated, mucinous and are more commonly seen in females and in older 
patients [218]. 
Molecular characteristics differ between the right and left colon in which right-sided 
tumors are often MSI-H or have dMMR-status, have a higher tendency to RAS and BRAF 
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mutations and a CIMP-H status while left-sided tumors are associated with the CIN 
pathway and the EGFR (or ErbB) signaling pathway [219]. 
Worse survival has been associated in right-sided tumors compared to left-sided 
tumors in metastatic CRC but not in stage II-III CRC [219-221]. 
A recent meta-analysis that analyzed tumor sidedness with regard to OS and PFS in 13 
first-line clinical trials in mCRC found that the poor DFS in OS in right-sided tumors 
versus left-sided tumors was observed regardless of the chemotherapy regimen and the 
biologic agent [220]. 
A pooled analysis of six 1st-line randomized trials, total of 5760 mCRC cases, also 
confirmed a better prognosis in left-sided tumors compared to right-sided tumors, as well as 
a benefit for chemotherapy plus EGFR-inhibition versus chemotherapy alone or 
chemotherapy plus bevacizumab for left-sided RAS wild-type tumors [222]. 
These findings have prompted a 1st line treatment strategy based on tumor sidedness, 
see Figure 6. [223]. 
 
 
 
Figure 6. 1st-line treatment strategies in mCRC based on RAS/BRAF and sidedness.  
(Reprinted, with permission, from Sandhu et al, J Surg Oncol 2019) 
MT, mutated; WT, wild-type; Cmab, Cetuximab (EGFR-inhibitor); FOLFIRI, fluorouracil, leucovorin and 
irinotecan; FOLFOX, fluorouracil, leucovorin and oxaliplatin; Pmab, Panitumumab (EGFR-inhibitor) 
6.2.7 Immunotherapy 
Positive results from clinical trials that used the check point inhibitor, anti-PD1 therapy, in 
refractory dMMR or MSI-H mCRC has led the U.S. Food and drug Administration (FDA) 
to approve in May 2017, pembrolizumab ((Keytruda®) after progression to prior treatment 
with conventional chemotherapy and biologic agents [224]. 
Positive results have also been reported for another PD-1 inhibitor, nivolumab 
(Opdivo®), in patients with dMMR mCRC in a report from the Checkmate 142 phase II 
study [225]. In 2018, FDA approved the use of nivolumab (Opdivo®) plus ipilimumab 
(Yervoy®, a CTLA-4 inhibitor) in dMMR/MSI-H mCRC that has progressed after 
treatment with standard chemotherapy drugs. 
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Of interest will be the results from the phase III study, KEYNOTE-177 which 
randomizes pembrolizumab versus investigator choice of chemotherapy for dMMR/MSI-H 
first-line therapy in mCRC [226]. 
There are about 5% of mCRC that have a dMMR/MSI-H status and not all of them 
respond to checkpoint inhibitor treatment. The challenge remains in identifying further 
predictive markers of immunotherapy efficiency as well as finding newer agents 
/modalities alone or in combination with PD-1 inhibitors that may benefit these patients but 
also patients with pMMR/MSS tumors. 
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7 PROGNOSTIC / PREDICTIVE FACTORS IN CRC 
Factors or biomarkers can be prognostic or predictive and at times both. A prognostic 
factor is a patient characteristic or a patients tumor characteristic that identifies subgroups 
of patients having different outcomes. It provides an estimation of disease outcome. A 
factor that predicts treatment effect, i.e. a predictive factor, is a patient characteristic or a 
tumor’s characteristic that identifies subgroups of treated patients having different 
outcomes due to the treatment. 
Validated and clinically established prognostic and/or predictive tissue-based factors in 
CRC are RAS-status, BRAF-status, MMR-status. They are in part discussed in the chapter 
pertaining to molecular pathogenesis of colorectal cancer as well as colorectal cancer 
treatment. They will be further discussed in this chapter.  
Tumor location which is considered to have prognostic value and potentially a 
predictive value has been discussed in the mCRC treatment section. 
This chapter will provide focus on the already established prognostic/predictive factor 
of MMR-status but also on the potential prognostic/predictive factors of TS protein 
expression, tumor budding, tumor border configuration and T-cell infiltration on primary 
CRC. 
7.1 RAS, BRAF and Other Potential Factors 
A critical pathway in the regulation as well as the proliferation and survival of cancer cells 
in CRC and other cancers is the mitogen activated protein kinase (MAPK) pathway. The 
pathway has an intracellular signalling cascade consisting of RAS, RAF, MAPK 
extracellular signal-regulated kinase (MEK) and extracellular signal-regulated kinase 
(ERK1/2). It is known that activating mutations in RAS and RAF will activate this pathway 
[227].  
KRAS mutations found in about 35-45% in CRC, occur primarily in codon 12 and 13, 
appear at a relatively early stage in tumorigenesis and are associated with tumors derived 
by the CIN pathway. Mutations in NRAS are found in about 4% of cases and in HRAS in 
about <1% of cases [227]. 
Implications of a RAS mutation in the treatment of a patient with mCRC have been 
discussed previously.  
The BRAF mutation which occurs in about 10% in CRC, is associated with the MSI, 
CIMP and the serrated pathway. More than 80% of BRAF mutations are caused by a single 
mutation in nucleotide 1799 (T-A), known as BRAF-V600E, changing the amino acid from 
valine to glutamic acid in the BRAF protein. This results in a constitutive activation of 
BRAF [228]. 
As mentioned previously BRAF mutations in CRC are associated with a shorter PFS 
and OS. 
The Epidermal Growth factor (EGFR) also known as ErbB-1 or HER1 belongs to a 
family of ErbB receptors, among then HER2/neu (ErbB-2), Her 3 (ErbB-3) and Her 4 
(ErbB-4).  
EGFR-mediated signalling pathways include the RAS-BRAF-MEK-ERK1/2 (MAPK 
pathway), the PI3K-AKT-mTOR /PTEN as well as the JAK – STAT3-STAT3/STAT3 
pathway. The insulin growth factor-1 receptor (IGF-1R) and the human epidermal growth 
factor receptor 2 (Her2) can also activate the MAPK pathway and the PI3K pathway. 
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Loss of phosphatase and tensin homolog (PTEN) reverses the activation of the PI3K 
pathway by dephosphorylating 3,4,5-triphosphate (PIP3) to 4,5-biphosphate (PIP2).  
Mutations in PIK3CA are observed in CRC in approximately 8-9% of cases [227]. 
Unlike melanoma patients, the attempt to treat patients with mCRC and harboring a 
BRAF-V600E mutation with Braf-inhibitor was not successful. The mechanism behind this 
is believed to be the overactivation and crosstalk of the parallel pathway, PI3K-AKT-
mTOR with the MAPK pathway. Even an EGFR activation can contribute to this [229].  
Patients with RAS and BRAF mutated mCRC have restricted treatment options. There 
are no RAS inhibitors available for patients with RAS-mutated mCRC. For these patients 
and to some extent for patients with BRAF-mutated tumors, preclinical data supports dual 
target inhibition of MEK as well as one or more of the PI3K effectors as future treatment 
options for these patients. 
An interesting finding in preclinical data is the activation of the Wnt pathway in KRAS 
and BRAF mutated tumors treated with MEK inhibitors. A possibility in the future could 
be combining inhibition of the Wnt pathway (i.e. with cyclosporine) with MEK1/2 
inhibition [230]. Figure 7 illustrates the above named signaling pathways in CRC [230]. 
 
 
Figure 7._ Cell signaling pathways in colorectal cancer. (Reprinted, with permission, from Moorcraft et al, 
Therap Adv Gastroenterol 2013) 
AKT, protein kinase B; APC, adenomatous polyposis coli; EGFR, epidermal growth factor receptor; ERK, 
extracellular signal-regulated kinase; Fz, Frizzled receptor; HER2, human epidermal growth factor receptor 2; 
IGF, insulin-like growth factor; mTOR, mammalian target of rapamycin; MEK, mitogen-activated protein 
kinase kinase; MYC, v-myc myelocytomatosis viral oncogene homolog (avian); PI3K, phosphoinositol 3 
kinase; PTEN, phosphatase and tensin. 
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7.2 MMR  
One of the best-defined biomarkers for primary colon cancer is DNA MMR status. The 
function of the MMR enzymatic process which recognizes and repairs DNA damage as 
well as the concept of MSI that results from MMR defect is described earlier in section 2.3. 
Close to 15% of CRCs, stage II and III, display MSI which is due to a defective MMR 
system most often caused by hypermethylation of the MLH1 promoter [231]. In cases of the 
Lynch syndrome it is caused by autosomal dominant constitutional mutations in DNA 
MMR. Identification of a dMMR is done by IHC as described in section 9.2 while MSI is 
diagnosed via PCR method (described briefly in section 2.3.1). Sporadic MSI-H/dMMR 
CRC is associated with an activating BRAF mutation while Lynch syndrome is associated 
with wildtype Braf status. In advanced CRC, stage IV, approximately 4-5% of tumors have 
dMMR/MSI-H status [231]. 
Focus on MMR status assessment is due to its role in Lynch syndrome detection as 
well as its prognostic role in CRC and its more debated predictive role of chemotherapy. 
More recently it has also gained predictive significance in advanced CRC where dMMR-
status or MSI-H cancers have responded to immunotherapy with immune checkpoint 
inhibitor when compared to p-MMR status or MSS cancers.  
The association of a higher density of T-cells in dMMR/MSI-H status CRC is believed 
to be explanatory to these findings [232, 233]. 
7.2.1 MMR -status as a prognostic factor 
A better prognosis for dMMR CRC compared to pMMR has been demonstrated in several 
studies in which most used the PCR technique for MSI-assessment [234]. Studies evaluating 
MMR-status as a prognostic factor are heterogeneous with a blend of colon cancer to CRC, 
they are mostly retrospective studies, only a few are randomized trials and they use 
different chemotherapy regimens. 
 
Stage II-III: 
The first systematic review and meta-analysis from Popat et al, 2005 included 32 mostly 
retrospective studies with 7642 cases [121]. It included different stages (stage I-IV) in which 
the majority of the patients were from stage II-III. They found 1277 (16.7%) cases with 
MSI-H status and an overall improved OS was found for MSI-H compared to MSS (HR 
0.65, 95% CI 0.59-0.71). No benefit from adjuvant 5-FU was found for patients with stage 
II MSI-H (HR 1.24, 95% CI 0.72-2.14). A second systematic review and meta-analysis 
from Guastadisegnia et al, 2010 included 31 studies with 12,782 cases where 1899 (14.9%) 
had MSI-H status [235]. Most studies were retrospective and seven of the studies were 
randomized. As in the Popat meta-analysis, they also found that MSI-H correlated with an 
improved DFS and OS and that MSS tumors had a significant beneficial effect of 5-FU 
therapy (OR 0.52, 95% CI 0.4-0.6, p<0.001).  
A study from our group on MMR-expression on CRC stage II-III (randomized Nordic 
adjuvant trials) also found that a dMMR-status was an independent prognostic factor in 
sporadic CRC [236]. 
The prognostic effect of MSI was also retrospectively analyzed in 1404 cases, 210 of 
them with MSI-H (15%), included in the adjuvant PETACC-3 trial, stage II-III colon 
cancer randomized to 5-FU/LV alone or 5-FU/LV + irinotecan (FOLFIRI). MSI-H colon 
cancer was associated with a better relapse-free survival (RFS) and OS compared to MSS 
colon cancer [237]. The same patient material from the PETACC-3 trial was also later 
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analyzed by Klingbiel et al in 190 patients with MSI-H CRC and found a superior OS and 
RFS in stage II MSI-H CRC patients compared to MSS CRC patients [238]. Further analyses 
after adjustment for KRAS and BRAF v600E mutations showed the survival advantage for 
MSI-H versus MSS was for tumors located in the proximal colon but not in the distal 
location [239]. In their analysis the positive effect for patients with stage III MSI-H CRC 
seems to be limited to CRC in which a constitutional defect caused the MSI. Thus, it 
emphasizes to control for Lynch syndrome with germline analysis when needed. 
In another retrospective analyses of randomized adjuvant trials (5-FU/LV +/- 
oxaliplatin) from NSABP with colon cancer stage II-III showed that dMMR was prognostic 
for recurrence compared to pMMR/MSS CRC patients but that MMR status was not 
predictive of oxaliplatin efficacy [240, 241]. Analysis of 986 patients from the MOSAIC 
adjuvant stage II-III colon cancer trial, randomized between 5-FU/LV alone versus 
FOLFOX found 95 (9.6%) patients with dMMR tumor status. A better DFS from FOLFOX 
compared to 5-FU/LV was found for a small number of cases with a dMMR status [242]. 
A more recent trial with 443 patients with dMMR colon cancer, randomizing 5-FU/LV 
versus FOLFOX in stage II-III CRC, found an improved DFS for FOLFOX only in stage 
III tumors and sporadic cases [124]. Retrospective analysis of 314 patients with MSI-H, 
KRAS-wild type stage III colon cancer in the NCCTG randomized CRC adjuvant trial 
between FOLFOX +/- cetuximab (anti-EGFR antibody) showed improved DFS in cases 
with tumors located in the proximal colon compared to the distal colon [243]. Adjustment 
was done in the analysis for prognostic factors including KRAS, BRAF mutations. The trial 
did not show a survival advantage for the addition of cetuximab [131]. 
Another recent study of 1250 patients with stage I-III colon cancer in which 138 
had tumors with dMMR/MSI-H status, found MSI-H was associated with a reduced 
risk of nodal and distant metastases and a better DFS in stage I-II compared to stage I-II 
MSS [244]. In stage III, dMMR/MSI-H status was associated with worse pathological 
features and survival than pMMR/MSS . 
7.2.2 MMR -status as a predictive factor 
Stage II-III: 
Ribic et al published in 2003 a retrospective analysis of 5 randomized trials comparing with 
or without adjuvant 5-FU chemotherapy in patients with MSI-H colon cancer (n=95) of the 
total of 570 cases [245]. They showed that 5-FU treatment benefited patients with stage II or 
stage III with MSS/MSI-L colon cancer but not patients with MSI-H colon cancer. 
A large retrospective analysis supported this finding in which 253 patients with MSI-H 
CRC (mostly stage I-III with some stage IV cases) were found in the total of 1263 cases 
and no improvement of survival by adjuvant 5-FU treatment was found for MSI-H CRC 
patients [246]. The meta-analysis by Des Guetz et al with 6 studies of stage II-III CRC with a 
total of 3254 patients, of which 454 were MSI-H (14%) also found for MSI-H patients that 
there was no significant difference for RFS whether or not they received 5-FU 
chemotherapy [247]. A significant interaction between MSI status and therapeutic status was 
found which suggests a decreased 5-FU benefit for MSI-H compared to MMS status. 
Further corroboration to this finding was done by Sargent et al’s retrospective analysis of 5 
randomized clinical trials in stage II-III colon cancer between adjuvant 5-FU versus no 
adjuvant treatment [123]. For patients with MSI-H or dMMR tumors no benefit was found 
for adjuvant 5-FU in both stage II and stage III. A significant interaction was found 
between MMR status and treatment efficacy for DFS. However, authors from the studies 
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caution that this finding is to be interpreted with caution and to not omit standard 5-FU-
based chemotherapy from stage III /MSI-H or dMMR CRC. 
The first prospective trial showed that patients with CRC and dMMR status did not 
seem to benefit from 5-FU-based chemotherapy [248]. 
A study (QUASAR, multicentre trial) that did not show MMR-status to be a predictive 
marker, analyzed 1913 stage II-III CRC patients (218, 11.4% MSI-H) and the patients were 
randomized between adjuvant 5-FU or no adjuvant treatment. In their analysis, rate of 
recurrence (ROR) was significantly lower with adjuvant 5-FU than in the observation 
group. No marker, including MMR-, KRAS-, BRAF-status predicted benefit from adjuvant 
chemotherapy [249].  
One systematic review and meta-analysis from 2015, analyzed 14 studies, 9312 
patients with CRC (mostly stage II-III) in which 1398 had MSI-H status (15%) receiving 
single or mixed 5-FU-based regimens [250]. They concluded that the effect of 5-FU was not 
statistically significant for DFS or OS in MSI-H and therefore MSI was not a predictive 
marker. Included in this meta-analysis was the study from our group on MMR-expression 
on CRC stage II-III (randomized Nordic adjuvant trials) that did not find MMR-status to 
predict survival benefit from adjuvant 5-FU-based chemotherapy [236]. 
In conclusion, although there are some conflicting reports it is recommended to test 
MMR-status for patients with stage II CRC since they appear not to benefit from adjuvant 
5-FU chemotherapy. The prognostic significance of a dMMR/MSI-H status in stage II 
CRC is more confirmed and accepted. It is still unresolved as to why the impact of an MSI-
H status is different between stage II and stage III CRC and whether 5-FU chemotherapy is 
harmful in stage II dMMR/MSI-H CRC.  
7.2.3 Role of MMR-status in mCRC 
There are fewer studies on the role of MMR-status in mCRC. The better prognosis and 
assumed protective effect of a dMMR/MSI-H status in earlier stage CRC seems to diminish 
in advanced CRC [251]. 
One study explored the impact of BRAF mutation and dMMR/MSI-H status in mCRC 
in which of 524 patients 57 (11%) of them were BRAF-mutated [252]. The patients with 
BRAF mutated tumors had a poorer survival compared to BRAF wild type tumors as well 
as higher rates of peritoneal metastases and distant lymph node metastases and lower rates 
of lung metastases. In the study the patients with MSI-H tumors compared to the patients 
with MSS tumors had significantly poorer survival (11.1 months vs. 22.1 months, 
p=0.017). However, this difference was not observed in the BRAF mutant group. Thus, the 
poorer survival in mCRC seen in dMMR/MSI-H patients is most likely ‘associated’ with 
the negative effect of a BRAF mutation [253]. 
In 152 dMMR/MSI-H mCRC cases deriving from a pooled analyses of four phase III 
first-line treatment studies a worse DFS and OS was observed compared to pMMR/MSS 
mCRC [254].  
An interesting observation is that recurrent CRC with a dMMR/MSI-H status has a 
lower response to conversion therapy. A theory is that chemoresistance may be due to the 
dMMR/MSI-H status [255]. 
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7.2.4 Predictive role of dMMR/MSI-H for immunotherapy 
A groundbreaking discovery for mCRC was the success of checkpoint inhibitors in 
dMMR/MSI-H. Thus MMR-status is now considered a predictive factor for immune 
therapy.  
The improved prognosis in early stage dMMR/MSI-H CRC is thought to be due to the 
pronounced T cell infiltration. Defect in MMR causes hypermutations and increases the 
tumor neoantigen load, or the tumor mutational burden, which elicits an immune response.  
In MSI-H mCRC it is believed that the process of adaptive resistance is triggered in 
which active T cells (Th1/CTL) and the tumor microenvironment cause a compensatory 
induction of checkpoints that protect the tumor from immune-mediated elimination [256]. 
More information on immune therapy is found in the section of immunotherapy 6.2.7. 
7.3 Thymidylate Synthase (TS) 
TS protein expression and mRNA levels in CRC have been the subject of research for 
many years due to its relationship to DNA synthesis and its role as a target of 5-FU. 
TS is the rate-limiting target cytosolic enzyme of the necessary precursor of DNA 
synthesis (Figure 8) [257], 2’-deoxythymidine-‘5’-monophosphate (dTMP) and the primary 
target of 5-FU, capecitabine, UFT as well pemetrexed and ralitrexed. The mechanism of 5-
FU and the function of TS are reviewed in detail in section 4.2.1. As TS is a crucial part of 
the de novo source of dTMP, its inhibition results in the cessation of cellular proliferation 
and growth. 
 
 
Figure 8. The thymidylate biosynthesis pathway. (Reprinted, with permission, from Wilson et al, Nat Rev 
Clin Oncol 2014) 
 
TYMS, the human gene coding for the 36 kDa homodimeric TS protein, is located in the 
telomeric region on the short arm of chromosome 18, band 18p11.32 [258]. The TYMS gene 
contains a variable number of 28-base pair tandem repeats (VNTR) in the 5’untranslated 
region (UTR) that acts as an enhancer to the TYMS promoter [259]. It is proposed that three 
different polymorphisms in the UTR region act as modulators of TS mRNA transcriptional 
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and translational efficiency [260]. The majority of TS alleles carry either 2 or 3 VNTR 
repeats which define genotypes as 2R/2R, 2R/3R and 3R/3R [104]. 
About 25% of European patients are TYMS 3R/3R homozygous which increases 
TYMS expression and are less likely respond to 5-FU-based chemotherapy. The TYMS 
2R/2R homozygous genotype, which decreases TYMS expression is seen in 20% of 
European patients [261]. 
An increase in 5-FU cytotoxicity may thus be caused by low TYMS expression, 
reducing the expression of the target TS and thus lowering the threshold to inhibit 
pyrimidine biosynthesis while a high TYMS expression may decrease the 5-FU 
cytotoxicity. 
The QUASAR2 study in which 927 patients with CRC were treated with the oral 5-FU 
prodrug, capecitabine, showed that toxicity was associated with the TYMS polymorphism 
2R/3R and 3’UTR6bp insertion-deletion and with the DPYD alleles 2846T>A and *2A 
[262]. 
There are no prospective trials studying whether pre-emptive TYMS genotyping is 
helpful in guiding fluoropyrimidine treatment management. Guidelines do not endorse 
TYMS genotyping and it is not performed in clinical practice. 
TS transcription is regulated by several protein factors in which overexpression of 
E2F-1 seems to result in a TS mRNA and protein level increase [263]. The E2F gene family, 
in particular E2F-1, has a central role in regulating the transition in the cell cycle from G1 
to S phase. TS is mostly active during the S-phase of the cell cycle [264]. The transcription 
factor, E2F-1, represses gene transcription when bound to the retinoblastoma (RB) protein 
as well as other corepressor molecules in nonmitotic cells. Upon loss of RB function, a 
constitutive induction occurs of E2F-1 genes that encode DNA synthesis enzymes, among 
them TS as well as DNA polymerase α and others. Rahman et al studied whether TS is a 
downstream effector of E2F-1 and thus might participate in the oncogenic pathway. They 
discovered that overexpression of TS resulted in neoplastic transformation in murine cells 
in vivo and in vitro and upon removal of serum containing survival factors, apoptotic cell 
death occurred [265].  
Studies have shown that tumor cells have higher levels of TS mRNA than normal cells 
and this seems to correlate with a negative outcome [266].  
Increased levels of TS protein levels as well as resistance to drugs targeting TS is 
caused by TS gene amplification, increased stability of the TS protein and translational 
derepression [267]. 
TS has been for several years, the subject of research as a potential prognostic and 
predictive marker in colorectal cancer. 
7.3.1 Prognostic value of TS 
Results from studies of the prognostic value of TS in the adjuvant CRC setting have been 
mixed. The majority of studies on mCRC have shown high TS levels to be associated with 
a poorer outcome [268]. 
A meta-analysis that included adjuvant as well as mCRC analyzed seven studies with 
regard to TS’s prognostic value in the adjuvant setting (n=2610 patients) and thirteen 
studies (n=887 patients) in the metastatic setting [269]. All of the studies included were based 
on retrospective analysis and in 14 of the 20 studies treatment was given within a clinical 
trial. Smaller sample size was used in the metastatic studies with a median of 48 compared 
to the sample size of 184 in the adjuvant studies. In two of the adjuvant trials in which one 
of them is one of our previous studies, patients were randomized to either surgery alone or 
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surgery followed by adjuvant therapy [270, 271]. In one study, adjuvant treatment was given 
postoperatively to all patients [272] while in another study no postoperative adjuvant 
treatment was given [273]. The other 3 adjuvant studies were heterogeneous which included 
surgery alone, immunotherapy and chemoimmunotherapy [274-276]. 
All of the adjuvant studies in the meta-analysis used IHC as the TS evaluation method 
in which six studies used the TS106 monoclonal antibody as in our TS studies and one used 
a polyclonal antibody and an enzyme assay to evaluate TS [275]. In five of the seven 
adjuvant studies, TS expression was related to chromagen intensity and all adjuvant studies 
graded 0-2 as low and 3-4 as high levels of TS expression. One study [276] also graded high 
as grade 3 alone which we also did in our TS studies (Paper I, II) [277]. The median 
proportion of cases with high TS levels in the adjuvant setting was 50% (range 19%-77%) 
and was similar to the median proportion in the metastatic setting of 53% (range 14%-
80%).  
In the metastatic setting TS evaluation was more varied in which IHC was used in six 
cases, reverse transcriptase polymerase chain reaction (RT-PCR) in 5 cases, enzyme assay 
in one case and both IHC and enzyme assay in one case.  
The conclusion of the meta-analysis was that tumors expressing high levels of TS seem 
to have a poorer OS compared to tumors with low levels where the combined HR for OS 
was 1.35 (95% CI, 1.07-1.80) in the adjuvant situation and 1.74 (95% CI: 1,34-2.26) in the 
metastatic situation. However, one has to consider that there may be publication bias, 
underpowered studies, heterogeneity with methodology and TS scoring between the 
studies.  
A study done in our group by Öhrling et al, investigated whether TS expression in 
lymph node metastasis in stage III CRC was a prognostic marker [278]. In the entire study 
group (n=348) a significantly longer OS and DFS was correlated with low TS expression in 
the lymph node metastasis (multivariate, p=0.02 OS, p=0.04 DFS). In subgroup analysis, it 
was only a significant prognostic marker for patients in the surgery alone arm (OS p=0.04; 
DFS p=0.03) but not in the adjuvant chemotherapy arm. This could be due to adjuvant 
chemotherapy having a positive effect on tumors with high TS expression thus reducing 
DFS and OS differences between the arms. 
A recent prospective analysis of TS as a biomarker for primary colon cancer showed 
that high tumor TS levels were associated with better DFS and OS compared to low levels 
[279]. Their study population was derived from two adjuvant studies, C89803 and C9581. 
The C89803 trial randomized 1,264 patients with stage III colon cancer to either 
postoperative adjuvant 5FU/LV or 5FU/LV plus irinotecan (IFL) [125]. The C9581 trial 
randomized 1,738 patients with stage II colon cancer to postoperative treatment with 
edrecolomab (an antibody inhibiting EpCAM) versus observation alone [280]. TS data was 
available for 435 (25%) patients with stage II and 463 patients (37%) with stage III. IHC 
using the monoclonal antibody TS106 was used for TS analysis and scoring with 0-1 as 
low and 2-3 as high. They also used an automated TS quantitative analysis (AQUA) for the 
C89803 cases. It measured TS localized in the nucleus, cytoplasm, sum of the two and ratio 
as continuous measurement. For all the 898 patients with TS available, 52% had high TS 
levels which is similar to the levels from other studies [269]. Substage analysis showed a 
significant difference with 44% high TS in stage III and 60% in stage II. In the entire group 
of 898 patients, patients with high TS expressing tumors had a DFS HR of 0.67, 95% CI 
(0.53-0.84) and OS HR of 0.68, 95% CI (0.53-0.88), log rank p=0005. TS was not 
significant in multivariable analysis of OS. 
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7.3.2 Predictive value of TS 
The majority of studies have used IHC as the methods for assessment of TS expression.  
There are conflicting results concerning the predictive value of TS in the CRC adjuvant 
setting. 
Several studies, including Paper I in the thesis, have shown in primary CRC treated with 
adjuvant 5-FU chemotherapy that a high TS expression in the primary tumor seems 
predictive of a better outcome [275, 277, 281-287].  
However, in five studies, in which the majority also assessed TS with IHC, no 
difference was found between low and high TS expression and their response to 5-FU 
adjuvant treatment [268, 270, 274, 276, 288]. In a study with neoadjuvant 5-FU therapy given to 
stage II-III rectal tumors, a better response was observed in patients whose tumors 
expressed low TS (analyzed using RT-PCR) [289]. Another study also showed a better 
response for adjuvant 5-FU in low TS expressing stage II-III CRC [290]. This study used in 
contrast to the other studies TMA instead of whole tissue assessment with IHC and could 
thus underestimate the presence of high TS expression in some areas of the tumor. 
A recent prospective analysis mentioned earlier, with patients derived from two 
adjuvant trials, found that TS expression did not predict benefit of 5-FU based 
chemotherapy [279]. The predictive value of TS has been more convincing in studies done on 
mCRC.  
In most mCRC studies in which the majority are retrospective, a low TS expression in 
the metastases has been associated with a better response to 5-FU [291-302]. Most studies 
tested TS in lesions from the primary tumor. One study that tested TS expression in the 
metastasis as well as the primary tumor found that low TS was predictive for response with 
assessment from the metastasis but not from the primary tumor [303]. 
Three studies did not find that TS expression in the primary tumor predicted response 
to 5-FU-based chemotherapy in advanced CRC [303-305]. 
One prospective study in mCRC patients (n=58) receiving either 5-FU/LV plus 
oxaliplatin or irinotecan, analyzed TS and DPD expression and did not find that low TS 
expression in the metastasis correlated with a better outcome [306]. 
In another prospective mCRC trial, tumor material (91 from liver lesions, 37 from the 
primary lesion) from 128 patients was analyzed for TS mRNA expression levels with 
reverse transcriptase polymerase chain reaction (RT-PCR) technique [307]. They found 82 
patients (64%) had high TS and 46 patients (36%) had low TS. Patients in the low TS 
category as well as the high TS category were randomized to either 5-FU/folinic acid and 
irinotecan (FOLFIRI) or 5-FU/folinic acid (FUFA). They found a trend to a better overall 
response to FOLFIRI compared to FUFA in the TS high group (p=0.077). In the liver 
biopsy group with high TS expression, there was a significant better overall response for 
the FOLFIRI treatment (p=0.035). In the low TS group no difference in overall response 
was found between FOLFIRI and FUFA treatments. 
The most recent prospective study, the phase II Eastern Cooperative Oncology Group 
(ECOG) E4203 trial, selected treatment for previously untreated mCRC patients based on 
tumor TS expression determined in mCRC tissue by IHC staining [308]. Of 186 eligible 
patients, 127 (68%) had high TS expression (score 2+ or higher) and 59 (32%) had low TS 
expression (score 0-1). The high TS group was randomized to either irinotecan and 
oxaliplatin plus bevacizumab (IROX/Bev) (n=61) or 5-FU/LV, leucovorin, and oxaliplatin 
plus bevacizumab (FOLFOX/Bev) (n=66) while the low TS group (n=59) received 
FOLFOX/Bev. The theory behind the treatment choice was that low TS tumors would 
respond better to a 5-FU/LV treatment combination than the high TS tumors. In summary, 
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TS expression was prognostic. Patients with low TS tumors receiving FOLFOX/Bev had a 
longer PFS and a trend to a longer OS, than patients with high TS tumors. No difference in 
benefit was seen between IROX/Bev and FOLFOX/Bev for the patients with high TS 
tumors. 
7.4 Tumor Budding 
Tumor budding is defined in literature as individual tumor cells or groups of up to four or 
five cells that are detached from the main tumor mass at the tumor invading front [309-311]. It 
is also known as peritumoral tumor budding and is observed in about 20-40% of CRC cases 
[312]. It was first recognized in the 1950s, described then as “sprouting” at the invasive edge 
of the tumor, and was thought to correlate with an increase in tumor growth rate. The term 
“tumor budding” was used first in a CRC study by Hase et al in 1993, in which they 
demonstrated a significant decrease in 5-year and 10-year survival rates with increasing 
budding [313]. Tumor budding was first used as a histopathological marker to estimate the 
aggressiveness of rectal cancer [309]. Studies and meta-analyses in CRC have demonstrated 
since then that tumor budding is an independent histopathological prognostic risk factor for 
a poorer outcome, especially in primary tumor stage II-III [311, 314-323]. 
7.4.1 Molecular background on tumor budding 
Tumor buds are believed to be in a partial epithelial-mesenchymal transition (EMT)-like-
state. EMT is a development regulatory ‘program’ that is thought to be the process by 
which transformed epithelial cells acquire a mesenchymal phenotype with the ability to 
invade, resist apoptosis and disseminate [324]. EMT involves epithelial cells losing cell to 
cell adhesion. A characteristic of mesenchymal cells is the increased expression of 
extracellular proteases and transcription factors (e.g. snail, slug, twist) that in turn stimulate 
cells to produce collagen, fibronectin, vimentin, α-smooth muscle actin [325]. Degradation of 
the extracellular matrix by metalloproteases and disruption of the basement membrane 
allows cancer cells to move along the matrix. A conversion from an epithelial to a 
mesenchymal state is complex with several steps and intermediate phenotypes. A 
‘hallmark’ of EMT is the loss of the membranous localization of the adherens junction 
molecule, E-cadherin [326]. E-cadherin has been reported as a potential biomarker for 
colorectal cancer [327]. β-catenin interacts with E-cadherin at the adherens of epithelia. The 
loss of E-cadherin interaction with β-catenin is thought to result in nuclear translocation of 
β-catenin and activation of the Wnt signaling pathway, a process seen in the CIN-pathway 
of carcinogenesis [325], (see section 7.4.1, Figure 2). Disturbance of E-cadherin expression 
as well as the loss of cell membrane B-catenin expression is commonly observed in tumor 
buds [325].  
Thus, a dysregulation of the Wnt-pathway contributes to cancer progression by 
disruption of cell adhesion and migration. The Wnt signaling pathway also has a role in the 
initial activation of stem cells, stem cell maintenance as well as crypt homeostasis [328]. A 
future therapy in CRC could be one targeting the Wnt-pathway.  
Tumor buds are linked to partial-EMT and not a complete-EMT profile since they 
express some EMT-related markers but their association with increased levels of 
mesenchymal markers is not conclusive [325]. 
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7.4.2 Tumor budding methodology 
Tumor budding can be underestimated due to factors such as active fibroblasts in the 
desmoplastic stroma that liken tumor buds as well as dense inflammatory infiltrate that can 
obscure tumor budding cells [329, 330].  
To avoid this underestimation many studies on tumor budding in CRC have used pan-
cytokeratin IHC to highlight the tumor buds [329, 331-334]. 
Studies have shown that tumor budding is underestimated when using hematoxylin and 
eosin (H&E) compared to IHC [329, 335]. 
Prall et al, showed in stage I-II CRC that IHC with MNF116 discovered more high-
grade tumor budding (59/186) than H&E (26/186) [329]. 
There has been a lack of standardization with regard to the field-of-view depending on 
the microscope used as well as specifying the area (mm2) analyzed. Choice of tumor field 
has varied from overall tumor, entire advancing edge and field of maximum tumor 
budding. 
Different approaches have been used as to whether tumor budding should be 
categorized subjectively or qualitatively, semi-quantitatively or with a specific count and 
cut-off. The cut-off of what should be considered high-grade tumor budding versus low-
grade tumor budding has been varying and acquired with different methods. Figure 9 
illustrates the different approaches [336]. 
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Figure 9. Visualisation of proposed tumor budding scoring systems. (Reprinted, with permission, from 
Lugli et al, British journal of cancer 2012). 
(A,B) According to Hase et al, 1993 [313] 
(C,D) According to Nakamura et al, 2005 [337] 
(E,F) According to Ueno et al, 2002 [309] 
(G) Recommended by Lugli et al, one high-power field average [336] 
(H) Recommended by Lugli et al 2012 [336] 
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Puppa et al, 2012 studied the reproducibility of five tumor budding assessment methods 
among 10 investigators, using H&E and AE1-3 cytokeratin stained whole-slide digital 
scans from 50 pT1-T4 CRC [338]. They found in general a fair level of diagnostic agreement 
for tumor budding that was significantly higher in early cancer as well as among 
experienced gastrointestinal pathologists. Interestingly, cytokeratin IHC did facilitate 
detection of tumor buds but it did not affect interobserver agreement. 
A review by Zlobec, 2013 [339] as well as a review by De Smedt, 2016 [312] recommends 
using a 10-HPF method on pan-cytokeratin-stained sections established by Karamitopolou 
et al, 2013 [340] as this method had the best inter-observer agreement. This method used the 
cut-off 10 tumor budding cells determined by receiver operating characteristic curve 
analysis with OS as end-point [340]. Paper IV in the thesis has adapted this method for tumor 
budding assessment. 
Irrespective of which scoring system is used to quantify tumor budding, studies have 
shown that the more tumor buds identified by histological evaluation in CRC, the worse the 
prognosis [311]. The potential clinical value of tumor budding assessment is hindered by the 
lack of its universal implementation in diagnostic practice. This is due in large part due to 
the absence of standardization of tumor budding evaluation. However, the International 
Tumor Budding Consensus Conference (ITBCC) held in 2016 has reached a consensus that 
is evidence-based with a standardized scoring system for tumor budding in routine practice 
[341]. The guidelines recommend using H&E slides and analysis of tumor budding in one 
hotspot field with a specific size of 0.785mm2. Classification of tumor budding is then done 
into three categories with low budding defined as 0-4 buds, intermediate budding (5-9 
buds) and high budding (≥10 buds). 
The recent AJCC 8th edition as well as the College of American Pathologists guidelines 
now include tumor budding as an optional reporting field [342].  
7.4.3 Tumor budding in malignant polyps, preoperative biopsy 
Multiple studies have shown that in malignant colorectal polyps (pT1) tumor budding is 
associated with an elevated risk to develop lymph node metastases [343-346]. 
Two studies showed a significant decrease in survival when high grade tumor budding 
was present in pT1 CRC [309, 313]. 
Tumor budding can also be present within the tumor and is referred to as intratumoral 
tumor budding. It is used especially in preoperative biopsies and has shown that tumor 
budding is associated with the presence of lymph node metastasis, a higher tumor grade, 
lymphovascular invasion, in the resected specimen and distant metastasis [344, 347-350]. 
Poor response to neoadjuvant therapy in rectal tumors was observed for patients whose 
preoperative biopsy showed presence of intratumoral tumor budding [347]. 
Due to these findings the National Comprehensive Cancer Network (NCCN), version 
2.2017 has added tumor budding as something to be considered in clinical treatment and 
cautions against polypectomy as an adequate treatment for pT1 malignant polyps with 
signs of tumor budding [351]. 
7.4.4 Tumor budding stage I-II 
An association was observed in resected stage I CRC, pT1/2 N0 M0 between high grade 
tumor budding and an increase in risk for lymph node metastasis [343, 346, 352, 353]. 
A main research focus is on tumor budding and stage II CRC in order to determine if 
high-grade tumor budding should be a factor to be considered in treatment decision of 
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adjuvant chemotherapy. Stage II CRC is a diverse group with differing survival in which 
survival can differ from stage IIA (T3N0M0) in colon cancer with 66.5% to rectal cancer 
stage IIC (T4bN0M0) 32.3% and a worse survival for colon cancer stage IIb (T4aN0M0) 
compared to stage IIIa (T1-T2 N1/N1cM0) [342, 354]. 
Several studies despite different methods of tumor budding assessment and scoring 
have shown that tumor budding in stage II CRC is an adverse prognostic factor, associated 
with poor DFS and OS [313, 329, 355-361]. 
One of the studies by Koelzer et al had a prospective cohort that also determined high 
grade tumor budding to be a negative factor for survival in stage II [358]. 
7.4.5 Tumor budding stage II-III 
Several studies combine stage II-III CRC or at times stage I-IV in their analysis of tumor 
budding. While tumor budding is regarded as a marker of tumor progression even in more 
advanced (stage III) and metastatic CRC (stage IV), its role in clinical practice has to be 
further investigated.  
One study that explored tumor budding solely in stage III CRC with 447 patients, 
using H&E slides and a x200 field of densest budding and a cut-off of ≥9 buds as high-
grade tumor budding, found no association between tumor budding and survival outcome 
[362]. A study done recently with stage III colon cancer (n= 150) and using the 
recommended ITBCC guidelines for tumor budding assessment found tumor budding to be 
an independent variable that predicted recurrence [363]. 
Two studies on rectal cancer, both using H&E slides and densest tumor budding area 
in x200 field, found high grade tumor budding to be associated with decreased OS [309, 364]. 
One of the studies included stage I-III (n=638) and had a cut-off of 10 [309] while the other 
included stage II-III (n=90) and had a cut-off of >25 [364]. 
A study including stage I-IV CRC (n=381) using H&E slides, a x200 field and cut-off 
of 10 found tumor budding to be associated with an unfavorable outcome in cancers with 
mucinous differentiation [365]. 
Another study prospectively including stage I-IV CRC (n=299) and pan-cytokeratin 
staining slides with a x400 field found high grade tumor budding to limit PFS [366]. 
One study of Karamitopoulou et al, also using stage I-IV CRC (n=215) and pan-
cytokeratin stained slides as well as the 10-HPF method in x400 field with a cut-off of 10, 
showed good prognostic relevance for tumor budding [340]. Paper IV in the thesis has 
implemented the tumor budding assessment method from this study. A larger study with 
553 patients with CRC, stage I-IV, using H&E slides in a x200 field with a cut-off of 10 
buds also confirmed a prognostic significance for tumor budding [367].  
7.4.6 Tumor budding in mCRC 
Tumor budding has not been extensively studied in mCRC. One study determined that 
tumor budding was associated with poor response to EGFR-inhibition therapy in mCRC 
[368]. Presence of tumor budding in CRC was a prognostic factor for lung metastases [337]. 
7.5 Tumor Border Configuration 
The histomorphological feature of tumor border configuration or the growth pattern at the 
invasive margin in CRC, should not be confused with tumor budding in which tumor 
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budding is diagnosed at high magnification while tumor border configuration is more easily 
diagnosed, even on standard H&E slides, at a lower magnification [369]. 
An infiltrative growth pattern is characterized by tumor tissue disrupting the anatomic 
structures of the bowel wall and has little or no desmoplastic stromal reaction, including the 
absence of T-lymphocytes [370, 371]. The expansive or pushing growth pattern displays a 
distinct boundary between tumor and host tissue where a desmoplastic stromal reaction 
with the presence of T-lymphocytes is more commonly observed [370, 372, 373]. 
Classification of tumor border configuration has been described as either infiltrative or 
pushing/expansive by Jass et al [374] or as a three-tier system of infiltrative, intermediate or 
expansive by Morikawa et al [375]. An invasive tumor border configuration can be focal and 
not involve the complete tumor border which leads to variability of interpretation. In study 
IV we chose to analyze tumor border configuration by the Morikawa method in which the 
tumors classified as infiltrative had an unambiguous infiltrative growth pattern throughout 
the entire tumor border. In order to establish tumor border configuration in daily diagnostic 
practice, a more standardized consensus of its quantification is required. 
An infiltrative tumor border configuration in CRC is considered a stage-independent 
negative prognostic indicator indicating an aggressive tumor with a higher risk for nodal 
and distant metastasis [371, 375-380]. 
Studies in CRC have shown that tumors with an infiltrative tumor border configuration 
often have high grade tumor budding which suggests an inter-relation in their biological 
formation [379, 381].  
Association of an infiltrative tumor border configuration and other adverse molecular 
alterations / clinicopathological features including BRAFV600E mutation [375] and vascular 
invasion has also been described [379, 380].  
The pMMR status in CRC is associated with an infiltrative tumor border configuration 
while the expansive one is associated with a dMMR status, especially in Lynch tumors [372, 
373, 382].  
A study by Zlobec et al on stage II-III CRC with pMMR-status showed that an 
infiltrative tumor border configuration was associated with a higher local recurrence 
compared to an expansive tumor border configuration independent of CD8+ TILs and 
lymph node status [378]. Morikawa et al showed that tumor border configuration was an 
independent prognostic factor independent of peritumoral lymphocytic infiltration [375]. 
 To further identify patients with high risk of recurrence and optimize a therapy 
approach, the AJCC recommends assessment of tumor border configuration for transmural 
invasive CRCs, especially stage II tumors. Due to inconclusive data it is not yet 
recommended for early stage CRC, stage I [369].  
7.6 T-lymphocyte Infiltration in CRC 
7.6.1 Background on immune system  
The immune system plays an important role in preventing occurrence of cancer. The 
immune host response has been of interest especially in terms of tumor infiltrating immune 
cells [383, 384]. 
Histopathological reports confirm that colorectal cancer tissue is invaded by immune 
cells from the host. The immune microenvironment and the immune response towards the 
tumor is created when the CRC neoplasia invades through the muscularis mucosa into the 
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submucosa causing a local host reaction with the accumulation of proinflammatory cells 
along the tumor margin [385]. 
The immune system is said to be an effective “gate-keeper” against cancer in normal 
conditions. The initial antitumor activity is mediated by the innate immune system entailing 
effector cells like Natural Killer cells (NK), neutrophils and macrophages. Thereafter a 
specific adaptive immunity is activated generating memory cells, B and T cells. T cells can, 
in general, be classified as helper T cells (Th cells, CD4+) or cytotoxic T cells (Tc cells, 
CD8+). Of special importance is the differentiation of naïve CD4+ Th cells into Th1 cells 
that produce interferon gamma (IFN-γ), promoting CD8+ T cell-mediated adaptive 
immunity. The presentation of tumor antigens by dendritic cells (DCs) to CD4+ Th cells 
occurs via the Major Histocompatibility Complex (MHC) class II complex and to CD8+ Tc 
cells via the MHC class I. T-cell activation requires not only presentation and recognition 
to the antigen presented by the antigen presenting cell (APC) but also activation of 
costimulatory molecules (CD80/CD28, CD40/CD40L) and cytokine recruitment 
(interleukin (IL)-1, IL-2, IL-6, IL-12, IFN-γ) [384, 386].  
While activated CD8+ Tc cells (effector T cells) are able to recognize and lyse tumor 
cells by perforin and granzymes, activated CD4+ Th cells are able to modulate the 
antitumor response into a Th1 response or a Th2 response [387]. 
An antitumor response is promoted by a Th1 response and a pro-tumor response seems 
to correlate with a Th2 response. The CD3 complex serves as a T cell co-receptor which 
associates with the T cell receptor (TCR) and is useful as an identifier of T cells in general 
by CD3 antibody staining with IHC [388]. A CD45R0+ T cell refers to a subset of T cells 
that are memory T cells. Specifically, they are experienced T cells that have previously 
encountered an antigen and can upon a second encounter reproduce a fast and strong 
immune response. 
It is still however debated whether the immune system eliminates continuously arising 
transformed cells. The timely elimination of pathogens and inflammation seems to be 
important so as to prevent the establishment of a constant inflammatory environment 
conducive to tumorigenesis [383, 384]. The tumor immunoediting concept explains why 
tumors still develop despite an active tumor immune surveillance in which the immune 
system specifically identifies and eliminates tumor cells on the basis of tumor-specific 
antigens or molecules induced by cellular stress. The three phases involved in tumor 
immunoediting, termed the 3 Es of tumor, are: elimination (cancer immune surveillance), 
equilibrium (cancer persistence) and escape (cancer progression) [389]. 
There is gaining evidence supporting the theory that cancer cells may escape the 
immune host responses by two mechanisms: immunoselection, selection of non-
immunogenic tumor cell variants, and immunosubversion, active suppression of the 
immune response [328, 383]. Immunoselection refers to the induction of central or peripheral 
tolerance [390]. Central tolerance is when self-reactive T cells are deleted or converted to a 
regulatory phenotype in the thymus. Peripheral tolerance is seen when tumor growth can 
induce T cell tolerance in the periphery by mechanisms such as deletion, induction of 
antigen unresponsiveness, change of Tcell response. 
Immunosubversion can be attributed to the tumor microenvironment such as 
expression of T-cell inhibitory molecules (such as B7-H1, HLA-G) by tumor cells, tumor 
antigen loss or downregulation of MHC molecules and suppressive factors such as 
transforming growth factor (TGF-β), VEGF, IL-10, indoleamine 2,3-doxygenase (IDO) 
expressed by tumor cells [383]. 
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7.6.2 Immune response in CRC  
Evidence for CRC immunoediting in humans is found in MSI tumors. Tumors with 
dysfunctional MMR genes (such as MLH1, MSH2) give rise to an accumulation of 
mutations that are not repaired in microsatellite repetitive DNA sequences thus resulting in 
microsatellite instability (MSI). As mentioned previously the MSI form of genetic 
instability is believed to be involved in the development of 10-15% of sporadic CRC. MSI 
tumors are often seen to be infiltrated by cytotoxic T lymphocytes (CD8+ T cells) and the 
presence of lymphoid follicles are common [232, 233].  
Studies have shown that primary CRC patients with a dMMR status, or MSI status, 
have a better OS compared with patients with a pMMR tumor or MSS tumor [121, 246]. A 
theory is that the MSI defect causes high levels frameshift mutations potentially generating 
antigenic peptides thereby inducing the adaptive immune response (CD8+ T cells) which 
would then limit tumor growth and metastases [384].  
An improved prognosis has been noted for patients with tumor infiltration by T cells, 
NK cells or NK T-cells for several tumor types [383]. Tumors with chronic inflammation and 
the presence of M2 macrophages seemed however to favor tumor growth and spreading 
[391]. The M2 macrophages secrete cytokines IL-4, IL-10, IL-13 and TGFβ and have an 
anti-inflammatory role as well as promoting angiogenesis. In contrast, M1 macrophages 
have a pro-inflammatory role, they secrete pro-inflammatory cytokines (IL-1, IL-6 and 
TNF) and are able to release reactive oxygen and reactive nitrate species. 
The clinical importance of host response has been of interest especially in terms of 
tumor infiltrating immune cells. The presence of tumor infiltrating lymphocytes (TILS), 
where they can be found in the stroma, peritumoral and intratumoral areas, has been 
associated with decreased involvement of blood, lymph vessel and lymph node 
involvement [392]. 
The role of Treg cells is much debated in CRC as well as in other tumors due to 
conflicting reports. They are CD4+ and CD25+ T cells and express the nuclear 
transcription factor, Forkhead box P3 (FoxP3) by which they can be identified. The antigen 
specificity of TIL Treg cells is not yet established in humans. A theory is that the tumor 
microenvironment may influence them to be detrimental when blocking anti-tumor effector 
T cells or beneficial when decreasing chronic inflammation [384]. 
Poor prognosis in CRC has been associated with the presence of Th17 cells 
[393]. 
7.6.3 Tumor infiltrating lymphocytes (TILS) in CRC  
Several studies in cancer as summarized in a meta-analysis have demonstrated that a better 
prognosis is associated with the presence of peri- and intratumoral T cells (CD3+TH1 cells, 
CD8+cytotoxic T cells, CD45RO+ memory cells) [394]. 
In CRC all subsets of T cells are present both at the core and at the invasive margin of 
the tumor. The density of CD4+ memory T cells and CD8+ memory T cells (cytotoxic T 
cells) is decreased in T4-stage tumors (advanced local tumor invasion) compared with T1-
stage tumors (limited local tumor invasion) [395]. Tumors seem to recur less if the primary 
tumor had high infiltrates (especially in the core) of CD4+ and CD8+ memory T cells [384, 
394]. 
In stage II and III CRC an improved outcome is observed, less disease recurrence and a 
better OS, as the amount of intratumoral CD8+ T cells (cytotoxic) and memory T cells 
increased [396]. A better DFS and OS in high-risk stage II and stage III colon cancer was 
predicted by a higher quantity of lymphocytes in the tumor samples [397, 398]. 
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CRC studies on stage II-III have shown a favorable outcome with higher CD3+ 
densities [399-403] or in both CD3+ and CD8+ [404] where four of these studies provided 
multivariate analyses which confirmed an independent prognostic value [399, 401-403]. 
One of these studies analyzed 587 patients stage I-II with CRC that had an MSS profile 
and found a high density of CD8+ to be an independent factor for better cancer specific 
survival (CCS) [403]. 
Two studies analyzing stage I-IV CRC showed a high density of CD8+ was correlated 
with an independent CCS [405] and OS [385]. One study analyzing CD3+ and CD8+ in stage 
I-IV, CRC was prognostic in univariate OS analyses but not in multivariate [406]. A study 
investigating in tissue microarrays (TMA) CRC stage II-III (n=445), Treg (FOXP3+) as 
well as CD8+ and CD45R0+ found that high density of Treg FOXP3+ in normal mucosa 
was associated with an independent adverse outcome while a high density in tumor tissue 
was associated with a better outcome [407]. They found high density of CD8+ and CD45R0+ 
to be prognostic only in univariate analyses, not in multivariate analyses. A similar larger 
study by Nosho et al studying CD3+, CD8+, CD45R0+ and Treg (FOXP3+) and using 
TMA, in stage CRC I-IV (n=768) found high densities of CD3+, CD8+, Treg (FOXP3+) to 
be prognostic of survival in univariate but not multivariate analyses while high densities of 
CD45R0+ were independently prognostic for survival [408]. 
In their multivariate analyses they adjusted for several molecular features such as 
KRAS, BRAF, PIK3CA mutations, MSI, CIMP and LINE-1 hypomethylation, all of which 
are associated with prognosis. They also found that MSI-H and LINE-1 methylation level 
are independent predictors of CD45R0+-cell density. Thus, the study supports the 
implication that a better survival due to a MSI-H profile could be due to tumor-infiltration 
of T-cells, specifically CD45R0+ T-cells. 
Other studies in CRC, including stage I-II [409], II [410], III [411], and I-IV [409, 412] have 
also reported an improved survival with CD45R0+ cell density but have not adjusted to the 
molecular features named in the Nosho et al study [408]. One study evaluated DFS in 
patients (n=149) with colon cancer stage I-IV (I=43 patients, II=56 patients, III=34 
patients, IV=16 patients) with regards to MMR-status and T-lymphocyte infiltration. They 
found a 5-year DFS of 59% for patients with pMMR or MSS tumors with no T-lymphocyte 
infiltration compared to DFS of 79% for patients with dMMR or MSI-H tumors with 
present T-lymphocyte infiltration [413]. The presence of a high lymphocyte density, 
measured using immune score, is indicative of a better prognosis in patients with CRC and 
seems more accurate than MMR-status itself [414]. 
7.6.4 Assessment of immune infiltrate  
The Klintrup--Mäkinen (KM) grade has been used to assess the generalized inflammatory 
cell infiltrate at the tumor invasive margin in CRC. It has in studies shown prognostic value 
and is a semi-quantitative measurement done in H&E slides. It applies a 4-point scale 
ranging from low grade with no increase or mild increase in inflammatory cells to high 
grade with a prominent inflammatory reaction [415, 416]. 
Another method to assess T-lymphocyte infiltration, specifically CD3+ and CD8+ 
done by Ogino et al and Dahlin et al is also the method used in Paper IV [417, 418]. The 
method entails IHC of CD3+ and CD8+ T-cells that are then semi-quantitatively assessed 
under light microscope in representative areas at the invasive tumor front, tumor center and 
within the tumor epithelium. These 3 areas are scored according to score 1 as no or 
sporadic infiltration, score 2 as moderate infiltration, score 3 as abundant infiltration and 
score 4 as highly abundant infiltration. For each case the mean value of the added scores for 
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the subsites is then used to establish a total score for CD3+ and CD8+ T-cells. The total 
score with a range of 3 to 12, is then categorized as low expression (3-4), intermediate (5-6) 
or abundant (7-12). 
The immunoscore (IS) method that also assesses densities of CD3+ and cytotoxic 
CD8+ Tcells by IHC has recently been internationally validated for colon cancer in a study 
done by Pagès et al [419]. The CD3+ and CD8+ T-cell densities are evaluated in the tumor 
and in the invasive margin but differs from the other methods in that quantification is done 
by digital pathology. A specially developed IS module integrated into an image-analysis 
system is used. The IS for each patient is calculated from the mean of four density 
percentile. The three-category IS analysis is scored with density of 0-25% as low, 25%-
70% as intermediate and 70-100% as high while a two-category IS density of 0-25% is low 
and density of 25-100% as intermediate plus high. 
The goal of the study was to establish IS as a reproducible, objective and robust 
method compared to manually assessing density of TILS which is subjective and less 
reproducible. The study in which 13 countries participated, analyzed IS in 2681 patients 
with stage I-III colon. The patients were divided into three sets, the validation set of 700 
patients, the internal validation set of 636 patients and the external validation set of 1345 
patients. A high level of reproducibility was observed between the observers and the 
centers. The finding in the training set of patients with a high IS having an independent 
significant lower risk of recurrence was validated in the two validation sets. It was 
independent to age, sex, T stage, N stage, MMR status and existing prognostic factors 
(p<0.0001). In stage II (n=1424 patients), the high IS patients had a significantly less 5-
year risk of recurrence compared to the low IS patients (HR 0.33, 95% CI 0.21-0.52, 
p<0.0001; Cox multivariable p<0.0001). 
Even a previous large CRC study with more than 4000 patients measuring density of 
CD3+ and CD8+ T cells using the method IS has validated the method and demonstrated 
that it was a stronger predictor of patient survival than MSI [414].  
Thus, the IS is considered reliable and has possibly a higher contribution than the 
TNM-classification as an indicator for risk of recurrence of colon cancer. It strongly 
supports its implementation as a component of a TNM-Immune classification. 
7.6.5 Immune checkpoint  
Tumors have the ability to suppress an immune response by acquiring characteristics to 
escape detection or through activation of negative regulatory pathways that are called 
‘checkpoints’ which are in turn key players in immune homeostasis [420, 421]. 
The treatment care of a number of malignancies which include melanoma, non-small-
cell lung cancer, renal cell carcinoma has been revolutionized by immunotherapy. Positive 
results have been noted in dMMR/MSI-H mCRC when using immune checkpoint 
inhibitors, nivolumab a PD-1 blocking antibody or ipilimumab, a CTLA-4-blocking 
antibody. 
Attention is especially focused on these two checkpoints, the cytotoxic T-lymphocyte 
protein 4 (CTLA4) and the programmed cell death protein 1 (PD-1). Activated T-cells 
express the cell-surface receptor PD-1 which can then bind to one of two ligands, PD-L1 
and PD-L2 [422]. The PD-L1 ligand is expressed by tumor cells and immune cells after 
cytokine (e.g. interferon-γ) exposure. Expression of the PD-L2 ligand occurs for the most 
part on dendritic cells in normal tissue. An inhibitory signal is produced which impairs T 
cell activity. CTLA4 is a homolog of the co-stimulatory molecule CD28 which is only 
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expressed on activated CD4 and CD8+ T cells but is also constitutively expressed in Tregs. 
It competes with CD28 for binding to the shared ligands CD80 or B7.1 and CD86 or B7.2.  
Anticancer immunity requires certain conditions to be effective. Three types of 
phenotypes have been identified by examining histological sections of tumor biopsies. 
They reflect specific underlying biological mechanisms. One phenotype is the ‘immune-
desert tumor’ which is due to immunological ignorance, induction of tolerance or failure of 
appropriate T cell priming / activation. The immune-excluded tumor phenotype is caused 
by specific chemokine state, presence of barriers or vascular factors or stromal inhibition. 
The third phenotype is the ‘inflamed tumor’ in which infiltration of a variety of immune 
cells (including CD4 and CD8 T cells, myeloid cells, monocytic cells) and 
proinflammatory / effector cytokines are demonstrated. This scenario is believed to indicate 
an arrested pre-existing antitumor immune response that has been immunosuppressed in the 
tumor bed [422].  
Response to anti-PD-1/PD-L1 therapy occurs mostly in patients with ‘inflamed’ 
tumors [423]. The presence of PD-L1 on infiltrating immune cells and at times tumor cells 
has been demonstrated [424]. A notable up-regulation of check point inhibitors such as PD-1, 
PD-L1, CTLA-4, LAG-3 and IDO has been demonstrated in the tumor microenvironment 
of MSI-H cancers [256]. 
In CRC the tumors with a dMMR/MSI-H status are often shown to be ‘inflamed’ with 
the infiltration of T-cells which accounts for a higher probability that they will respond to 
anti-PD1/PD-L1 or anti-CTLA4 therapy. Figure 10 illustrates mechanism of immune 
checkpoint inhibitor therapy [234]. 
 
 
 
Figure 10. Mechanism of Immune Checkpoint Inhibitor Therapy. (Reprinted, with permission, from Ryan 
et al, Crit Rev Oncol Hematol 2017) 
Before immunotherapy (top picture), the tumor cell’s PD-1 ligand (PD-L1) molecule (red) binds to T-cells enabling 
the tumor cell to evade destruction by the immune system. 
With immunotherapy (bottom picture), an anti-PD-1 inhibitor (green) blocks PD-L1 binding, thus enabling the T cell 
to target the tumor cell. Although, in this figure, the tumor cell is drawn as the source for the PD-L1, in some tumors 
such as dMMR/MSI-H CRC the main source may be macrophages or other TILs and myeloid cells). 
 
The PD-L1 expression in MSI-H CRC has been found on TILS and/or myeloid cells, not 
on tumor cells [425].  
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8 AIMS OF THE THESIS 
The overall aim of this thesis is to identify prognostic and predictive factors in primary 
CRC, stage II-III, so as to better define which patients, especially in stage II, would benefit 
from adjuvant chemotherapy. 
 
Specific aims: 
I. To analyze thymidylate synthase (TS) expression in primary CRC, stage II-III, as a 
prognostic / predictive factor of benefit for adjuvant chemotherapy. 
II. To investigate if a combined rather than a single marker analysis of MMR-status 
and TS expression has a prognostic advantage and predicts response to 5-FU-based 
chemotherapy in stage II-III colon cancer. 
III. To assess whether tumor budding grade in pMMR and dMMR primary CRC 
differed with regard to the development of local recurrence or metastases.  
IV. To study the prognostic value of tumor budding, tumor border configuration and T-
cell infiltration in stage II-III colon cancer with known MMR-status. 
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9 MATERIALS AND METHODS 
9.1 Patients and Sample Material 
 
Paper I to IV 
The primary tumor samples analyzed for Paper I-IV were collected from patients who were 
included in the adjuvant CRC Nordic trials [426]. 
A total of 2224 patients with stage II-III CRC were randomized in the adjuvant Nordic 
trials to either surgery alone or surgery followed by 5-FU-based adjuvant chemotherapy 
during the period 1991-1997. Adjuvant chemotherapy was started within 11 weeks of 
surgery. Patients up to the age of 75 years were included.  
Data censoring occurred at 120 months and follow-up ended November 2004. 
The 1389 patients in Paper I, 716 patients in Paper II, 134 patients in Paper III and 478 
patients in Paper IV are recruited from the original 2224 patients. See flow chart in Figure 
11. 
All of the studies performed for this thesis are retrospective. 
Tumor samples were retrieved from a total of 52 hospitals, 50 from Sweden och 2 from 
Denmark.  
Parameters of clinical outcome were obtained from 6 Regional Cancer Centers in 
Sweden for studies in Paper I-IV and for studies in Paper I-II data for the included Danish 
patients was obtained from one Danish center of epidemiological oncology. 
In Paper I, results of the analyses of 862 patients with CRC, stage II-III were 
previously reported by Edler et al [270]. Additional analyses of 527 specimens was 
performed for Paper I in order to achieve a larger group of patients (1389 patients) and a 
longer follow-up time. 
In Paper II and IV only colon cancer Stage II-III was analyzed so as to avoid 
confounding factors such as pre-irradiated tumors. 
Paper III was an exploratory study which was limited by the few available dMMR 
cases that developed recurrence or distant metastases. To increase available cases, rectal 
cancer was included, though only non-irradiated ones. The groups (see Figure 11) were 
matched according to age, gender and treatment arm.  
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Abbreviations: TS, thymidylate synthase; MMR, mismatch repair; dMMR, deficient MMR; pMMR, 
proficient MMR; RT, radiation therapy; met-, did not develop metastases or recurrence; met+, developed 
metastases or recurrence; Group 2*: index group identified and then matched to groups 1, 3 and 4 
according to age, gender and treatment; **Edler et al [270]; ***Öhrling et al [236] 
Figure 11. Patient Flow Chart for Paper I-IV. 
 
For our studies (Paper I-IV) the tumor specimens obtained have been formalin-fixed, 
paraffin embedded tissue blocks. 
Two sections, one section from each of the two available paraffin-embedded tissue 
blocks), each 4 µm-thick, were taken from different parts of the tumor for the TS and 
MMR IHC analysis.  
For the tumor budding analyses in Paper III and Paper IV as well as for the tumor 
border configuration and T-cell infiltration, two paraffin blocks representing the tumor 
invasive regions were available for the majority of the cases. The respective sections which 
were stained with H&E were reviewed by investigators (DE MH) for Paper III and by 
investigator/pathologist (AM) for Paper IV. One section/block per case with the maximum 
tumor invasion was then chosen before performing immunohistochemical analysis. 
The number of tumor material obtained for TS analyses and MMR analyses was 
dependent on what was submitted by the treating institutions that participated in the Nordic 
trials. For studies in Paper III-IV less tumor material was available as some paraffin tumor 
blocks had been returned to the original treating institutions. 
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For Paper I-II the 6th edition of the AJCC staging system was used. The 7th was used 
for Paper III-IV. 
A pathologist (AM) histologically reviewed the cases for Paper IV and contributed to 
the addition of mucinous status as well as T-stage. 
Patient and tumor characteristics for Paper I-IV are summarized in Table 7. 
The studies, Paper I-IV were approved by the ethics committee at Karolinska Institutet, 
Stockholm. 
 
Table 7. Patient and tumor characteristics Paper I-IV. 
Characteristics Paper I Paper II Paper III Paper IV 
Total 1389 716 134 478 
Age: Median 
 Below median 
65 
635 (46%) 
66 
354 (49%) 
66 
67 (50%) 
66 
229 (48%) 
Gender: Male 
 Female 
782 (56%) 
607 (44%) 
379 (53%) 
337 (47%) 
69 (51%) 
65 (49%) 
257 (54%) 
221 (46%) 
Tumor site: Colon 
 Proximal Colon 
 Distal Colon 
 Distal Colon + Rectum 
 Rectum 
984 (71%) 
 
 
 
405 (29%) 
 
389 (54%) 
327 (46%) 
 
71 (53%) 
 
63 (47%) 
 
266 (56%) 
212 (44%) 
Stage: II 
 III 
678 (49%) 
711 (51%) 
356 (49%) 
360 (50%) 
43 (32%) 
91 (68%) 
225 (47%) 
253 (53%) 
No. analyzed LN:  <12 
 ≥12 
 Unknown 
896 (88%) 
123 (12%) 
370 
459 (86%) 
72 (14%) 
185 
84 (80%) 
21 (20%) 
29 
293 (85%) 
53 (15%) 
132 
Tumor grade: G1 (well diff) 
 G2 (moderately diff) 
 G3 (poorly diff) 
 Unknown 
87 (6%) 
958 (73%) 
274 (21%) 
70 
57 (8%) 
489 (71%) 
144 (21%) 
26 
6 (5%) 
90 (68%) 
36 (27%) 
2 
44 (10%) 
323 (71%) 
88 (19%) 
23 
Treatment: Surgery alone" 
 Plus adjuvant CT 
708 (51%) 
681 (49%) 
370 (52%) 
346 (48%) 
62 (46%) 
72 (54%) 
255 (53%) 
223 (47%) 
TS Grade: 0-1 (low) 
 2-3 (high) 
 0-2 (low) 
 3 (high) 
399 (29%) 
990 (71%) 
929 (67%) 
460 (33%) 
 
 
443 (62%) 
273 (38%) 
  
MMR-status: dMMR 
 pMMR 
 Missing data 
 142 (20%) 
574 (80%) 
62 (46%) 
72 (54%) 
90 (20%) 
364 (80%) 
24  
Tumor budding: <5 (low) 
 ≥5 (high) 
 <10 (low) 
 ≥10 (high) 
  *64 (48%) 
*70 (52%) 
*101 (75%) 
*33 (25%) 
 
____________ 
**346 (72%) 
**132 (28%) 
Tumor border configuration: 
 Infiltrating 
 Pushing + mixed 
    
192 (40%) 
286 (60%) 
Total CD3 Score: 3-4 (low) 
 5-6 (intermediate) 
 7-12 (high) 
   113 (24%) 
237 (49%) 
128 (27%) 
Total CD8 Score: 3-4 (low) 
 5-6 (intermediate) 
 7-12 (high) 
   148 (31%) 
222 (46%) 
108 (23%) 
Abbreviations: CT, chemotherapy; diff, differentiation; LN, lymph nodes; MMR, mismatch repair;  
*tumor budding grading in Paper III; **tumor budding grading in Paper IV 
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9.2 Method Immunohistochemistry (IHC) 
A common method to detect specific proteins in histological intact tissue is the method of 
IHC. It applies the concept that antibodies, immunoglobulins created by the immune 
system, can be produced that bind to these specific proteins and are then visualized by a 
reagent attached to the antibody.  
It is a technique that has been used since the 1940s and is routinely used as a critical 
tool in health care and pathology for diagnostic purposes as well as for optimizing a 
patient’s treatment. Although visualization of targets in tissues using IHC is an established 
method, it is important that new assays require optimization depending on the tissue 
analyzed as well as the target protein [427]. 
It is the chromogenic stain that can be observed in light microscopy and be used to 
semi-quantitatively determine protein expression and has the stability allowing it to be 
reviewed years later.  
The advantage of IHC on tissue slides compared to the method of tissue microarray 
(TMA) which uses limited tumor tissue, is that it allows for a visual presentation of the 
target as well as the expression pattern among heterogeneous cell populations. 
Choice of antibody to detect the correct molecule of interest with good specificity and 
affinity is of importance in order to have a reliable interpretation of the assay. Optimization 
and titration of the antibody concentration is needed. If too much antibody is added it will 
increase the possibility of low-affinity off-target binding occurrences while too little 
antibody can lead to a false negative result. 
The two main types of antibodies used are the monoclonal or the polyclonal. 
Monoclonal antibodies bind to the same epitope while polyclonal antibodies bind to 
different epitopes on the target. The advantages of using polyclonal antibodies are that they 
are often very potent and can outweigh potential background noise but the disadvantage is 
their limited resource as they are derived from animal sera. Monoclonal antibodies are 
produced in hydridoma cell lines providing the advantage of continuity of production and 
are often well defined as to their epitope binding site. One still though has to be aware in 
cases of low specificity or if the target epitope is present in low amounts. 
 
The method of IHC was used in Paper I-IV 
The procedure entails that tissues upon retrieval from the patient are formalin fixed in 
paraffin-embedded tissue blocks so as to preserve epitopes and morphology as well as to 
prevent degradation. The paraffin blocks are then sectioned using a microtome into thin 
slices, about 4-10µm. In our studies 4µm slices were used. The slides are then mounted 
on glass slides, dried at room temperature and then baked for about an hour at 60ºC. 
Retrieval of the desired antigen or epitope requires first demasking of the epitopes so 
as to allow the primary antibody to bind its target. The first step is deparaffination of the 
tumor sections using xylene followed by rehydration in ethanol and washing in distilled 
water. This was done for all of the tumor sections included in Paper I-IV. 
The tumor slides (for Paper I-IV: TS MMR and MNF-116) were then incubated 
in 3% hydrogen peroxide to inhibit endogenous peroxidase activity. 
Retrieval of the antigen is carried out in citrate or EDTA buffer for 20 minutes in a 
microwave oven followed by 20 minutes of cooling at room temperature. This part of the 
process breaks down the molecular cross links formed by formalin fixation. 
For Paper I-II, regarding the TS expression analysis and in Paper III-IV with 
MNF-116 staining, citrate buffer (pH 6.0) was used for antigen retrieval while for 
Paper II-IV, regarding MMR expression analysis, 1mM EDTA (pH 9) was used. 
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Thereafter an overnight incubation (e.g. at 4ºC for TS and MMR analysis, Paper I + 
Paper I-IV) is done with the specific primary antibody. See section 9.2.1. 
Before incubation with the primary antibody in the TS analysis (Paper I-II), the slides 
were then blocked with 1.5% horse serum (same species as secondary antibodies) to reduce 
nonspecific background staining. 
After incubation with the primary antibody, the samples are rinsed and then incubated 
with the secondary antibody. 
 
This entailed for: 
➢ TS (Paper I-II): incubation with biotinylated horse antimouse secondary 
antibodies for 30 min, at room temperature. 
➢ MMR (Paper II-IV): incubation for 30 min at room temperature with an 
amplification system with a labelled polymer, EnVisionTM*/HRP rabbit/mouse 
and goat/rabbit, (DakoCytomation, Denmark). 
➢ MNF-116 (Paper III-IV): incubation for 30 min at room temperature with the 
amplification system (EnVision + System-HRP Dako A/S, EnVisionTM*, 
Dako, CA, USA). 
 
*EnVision system: a two step procedure where after primary antibody is added the 
polymeric conjugate in EnVision consists of peroxidase molecules and secondary antibody 
molecules bound directly to an activated dextran backbone. The stepwise procedure is 
meant to eliminate the problem of endogenous biotin [428]. 
Upon binding of the biotinylated secondary antibody to the primary antibody, the 
reaction of peroxidase with biotin causes visible staining 
The next step done in IHC analyses for Paper I-IV was to visualize the sites of bound 
peroxidase. Therefore, slides were washed and immersed in 0.05% 3,3’diaminobenzidine 
tetrahydrochloride (DAB), a chromogen, which is converted into a brown / bluish 
precipitate at the site of the reaction. The last step is counterstaining with hematoxylin 
which stains cellular cytoplasm a pale bluish color and stains cell nuclei a darker blue thus 
facilitating observation of histological features. See Figure 12 for an illustration of IHC. 
 
 
Figure 12. Indirect IHC. 
 
In Paper IV the IHC procedures for staining CD3+ and CD8+ T cells involved a staining 
machine (Ventana BenchMark Ultra, Ventana Medical Systems, Inc., Tucson, AZ, USA) 
utilized with the CC1 standard pretreatment and the iVIEW DAB detection kit (Ventana 
Medical Systems, Inc.) for visualization. 
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9.2.1 Primary antibody in PAPER I-IV 
9.2.1.1 TS 
The primary antibody we used to determine TS protein expression in Paper I-II as well as 
the previous TS study by Edler et al [270] was a mouse monoclonal antibody TS106 that 
detects TS of human origin (produced by NeoMarkers, Fremont, CA, USA), used at a 
dilution of 1:75. 
Data did not show any disadvantage between using the monoclonal TS antibody versus 
the also available polyclonal rabbit-antihuman TS antibody [429]. 
9.2.1.2 MMR 
The primary antibody used was a mouse immunoglobulin G monoclonal antibody: 
MLH1 (clone G 168-15; used at dilution 1:100), supplied by PharMingen, ,San Diego, CA, 
USA 
PMS2 (clone A 16-4; used at dilution 1:75), supplied by PharMingen, San Diego, CA, 
USA 
MSH2 antibody (clone FE-11; used at dilution of 1:100), supplied by Oncogene, 
Research Products, Boston, MA, USA. 
9.2.1.3 Tumor budding 
For Paper III and IV IHC was performed to aid in the detection of tumor budding by 
staining pan-cytokeratin with monoclonal mouse antibody MNF-116, used at dilution 1:75, 
produced by DakoCytomation, Glostrup, Denmark. 
9.2.1.4 T-cell, CD3 and CD8 
In Paper IV IHC was done to detect CD3+ T cells and CD8+ T cells with the primary 
polyclonal CD3 antibody (used at dilution of 1:50), produced by Dako, Glostrup, Denmark) 
and the primary polyclonal CD8 antibody (Clone C8/144B, used at dilution 1:50), 
produced by Dako, Stockholm, Sweden. 
9.2.2 Other methods to measure TS, MMR 
The testing methods to determine a defect in MMR include besides IHC, PCR (touched 
upon in section 2.3.1) and next-generation sequencing. Which method is used is determined 
by the institutional availability. 
Next generation sequencing is becoming more available at academic institutions, 
hospitals and even for commercial use. It entails more of a broad genomic sequencing that 
detects MSI as well as many other mutations. The importance of genetic testing and 
counseling (e.g. Lynch syndrome) has to be taken into account as testing becomes more 
prevalent. 
A method that has been used in several studies to analyze TS mRNA expressions is the 
semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). It is a valid 
and reliable method and has the advantage that it requires small amount of tissue to do the 
analysis [430]. The TS mRNA sequence serves as a template for reverse transcriptase 
generating a single-stranded DNA (cDNA) which in turn serves as a template for PCR. To 
identify the mRNA of interest, a primer is used with known coding regions. PCR is widely 
used as the method to exponentially amplify the DNA sequence of interest. The PCR 
process relies on thermal cycling that involves a DNA primer that is complementary to the 
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target DNA strand, a heat-stable Taq DNA polymerase and free nucleotides. Classical post-
PCR steps involve electrophoretic separation and precise quantification of electrophoretic 
bands. Another method that is widely used is high-performance liquid chromatography 
(HPLC)-based procedures which separates and quantifies PCR products by liquid 
chromatography. 
The quantitative gene expression is normalized to the expression of ‘housekeeping 
genes’ such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
9.3 Scoring 
9.3.1 TS (PAPER I-II) 
The method developed by Johnston et al [281] was used for visual, performed under light 
microscope, grading of the staining intensity of TS protein expression with a scale from 0 
to 3 (grade 0 = no staining, grade 1 = weak, grade 2=moderate, grade 3=intense staining). 
This method was applied in the previous study by Edler et al [270] with 862 specimens as 
well as for the 527 specimens analyzed in Paper I. Taking into account TS expression 
heterogeneity [431], analysis was done in two different areas from each primary tumor. A 
previous study by our group found an increase from 81% to 96% for detecting a maximal 
area of TS staining with a single tumor sample respective two tumor samples [431]. 
A granular cytoplasmic staining pattern was observed with the monoclonal antibody 
TS106. Normal colon epithelium shows a weak staining or no staining while TS staining 
can be observed in lymphocytes and macrophages ‘adjacent’ to the tumor.  
The highest intensity found in the tumor established the grade of the tumor even if the 
area of high intensity was small. Scoring was done by four of the authors (MK, KÖ, DE, 
MH) who were blinded to clinical and pathological data. 
Each time a set of tumor samples was stained two reference slides were included with 
previously determined staining intensity of TS grade 0-1 and TS grade 2-3 as controls.  
 The observers had a ≥90% level of agreement in scoring. Resolving of scoring 
discrepancies was done by consensus after re-examination. 
The cut-off of low grade versus high grade TS intensity has been TS 0-1 versus TS 2-
3, respectively in the majority of studies [269, 276] and was applied in Paper I. 
The categorization of TS grade 0-2 (low grade) versus TS grade 3 (high grade) as used 
in the study by Allegra et al [276] was used in Paper II and was an additional categorization 
used in Paper I. 
An observation noted while TS grading was performed is that grade 0 and grade 3 
were relatively uncomplicated to discern while grade 1-2 were more difficult. 
Figure 13 illustrates TS grades 0-3. 
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TS grade 1 
 
TS grade 2 
 
TS grade 3 
Figure 13. TS grading 0-3. 
9.3.2 MMR (PAPER II-IV) 
Two different areas from each primary tumor were analyzed for MMR protein expression 
considering the described intratumoral heterogeneity of its expression [432]. 
Examination was done under a light microscope and scored by two independent 
observers (KÖ, MH, DE) who were blinded to clinical and pathological data. A deficient 
MMR expression was defined by the tumor cells displaying a complete absence of nuclear 
staining with the respective monoclonal antibody. The internal positive control used was 
the intact nuclear staining of normal tissue (including nonneoplastic stromal cells and 
lymphocytes) adjacent to the tumor. A staining was considered positive if any area of the 
tumor displayed positive staining. 
Figure 14 displays the presence versus the absence of nuclear staining for the MMR-
protein, MLH. 
For Paper II-IV, the IHC method was used to detect MMR protein expression of 
MLH1 and MSH2 and when confirmation was needed of MLH1 deficiency even some 
cases of PMS2 were analyzed due to the known association between the two proteins (see 
section 2.3 for more information on the interaction of the different MMR-proteins).  
Data supports that the majority of dMMR cases are detected upon staining the two 
proteins, MSH2 and MLH1, with a reported sensitivity of 92% and a specificity of 100% 
[433]. 
Assessment of the nuclear staining of MSH2 was uncomplicated while MLH1 staining 
was more difficult to interpret as also reported in other studies [434]. For the 51 cases with 
unclear MLH1 status, staining of PMS2 was performed considering the functional 
interaction between MLH1 and PMS2 as described earlier. MLH1 staining was considered 
negative if PMS2 was found negative. One should note that it is unclear whether the IHC 
analysis of PMS2 gives the best clarification since, in sporadic CRC, promoter methylation 
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is responsible for the loss of protein expression of MLH1. In routine screening for Lynch 
syndrome all four MMR proteins (MSH2, MLH1, PMS2, MSH6) are analyzed in which 
mutations in PMS2 are relatively infrequent. 
For Paper IV MMR status was available for 454 (95%) of the 478 colon cancer cases. 
 
  
MLH1 negative 
  
MLH1 positive 
Figure 14. Illustration of IHC staining for MLH1. 
9.3.3 Tumor budding (PAPER III-IV) 
Studies done on tumor budding in CRC have used several different methods for assessing it 
as well as different cut-off values for defining high-grade versus low-grade tumor budding. 
The methods either had a qualitative approach or a quantitative approach.  
For both Paper III and IV we chose as other studies have also done [329, 335, 435, 436] to 
highlight the neoplastic epithelium by pan-cytokeratin staining in order to better identify 
tumor buds and avoid their underestimation. 
Consultation was done with a pathologist before Paper III to establish a suitable 
method for quantitative assessment of tumor budding.  
More consensus on methodology in the studies of tumor budding in CRC was observed 
in preparation of Paper IV, in which guidelines published by Karamitopoulou et al [340] 
gained interest and were applied in Paper IV. 
The International Tumor Budding Consensus Conference (ITBCC) has recently 
published guidelines for assessment and scoring of tumor budding so as to standardize the 
method and aid in its clinical implementation [341]. It uses H&E slides, analyzes tumor 
budding in one hotspot field with a specific size of 0.785mm2 and categorizes low-grade 
budding as 0-4 buds, intermediate-grade as 5-9 buds and high-grade budding as ≥10 buds. 
Examples of slides depicting low-grade budding and high-grade budding are shown in 
Figure 15. 
 
  
Fig A. Low-grade tumor budding, 20x 
  
Fig B. High-grade tumor budding, 20x 
Figure 15. A. Illustrates low-grade tumor budding. B. High-grade tumor budding. 
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9.3.3.1 PAPER III 
Two independent investigators (MK and CL) blinded to the clinical and pathological data 
performed the assessment of tumor budding with MNF-116 staining. Isolated single de-
differentiated cancer cells or cluster of fewer than five such cells at the invasive front were 
defined as tumor budding [309]. 
Scanning of the invasive front of the two available tumor samples per case was 
performed with a multihead microscope at low power magnification (10x) to identify the 
most suitable sample (containing maximum tumor invasive front). The chosen tumor 
sample was then used for counting the number of tumor buds. Counting of the tumor buds, 
at magnification of 20x, was done in a specified area (0.05mm2) defined by a grid along the 
entire invasion margin of the tumor. The median tumor budding value of 5 found in this 
study was used as a cut-off as well as the cut-off of 10, an optimal cut-off considered in 
other studies using H&E stained slides [309, 367] and cytokeratin staining [340]. 
9.3.3.2 PAPER IV 
Two paraffin blocks per case with representative colorectal tumor were available for most 
of the cases. The respective sections which were stained with H&E were reviewed by 
pathologist AM and one section/block per case with maximum tumor invasion was chosen. 
Thereafter, the 4um sections were cut and mounted on slides from the selected blocks and 
IHC staining with MNF-116 was performed as previously described. 
For Paper IV it was possible to apply digital imaging technology which allowed the 
investigators to share and study the specimen with improved accuracy.  
Digital pathology where images can be uploaded with appropriate software application 
is becoming more common in clinical use. It has the advantage of eliminating degradation 
of samples, it preserves quality and the images can be shared when needed to improve 
diagnostics and as an education tool. 
Slide digitalization in Paper IV of the MNF-116 stained slides was done with a Vslide 
slide scanning microscope (Metasystems, Alltlussheim, Germany) which scanned slides 
with a x10 objective and RGB led illumination for color deconvolution. Metaviewer 
software (Metasystems, Alltlussheim, Germany) converted the scanned digital slides into 
images of .tif format at a resolution of 0.65 micrometers per pixel.  
To assess tumor budding for Paper IV the guidelines published by Karamitopoulou et 
al were applied [340]. This entailed identifying the average number of tumor buds in 10-
high-power-fields (HPF) of view with most tumor budding (hotspots) along the invasion 
front.  
In Paper IV tumor budding was defined as a single detached cancer cell or a cluster of 
≤5 detached tumor cells [311]. 
HPF commonly denotes to x40 objective of the conventional microscope. The area of 
the field of view at x40 of the conventional microscopes used at the local pathology 
departments, was computed to be 0.49mm2 and was then used to simulate region of interest 
on the digital slide. The process involved thereafter was as follows: 
 
➢ Use of Photo Shop to view the .tif images at low magnification to localize the 
invasive margin of the tumor. 
➢ Identification of higher tumor budding regions at low/medium magnification.  
➢ Use of Photo Shop to digitally define, using a colored circle, the 10-HPF 
regions where each HPF had a defined area of 0.49mm2. 
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The digital images were reviewed by two independent investigators (MK and AM) 
blinded to the clinical and pathological data. For each field of view the number of tumor 
buds was recorded and the average number of buds in the 10-HPF per case was used to 
determine grade of tumor budding. As in Karamitopolou et al ([340]) high grade tumor 
budding was defined as ≥10 buds. In the few cases of discrepancy, scoring was resolved by 
consensus after re-examination.  
Figure 16 illustrates low-grade and high-grade tumor budding in 10 HPF as well as 
high-grade tumor budding in one HPF. 
A substantial agreement on budding count was observed between the investigators 
p=0.006, r=0.99, ICC=0.99. 
 
 
A. 10 HPF, low-grade tumor budding, High power field 
(HPF). 
 
B. 10 HPF, high-grade tumor budding. High 
power field (HPF). 
 
C. 1 HPF, high-grade tumor budding. High power field 
(HPF). 
 
Figure 16 A-C. Tumor budding examples in PAPER IV. 
(A) 10 HPF, low-grade tumor budding, High power field (HPF). 
(B) 10 HPF, high-grade tumor budding. High power field (HPF). 
(C) 1 HPF, high-grade tumor budding. High power field (HPF). 
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9.3.4 Tumor border configuration (PAPER IV) 
The same digital slides used for tumor budding in Paper IV were used to assess tumor 
border configuration by two independent investigators (MK and AM) blinded to the 
clinical and pathological data.  
Application of the method described by Morikawa et al [375] was used for assessment. 
This entailed evaluation of the invasive tumor border at low magnification (x10) and 
choosing the category which best represents the growth pattern: pushing (expansive), 
intermediate or infiltrative.  
The growth patterns are identified by the following features: 
➢ pushing: tumors with well circumscribed growth 
➢ infiltrative: irregular cords and clusters of cancer cells and small glands 
without a distinct border 
➢ intermediate: presence of the irregularity of the large and medium-sized glands 
at the invasive border 
9.3.5 T-cell infiltration (PAPER IV) 
Semi-quantitative analysis of the IHC stained CD3+ and CD8+ T-cells was done under 
light microscope by an independent observer (AL) blinded to clinical and pathological data. 
The most representative areas were chosen from 3 subsites: 
➢ the invasive tumor front: identified as the stromal area along the invasive 
margin defined by a depth of two HPF (x40 objective) underneath the invasive 
margin 
➢ the tumor center: defined as the stromal area within the tumor mass between, 
as well as clearly separated from the luminal border and the invasive front 
➢ within the tumor epithelium: defined as intraepithelial lymphocytes located 
within tumor cell nests 
Scoring of T-cell infiltration was assessed according to Dahlin et al [418] as follows:  
➢ score 1: no or sporadic infiltration 
➢ score 2: moderate infiltration 
➢ score 3: abundant infiltration 
➢ score 4: highly abundant infiltration 
All sections were examined twice (AL) and in cases of discrepant scoring, cases were re-
evaluated before setting a conclusive score. 
As described in Dahlin et al and Ogino et al [417, 418], the mean value of the added scores 
for CD3+ and CD8+ T-cells for each subsite (tumor front, center, intraepithelial) was 
calculated to reach a total CD3+ score and a total CD8+ score. The total score ranged from 
3 to 12, in which low expression was defined as 3-4, intermediate as 5-6 and abundant as 7-
12. Each case depending on its score was then placed into the appropriate category. 
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9.4 Statistical Analysis 
Statistical analyses were done for all papers included in this thesis. Statisticians were 
consulted (Bo Nilsson for Paper I-II-III, Yunxia Lu for Paper III and Hemming Johansson 
for Paper IV) concerning the suitable choice of statistical analysis. 
All statistical tests were performed using Statistica (StatSoft Scandinavia AB, Uppsala, 
Sweden), version 7 (Paper I and II) and version 10 (Paper III and IV). 
 
Paper I-IV 
The Chi-square test was used to compare the differences in distributions in the different 
groups which are considered unordered categorical variables.  
Statistical tests were two-sided in which differences with values of p<0.05 were considered 
statistically significant. 
 
DFS was defined as time from surgery to the first event of local recurrence, presence of 
distant metastases or death of any reason and OS was defined as time from surgery to 
death. 
 
The Gehan-Wilcoxon univariate test was used: 
➢ in Paper I to analyze relationships between survival and patients demographics and 
tumor characteristics and  
➢ in Paper II to examine the possible correlation between OS and the combined 
analysis of MMR status and TS expression.  
 
Cox univariate regression analysis was used in Paper III and IV to examine the 
relationships between OS and DFS and patients’ demographics and tumor characteristics. 
 
Survival curves were constructed with the Kaplan-Meier method. The logrank test was 
used to compare the difference between groups. Both the Kaplan-Meier method and the 
logrank test are examples of univariate analysis, ignoring the impact of other factors. 
 
Multivariable survival analyses were performed using the Cox proportional hazards 
regression model for calculation of hazard ratios (HR). A method which allows several 
variables to be evaluated simultaneously as to how they influence the rate (HR) of an event 
(e.g. death) at a specific point in time. 
 
Paper II 
To analyze the relationship between MMR status and TS expression we used the 
Spearman’s rank test.” 
 
Paper III-IV 
Linear correlation between the two observers’ tumor budding counts was assessed using 
Pearson correlation coefficient (r). The intra-class correlation coefficients (ICC) assessed 
interobserver agreement, in which values range from 0 (no agreement) to 1 (perfect 
agreement).  
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10 RESULTS AND DISCUSSION 
10.1 PAPER I 
Prognostic and Predictive value of Thymidylate Synthase Expression in Primary 
Colorectal Cancer 
Objective: To investigate thymidylate synthase (TS) expression in primary CRC as a 
prognostic and predictive marker of benefit for adjuvant chemotherapy in a large group of 
patients with a longer follow-up time. 
Results: Analyses of 862 of the patients in this study have been previously reported [270]. In 
this study including 1389 patients (862 patients with the addition of 527 patients), 616 
patients died of whom 497 (81%) of them died of CRC during the median follow-up time 
of 75 months (range 1-120). The majority, 984 (71%), of the tumors were located in the 
colon. Of the 405 patients with rectal cancer, 214 (53%) were treated with preoperative 
radiation (5Gyx5). 
A better OS was independently significantly linked to the female gender, younger age (<65 
years), well differentiated tumors (low grade), stage II versus stage III and the removal of 
≥12 lymph nodes. 
In the entire study population, TS expression grade 0-1, defined as low, was found in 399 
(29%) primary tumors while TS expression grade 2-3, defined as high, was found in 990 
(71%) primary tumors. With the classification of TS expression grade 0-2 as low, we found 
929 (67%) tumors and with TS expression grade 3 as high we found 460 (33%) tumors. 
The majority, 530 (38%) of tumors had a TS expression of grade 2 while 21 (2%) had TS 
expression grade 0 and 378 (27%) had TS expression grade 1. 
TS expression was found to be independent of tumor localization and stage and in rectal 
cancer patients, it did not differ regardless of whether they received or not received 
preoperative RT. No method of TS classification found TS expression to be prognostic for 
OS or DFS in the entire study group. 
Analysis of the prognostic value of TS expression in the patients treated with surgery alone 
(n=708) and in those treated with surgery followed by adjuvant chemotherapy (n=681), 
showed low TS expression (0-1 or 0-2) to be independently associated with a longer OS 
and DFS, only for the patients in the surgery alone arm (p=0.045 or p=0.002, respectively) 
(Figure 17 A and B). No difference in OS was found in adjuvant chemotherapy patients 
regardless of whether the patients received ≥90% of the planned FU-dose (n=335) versus 
<90% (n=288) of the dose (n=58, excluded patients due to insufficient FU-dose 
information). 
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Figure 17. (A) Overall survival 
(OS) in 708 patients with colorectal 
cancer stage II and III treated with 
surgery alone according to 
expression of TS 01-2 versus 2-3. 
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Figure 17. (B) Overall survival (OS) 
in 708 patients treated with surgery 
alone according to expression of TS 
0-1-2 versus TS 3. 
 
Comparing the surgery alone group to the adjuvant chemotherapy in the low TS expression 
(grade 0-1 or grade 0-2), no difference in OS or DFS was found. However, this comparison 
in the high TS expression (grade 3) group showed a significant longer OS for the adjuvant 
chemotherapy group compared to the surgery alone group (p=0.0005) (Figure 18 B). It 
remained significant in the multivariate analysis (p=0.0008). The same analysis remained 
independently prognostic in the subgroups of colon cancer stage II-III (p=0.007), colon 
cancer stage III (p=0.005) and rectal cancer stage II (p=0.01), but not in colon cancer stage 
II, rectal cancer stage II + III and rectal cancer stage III.  
 
Analysis in the high TS grade group (grade 2-3), showed only a tendency to a longer OS 
for the group treated with postoperative adjuvant chemotherapy compared to surgery alone 
(p=0.07) (Figure 18 A). 
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Figure 18. (A) Overall survival (OS) in 
the group of 990 patients with high TS 
expression (TS 2-3) tumors according to 
treatment with surgery alone versus 
surgery plus adjuvant chemotherapy. 
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Figure 18. (B) Overall survival (OS) in 
the group of 460 patients with TS grade 3 
tumours and treatment with surgery alone 
versus surgery plus adjuvant 
chemotherapy. 
 
Discussion: Our finding that TS was not prognostic in our enlarged study population of 
1389 primary CRC patients or in the group treated with surgery followed by adjuvant 
chemotherapy was in contrast to our previous study of 862 patients in which a low TS 
expression (grade 0-1) correlated with a longer OS (p=0.04) [270].  
Popat et al’s meta-analysis from 2004 which included both CRC adjuvant and metastatic 
disease settings with a total of 3497 patients, concluded that patients with high levels of TS 
expression had poorer OS compared to ones with low levels [269]. One study included in the 
meta-analysis, using IHC to analyze TS expression in 465 colon cancer patients who were 
randomized to surgery alone or plus adjuvant chemotherapy also failed, as in our study, to 
show a significant association between TS expression and outcome [274]. Furthermore, 
another large study published after Popats meta-analysis including 779 patients with TS 
analyzed by IHC using a polyclonal antibody found no association between TS expression 
and survival [268]. However, a colon cancer adjuvant study included in Popats meta-analyses 
using the IHC method in tumor material from 706 randomized patients, found high TS 
grade (grade 3) to be prognostic of a shorter OS [276]. 
Isolating the adjuvant cases (2610 patients) in the meta-analysis, Popat et al found, as in our 
study, that high TS expression predicted worse OS for patients treated with surgery alone 
but not for patients treated with surgery followed by adjuvant chemotherapy [269]. 
In contrast to our finding that low TS expression (using both grade 0-1 and grade 0-2 as 
low) correlated to a better OS and DFS for the surgery alone group of patients, another 
large study found low TS expression (grade 0-2) correlated with a worse prognosis for this 
group [290]. Their study used TMA as tumor material to analyze TS by IHC from 945 CRC 
patients, who were non-randomly, treated with or without FU-based chemotherapy. An 
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explanation for their differing result could be that there is a risk of underestimating the true 
frequency of high TS expression using TMA since it analyzes a limited area of tumor tissue 
thus not accounting for heterogeneity and focal staining. 
There are conflicting results in studies as to whether TS expression in the primary tumor 
can predict response to FU-based regimens in the adjuvant setting [269]. In our study we 
found the trend of benefit of adjuvant 5-FU-based chemotherapy to be greater than in our 
previous smaller study for patients whose tumors expressed TS grade 2-3. With the 
classification of high TS as grade 3, we found a significant survival for patients receiving 
adjuvant chemotherapy compared to surgery only. Several studies support a survival 
benefit with adjuvant 5-FU chemotherapy for patients with high grade TS [275, 281-286] while 
other studies have shown no benefit regarding low grade versus high grade TS [268, 274, 276, 
288]. 
No harmful effect, for the low TS expression group, of adjuvant chemotherapy compared to 
surgery only was found in our enlarged study in contrast to our previous study [270]. 
The predictive value of TS is more conclusive in studies (using varying methods, e.g. IHC 
and TS mRNA with RT-PCR technique) done on metastatic CRC where low TS expression 
in metastases is associated with a better response to 5-FU [291, 293, 298, 301, 302].  
A recent prospective trial, phase II ECOG E4203, randomized first-line treatment for 
untreated mCRC patients based on tumor TS expression determined by IHC [308]. Patients 
with low TS expression (grade 0-1) received FOLFOX/Bevacizumab while those with high 
TS expression (grade 2-3) received irinotecan or oxaliplatin plus bevacizumab or 
FOLFOX/Bevacizumab. TS was found to be prognostic in that a longer PFS and trend to 
better OS was found in patients with low grade TS tumors in comparison with patients with 
high grade TS tumors, regardless of the treatment given in the high grade TS group. 
10.2 PAPER II 
A Combined Analysis of Mismatch Repair Status and Thymidylate Synthase 
Expression in Stage II and III Colon Cancer.  
Objective: To investigate if a combined analysis of MMR protein expression and TS 
expression analyzed with IHC in colon cancer has a prognostic value and can predict 
response to adjuvant 5-FU-based chemotherapy. 
Results: In the entire study population of 716 patients with colon cancer, local recurrence 
occurred in 63 patients (9%) while 187 patients (25%) developed distant metastases. There 
was a non-significant longer OS for the group of patients receiving postoperative adjuvant 
chemotherapy (87 months) compared to the group treated with surgery alone (82 months). 
Of the 327 patients who died in the 120-month follow-up, 270 (83%) died with colon 
cancer.  
Of the 716 patients, 142 (19.8%) were found to have tumors with a dMMR-status with the 
majority, 125 patients (17.4%), of them having a MLH1-deficiency, 14 (2%) a MSH2-
deficiency and 3 (0.4%) were deficient for both MLH1 and MSH2. A dMMR-status was an 
independent prognostic factor in the entire cohort (HR 0.65, 95% CI 0.34-0.96, p=.007). 
Patients with dMMR-tumors had an 8-month longer median OS compared to patients with 
pMMR-tumors. In the group of surgery alone, a dMMR-status remained prognostic 
(p=0.03) but showed only a trend (p=0.06) in the group receiving postoperative adjuvant 
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chemotherapy. Although a difference of a 12-month longer median OS was found for 
patients with pMMR tumors receiving postoperative adjuvant chemotherapy versus those 
with surgery alone, it was not significant. For patients with dMMR tumors no difference in 
OS was found comparing the treatment arms. 
TS-grade was not prognostic in the entire study population or in the different treatment 
arms.  
In the high TS grade (grade 3), a significant longer OS was observed for the group of 
patients receiving postoperative chemotherapy compared to group treated with surgery 
alone in stage II-III (p=0.05) and especially in stage III disease (p=0.004, multivariate 
analysis). 
Four different groups were created based on the combined analysis of MMR-status and TS 
expression (see Table 8). 
 
Table 8. TS expression (0-2 vs. 3) stratified by MMR status 
  dMMR  pMMR  Total 
Low TS 
Grade 0-2 
Group 1: n=84 (12%) Group 2: n=359 (50%) n=443 (62%) 
High TS 
Grade 3 
Group 3: n=58 (8%) Group 4: n=215 (30%) n=273 (38%) 
Total n=142 (20%) n=574 (80%) 716 
 
Summary of Survival differences in the Groups: 
Group 1 (dMMR and Low TS, Grade 0-2): median OS 88 months; no significant difference 
in OS between the treatment arms (surgery alone arm, n=45; adjuvant arm, n=39) in the 
entire group or stage-wise. 
Group 2 (pMMR and Low TS, Grade 0-2): median OS 84 months was the same for the 
entire group and subgroups of treatment arms (surgery alone arm, n=186; adjuvant arm, 
n=173). 
Group 3 (dMMR and High TS, Grade 3): median OS 92 months; the 13-month OS 
difference between the surgery alone arm (n=25, median OS 85 months) and the post-
operative adjuvant chemotherapy arm (n=33, median OS 98 months) was not significant. 
Group 4 (pMMR and High TS, Grade 3): median OS 75 months; the 21-month OS 
difference between the surgery alone group (n=114, median OS 67 months) and the post-
operative adjuvant chemotherapy arm (n=101, median OS 88 months) was not significant 
(p=0.09) (Figure 19 A). 
Stagewise a significant difference in median OS was found in stage III disease (n=116) for 
the group receiving post-operative adjuvant chemotherapy, p=0.01 (univariate analysis) 
(Figure 19 B) as well as in multivariate analyses, p=0.008 (HR, 0.53 [95% CI, 0.33-0.85]) 
see Table 9. 
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Figure 19 A. Overall survival for patients in 
Group 4 (MMR proficient tumors with a high 
TS, grade 3) according to treatment status, 
(n=215). 
Figure 19 B. Overall survival for stage III 
patients in Group 4 (MMR proficient tumors 
with a high TS, grade 3) according to treatment 
status, (n=116). 
 
Table 9. Group 4 Stage III (n=116) Multivariate analysis using Cox Proportional Hazards Model to 
identify significant variables and generate HR 
Analysis HR for death 95% CI p-value 
Age (≥66 vs. <66) 1.54 0.96-2.45 NS 
Sex (female vs. male) 0.78 0.48-1.28 NS 
Grade of differentiation (well/moderate vs. poor) 0.61 0.38-0.97 0.04 
Treatment (chemotherapy vs. no chemotherapy) 0.53 0.33-0.85 0.008 
Number of analyzed LN (>11 vs. 0-11) 1.52 0.69-3.37 NS 
Tumor site (proximal vs. distal) 0.70 0.44-1.12 NS 
Abbreviations: MMR, mismatch repair;MMR positive, MLH1 or MSH2 positive, MMR negative, MLH1 negative or MSH2 
negative; TS, thymidylate synthase; HR, hazard ratio; 95% CI, 95% confidence interval, proximal;To splenic flexure 
 
Comparison of group 1 and group 4 showed a non-significant difference in OS, p=0.09 in 
the entire study group. In the subgroup analyses of the surgery alone arm, group 1 had a 
tendency to an improved OS p=.06 (Figure 20 A) while no significant difference was found 
in the post-operative adjuvant chemotherapy group (p=0.70) (Figure 20 B). 
There was no relationship between MMR-status and TS expression (r=0.03, p=.46) 
 
 
 
Figure 20 A. Overall survival for patients in Group 
1 (MMR deficient tumors with a low TS, grade 0-
2) compared to patients in Group 4 (MMR 
proficient tumors with a high TS, grade 3) treated 
with surgery alone, (n=159). 
Figure 20 B. Overall survival for patients in Group 
1 (MMR deficient tumors with a low TS, grade 0-
2) compared to patients in Group 4 (MMR 
proficient tumors with a high TS, grade 3) treated 
with surgery and adjuvant chemotherapy, (n=140). 
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Discussion 
A combined analysis of MMR status and TS expression in colon cancer was done to 
explore if they could together provide information to improve treatment decision in the 
adjuvant setting. 
The prognostic value of MMR status in primary CRC has been established as described by 
a systematic review with dMMR tumors having an improved prognosis [121]. Concerning 
the predictive role of MMR-status in stage II-III CRC, most retrospective studies have 
found that patients with tumors displaying a pMMR-status benefit from adjuvant 5-FU 
treatment [123, 245, 246]. 
As mentioned in the discussion of Paper I, low TS expression has been correlated to a 
better outcome and the majority of retrospective studies indicate a high TS expression as 
predictive to a better response to adjuvant 5-FU in stage II-IIII CRC. 
With the 4 groups classified by TS expression stratified by MMR-status, our study focused 
on group 1 (patients with dMMR tumors and a low TS, grade 0-2) and group 4 (patients 
with pMMR tumors and a high TS, grade 3). Our result of no difference found in OS or 
DFS in group 1 (patients with dMMR tumors and a low TS, grade 0-2) concerning stage or 
treatment arm seems reasonable based on published data. We found a significant better 
survival in group 4 (patients with pMMR tumors and a high TS, grade 3), for the patients 
receiving adjuvant 5-FU treatment in stage III but not in stage II. The better clinical 
outcome found for group 3 (patients with dMMR tumors with high TS) could be due to an 
added favorable prognostic factor where group 3 had a higher percentage (20%) of >11 
lymph nodes analyzed than the other groups (10%). Conclusion is also hampered by the 
small size of group 3. 
The studies in CRC which analyze TS expression and MMR protein expression as a 
combined analysis have used varying methods for analyzing TS and MMR, included 
different stages as well tumor localization (colon vs colorectal) and treatment scenarios 
(adjuvant and palliative) (see Table 10). Thus, contradictory results arise and comparing the 
studies is a challenge. A similar study to ours where patients were included in clinical 
randomized trials with stage II-III colon cancer could not either establish a significant 
relationship between MMR status and TS expression [437]. No correlation between MMR 
status and TS expression was also observed in two other studies [438, 439]. 
Four of the studies found a significant relationship between a high expression of TS and 
MSI (dMMR) [440-443]. The theory was posed in two of these studies [440, 441] that this 
relationship could influence the lack of response of dMMR tumors to 5-FU-based-
chemotherapy . The larger study of these four studies (n=340) did not find that TS 
expression was associated with an improved survival or 5-FU resistance for patients with 
MSI-H/dMMR CRC [443]. All of the four studies included patients with stage IV disease 
which could influence results as TS expression is a stronger predictive marker in 
disseminated CRC [291-293]. The differing amounts of high TS, in part due to what accounts 
as high TS (grade 2-3 versus grade 3), is also a factor to be considered in the interpretation 
of the results.  
The latest study with a combined analysis of TS and MMR is a prospective one using 
tumor material from two adjuvant trials (Alliance for Clinical Trials in Oncology C9581 
and C89803) in colon cancer (in C9581 n=435 stage II; in C89803 n=463 stage III) [279]. 
The C9581 trial randomized patients to either edrecolomab (antibody inhibiting EpCAM) 
versus observation alone while the C89803 trial randomized patients to adjuvant 5FU/LV 
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or 5FU/LV and irinotecan (IFL). Although it was not an independent prognostic factor, 
they found that high TS expression (grade 2-3) correlated to better outcome (DFS: HR 
0.67. 95% CI 0.53-0.84; OS: HR 0.68 95% CI 0.53-0.88) for high versus low TS 
expression, respectively. Unlike our study, a correlation between high TS expression and 
dMMR was found p=0.0003. No prediction of benefit of 5-FU-based chemotherapy based 
on tumor TS expression was found. A limitation in their study is the inability to distinguish 
stage of disease and treatment. 
 
Table 10. The collected literature of a combined analysis of MMR protein expression and TS expression 
in colorectal cancer. 
Author Year [Ref] 
No. of 
pts 
Primary 
tumour 
Stage of 
disease 
Method 
MMR-
status 
Method 
TS 
% MSI-H 
/MMRP neg 
% 
TS High Correlation 
Calascibetta et al 2004 [438] 80 CRC ? PCR IHC+PCR MSI:60% 72% No 
Ricciardiello et al 2005 [440] 192 CRC II-IV IHC+PCR IHC MSI-H:18%, 
MLH1neg:10% 
21% MSI-H correlates with 
high TS (p< 0.001) 
Popat et al 2006 [439] 441 CRC I-III PCR IHC MSI:15% 59% No 
Sinicrope et al 2006 [437] 320 Colon II-III IHC+PCR IHC MSI-H:19%, 
MMRPneg:19% 
75% No 
Odin et al 2007 [441] 181 CRC I-IV PCR PCR MSI-H: 19% NE MSI-H correlates with 
high TS (p< 0.0001) 
Bendardaf et al 2008 [444] 73 CRC IV IHC IHC NE NE MMRP neg correlates 
with low TS (p=0.0001) 
Jensen et al 2008 [442] 130 CRC I-IV PCR IHC MSI-H:15% NE MSI-H correlates with 
high TS (p< 0.001) 
Jensen et al 2009 [443] 340 CRC II-IV IHC+PCR IHC MSI:14%, 
MMRPneg:17% 
25% MSI-H correlates with 
high TS (p=0.001) 
Öhrling el al 2013 [445] 716 Colon II-III IHC IHC dMMR 20% 74%* 
38%** 
No 
Niedzwiecki et al 2017  [279] 898 Colon II-III IHC IHC dMMR: 18% 52% dMMR correlates with 
high TS (p=0.003) 
MMR;Mismatch repair, TS;Thymidylate synthase, , No.;Number, pts;patients, CRC;Colorectal cancer, 
PCR;Polymerase chain reaction, IHC;Immunohistochemistry, MSI-H;Microsateliite instbility-high, 
MMRP;Mismatch repair protein, NE;Not evaluated, * TS High as grade 2-3; **TS High as grade 3 
10.3 PAPER III 
Tumor Budding Versus Mismatch Repair Status in Colorectal Cancer –  
An Exploratory Analysis 
Objective: To assess tumor budding in primary colorectal tumors with respect to MMR-
status and local recurrence/metastases. 
Results: For the whole study population of 134 patients we found a 5-year survival rate of 
52%, a median OS of 60 months and DFS of 49 months. The median follow-up of 
surviving patients was 100 months (range 62 to 120 months). OS was not significantly 
different when comparing stage II and III CRC in the study. Analysis of OS in the four 
different groups was done with the groups dMMR/met- and pMMR/met- having expected 
better OS compared to the pMMR/met+ and dMMR/met+ groups (Figure 21). 
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Figure 21. Overall survival in the four 
different groups. 
 
The distribution of dMMR tumors was higher proximal to the splenic flexure 40/71 (56%) 
compared to tumors distal to it 22/63 (35%). Analyses of the Met+ population (n=59) 
showed that the dMMR group had a higher number of patients (15/29) (52%) who had a 
local recurrence or metastases in the first year compared to the pMMR group (4/30) (13%) 
but with no significant difference in time to recurrence (p=0.4). 
In this study the tumor budding mean was 7 (SD±6), the median 5 and the range 0-35. 
Agreement of tumor budding assessment was substantial between the investigators 
(p<0.001, r=1.0, ICC=0.99). 
Using the cut-off of 5 and 10, a significantly higher frequency of high-grade budding was 
observed in the dMMR/met+ group (cut-off 5, 72%; cut-off 10, 45%) versus the 
dMMR/met- group (cut-off 5: 39%, cut-off 10: 21%) (p=0.009 and p=0.047, respectively). 
This was also observed in the dMMR/met+ (cut-off 5: 72%, cut-off 10: 45%) versus the 
pMMR/met+ group (cut-off 5: 40%; cut-off 10: 17%) (p=0.01 and p=0.02 respectively) as 
well as compared to the pMMR/met- group using the cut-off 10: 19%, p=0.012. For more 
information on the distribution of tumor budding between the four groups see Table 11. 
 
Table 11. Distribution of tumor budding in Groups 1-4 
Method Total 
 
n=134 
Group 1 
(dMMR/met-) 
n=33 
Group 2 
(dMMR/met+) 
n=29 
Group 
3(pMMR/met-) 
n=42 
Group 4 
(pMMR/met+) 
n=30 
TB cut-off 5:           
Low (<5) 64(48%) 20(61%) 8(28%) 18(43%) 18(60%) 
High (≥5) 70(52%) 13(39%) 21(72%) 24(57%) 12(40%) 
TB cut-off 10:           
Low (<10) 101(75%) 26(79%) 16(55%) 34(81%) 25(83%) 
High (≥10) 33(25%) 7(21%) 13(45%) 8(19%) 5(17%) 
Abbreviations: TB, tumor budding; dMMR, deficient mismatch repair; pMMR, proficient mismatch repair; met-, no 
recurrence or distant metastases; met+, with recurrence or distant metastases 
 
In the pMMR category as a whole, we found 50% and 18% had high-grade tumor budding 
using the cut-off of 5 and 10 respectively, compared to the dMMR category which had 
55% and 32%, respectively. 
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Regardless of cut-off used we found no significant survival advantages with regard to 
tumor budding grade. 
 
Discussion 
This exploratory study found a significantly higher frequency of tumor budding in the 
dMMR/met+ group compared to the other 3 groups including pMMR/met+. Using the 2-
cut-offs for high-grade versus low-grade we found no significant survival advantage for the 
low-grade tumor budding group. This is not surprising since the study is a small study 
designed to evaluate differences in tumor budding in prearranged subgroups. Our number 
of 35 patients with dMMR tumors who developed recurrence/metastases out of 1006 
patients reflects the inherent biology of dMMR primary CRC with a known favorable 
prognosis.  
High-grade tumor budding is believed to reflect cell de-differentiation which in turn has 
been correlated with the development of regional and distant metastases and a worse 
prognosis [310, 333, 446]. The process of cell de-differentiation can be observed in the 
epithelial-mesenchymal transition (EMT) and the activation of the Wnt signaling pathway 
[310, 447, 448]. CRC with a pMMR status is regarded as chromosomally unstable, commonly 
harbors an APC mutation and is driven by activation of the Wnt pathway [447]. This 
mechanism is thought to be the explanation behind the general finding of pMMR CRC 
having more high-grade tumor budding compared to dMMR CRC [333]. Tumor budding and 
its negative prognostic impact has been found in some studies to be independent of MMR-
status [348, 449].  
Our finding that dMMR/met+ had more high-grade tumor budding than pMMR/met+ 
could be due to the study design which may include a higher number of dMMR cases with 
recurrence or metastases than other studies. Table 12 summarizes studies which analyzed 
MMR-status with regard to tumor budding. Two studies used H&E stained slides [357, 449] 
while our study and Lugli et al’s [348] used cytokeratin 22 staining. Different assessment 
methods and cut-offs were used in the studies. 
 
Table 12. Clinicopathological studies analyzing high grade vs low grade  
tumor budding with regards to MMR-status 
Author & cut-off pMMR dMMR 
Lugli[348] ≤6 low PTB 21% 34% 
 >6 high PTB 79% 66% 
 ≤6 low ITB 56% 64% 
 >6high ITB 44% 36% 
Kevans[357] *low PTB 52% 74% 
 **high PTB 48% 26% 
Karlberg[450]<5 low PTB 50% 45% 
 ≥5 high PTB 50% 55% 
 <10 low PTB 82% 68% 
 ≥10 high PTB 18% 32% 
Wyk[449] <20 low PTB 15% 85% 
 ≥20 high PTB 85% 15% 
Abbreviations: pMMR, proficient mismatch repair; dMMR, deficient mismatch repair; PTB,  
peritumoral budding; ITB, intratumoral budding; SD, standard deviation; ND, no data given;  
*low PTB (median tb=0); ** high PTB (median ≥1) 
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There may be other mechanisms contributing to tumor budding in dMMR CRC than the 
Wnt signaling. One study found that dMMR tumor buds had lower β-catenin expression 
compared to buds found in pMMR tumors and that in especially CRC with MLH1-loss, 
high-grade tumor budding may have increased vessel involvement and nodal metastases 
rather than local invasiveness [451]. 
The cut-offs of 5 and 10, defining high-grade versus low-grade budding, used in our study 
were also used in other studies, with cytokeratin staining [340] and with H&E stained 
sections [309, 367]. Comparison of our results with other studies is difficult due to the wide 
heterogeneity in assessment methods and cut-off values. 
10.4 PAPER IV 
Prognostic value of Tumor Budding, Tumor Border Configuration and T-cell 
infiltration in Colon Cancer 
Objective: To examine the prognostic impact of tumor budding, tumor border 
configuration as well as T-lymphocyte density (CD3+ and CD8+) in primary colon cancer 
with known MMR-status. 
Results: The patients median age was found to be 66-years-old and a similar distribution 
was found for gender, colon site, stage II and III and treatment arm when patient and tumor 
characteristics were stratified by tumor budding grade status and T-lymphocyte (CD3+ and 
CD8+) score. MMR-status was not available for 24 patients (5%). Of the tumors with 
known MMR-status, 364 (80%) were pMMR and 90 (20%) were dMMR. In the dMMR 
category most 57/90 (63%) were located in the right colon, 15/90 (17%) in the transverse 
colon and 18/90 (20%) in the left colon compared to the pMMR category which had 
151/364 (41%), 31/364 (9%) and 182/364 (50%), respectively. 
In the whole patient material, 192 (40%) of the tumors had an infiltrating tumor border 
configuration while 286 (60%) had a pushing (181, 38%) or mixed (105, 22%) border 
configuration. A higher percentage of infiltrating border configuration was found in pMMR 
(160/364, 44%) tumors compared to dMMR tumors (22/90, 24%) (p<0.001).  
Tumor budding analysis of the 478 patients showed a mean budding count of 7.6 (SD±6), a 
median count of 5.85 and a range of 0 to ≥35. The agreement on tumor budding count 
between the investigators was substantial (p=0.006, r=0.99; ICC=0.99). With high grade 
tumor budding defined as ≥10 buds, we found 132/478 (28%) in this category and 
stagewise, 92/253 (36%) in stage III and less 40/225 (18%) in stage II (p<0.001). No 
significant distribution difference between high grade tumor budding or low grade was 
found when looking at tumor site and T-stage. There were significantly more tumors in the 
pN1-2 group with high grade tumor budding compared to the pN0 group, 38% and 18% 
respectively (p<0.001). A tendency to more high-grade tumor budding was seen for the G3 
tumors (poorly differentiated) (36%) versus the G1 (18%) and G2 (27%) tumors (p=0.068). 
Non-mucinous tumors had 31% high grade tumor budding compared to the mucinous 
tumors with 13% (p<0.001). 
The infiltrating tumor border configuration tumors had 98/192 (51%) with high grade 
tumor budding while the pushing/mixed tumor border configuration had 34/286 (12%) 
(p<0.001). This was consistent stagewise (stage III: 67/120, 56% versus 25/133, 19%, 
respectively, p<0.001; stage II: 31/72, 43% versus 9/153, 6%, respectively, p<0.001). 
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Analysis of MMR-status and tumor budding showed that pMMR tumors had more high 
grade tumor budding 109/364 (30%) than dMMR tumors 17/90 (19%) (p=0.035). 
When exploring tumor budding and T cell (CD3+, CD8+) scores we found that high grade 
tumor budding was associated with low total CD3+ and CD8+ scores (CD3+: p=0.0398; 
CD8+: p=0.026). See Table 13. 
 
Table 13. Tumor budding and total CD3+ and CD8+ score. 
  Tumor Budding 
Frequency N (%) 
  
Frequency N 
(%) 
Low 
(< 10 buds) 
n=346 
High 
(≥ 10 buds) 
n=132 P 
CD3 total:    0.039 
low 113 (24%) 84 (24%) 29 (22%)  
intermediate 237 (49%) 160 (46%) 77 (58%)  
high 128 (27%) 102 (30%) 26 (20%)  
CD8 total:    0.026 
low 148 (31%) 105 (30%) 43 (33%)  
intermediate 222 (46%) 152 (44%) 70 (53%)  
high 108 (23%) 89 (26%) 19 (14%)  
 
There were more high CD3+ and CD8+ score tumors in proximal colon tumors (CD3+: 
30%; CD8+: 25%) compared to distal ones (CD3+: 23%; CD8+: 19%) (CD3+: p=0.003; 
CD8+: p=0.220). A higher percentage of high CD3+ score (41%) and CD8+ score (40%) 
was observed in poorly differentiated tumors (G3) compared to well differentiated (G1) 
(CD3+: 20%; CD8+: 13%) and intermediate (G2) ones (CD3+: 23%; CD8+: 19%), (CD3: 
p=0.004; CD8: p<0.001). In non-mucinous colon tumors, a high score CD3+ of 30% and 
CD8+ of 25% was observed compared to mucinous tumors that had 14% and 8%, 
respectively (CD3: p<0.0001; CD8: p<0.001). 
A significantly higher amount of high score CD3+ (p<0.001) and CD8+ (p<0.001) was 
found in dMMR tumors (CD3: 39/90, 43% and CD8: 33/90 37%) compared to pMMR 
tumors (CD3: 77/364, 21% and CD8: 66/364, 18%). The pushing/mixed tumor border 
configuration tumors had more high score CD3+ (34%) and CD8+ (29%) than the 
infiltrating tumors (CD3+: 17% and CD8+: 13%) (CD3+: p<0.001; CD8+: p<0.001). 
Of the 478 patients, 42 (9%) were diagnosed with local tumor recurrence and 128 (27%) 
with distant metastases. A 5-year survival rate of 64% was found and the median DFS and 
OS was 78.5 months and 83 months, respectively. Of the 223 (47%) patients that died in 
the entire study group during the 120-month follow-up, 181 (81%) were found to have died 
with colon cancer. 
As data from our previously reported studies including MMR status [236] and the original 
Nordic trials [426] did not find any major difference between DFS and OS this study 
concentrates on data related to OS. 
A significant OS benefit was found for patients that were younger (<66-years-old) 
(p=0.040), had stage II versus stage III (p<0.001), had dMMR tumors (p=0.038) and had a 
N0 status (p<0.001). In this study no OS benefit was found for tumor location, treatment 
arm, tumor grade, mucinous status, gender and only a trend of benefit was found for T0-2 
stage versus T3-4 (p=0.0516). 
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In OS analysis regarding tumor border configuration, tumor budding and CD3+ / CD8+ 
score, we found a prolonged OS for patients with pushing/mixed border configuration 
tumors (p<0.001), for ones with low grade tumor budding tumors (p=0.016) and for 
patients with high total CD8+-score tumors (p=0.013) (Figure 22 A, B, D). For the patients 
with a high CD3+ score a tendency to a better OS was found (p=0.076) (Fig 22 C). A 
significantly better OS remained for low grade tumor budding in stage II patients (p=.079) 
but not for stage III. For patients with right-sided tumors, but not with left-sided tumors, a 
high CD3+ and CD8+ score was associated with a better OS in univariate analysis (CD3+: 
p=0.002; CD8+: p<0.001) but not in multivariate analysis (CD3+: p=0.792; CD8+: 
p=0.066).  
 
 
Numbers at risk 
Pushing/mixed 
 286 252 223 204 167 103 32 
 
Infiltrating 
 192 163 124 100 83 39 13 
22A) Overall survival according to tumor border configuration (TBC) 
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Numbers at risk 
Low grade tb 
 346 300 262 232 190 108 38 
 
High grade tb 
 132 115 85 72 60 34 7 
 
22B) Overall survival according to tumor budding grade  
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Numbers at risk 
 
Low CD3 score 
 113 98 78 67 57 36 9 
 
Intermediate CD3 score 
 237 206 170 144 121 67 22 
 
High CD3 score 
 128 111 99 93 72 39 14 
 
22C) Overall survival according to CD3-total score 
Low total CD3 score = 3-4 
Intermediate total CD3 score = 5-6 
High total CD3 score = 7-12 
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Numbers at risk 
Low CD8 score 
 148 127 99 82 69 41 11 
 
Interm CD8 score 
 222 194 163 142 119 70 23 
 
High CD8 score 
 108 94 85 80 62 31 11 
 
 
22D) Overall survival according to CD8-total score 
Low total CD8 score = 3-4 
Intermediate total CD8 score = 5-6 
High total CD8 score = 7-12 
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Figure 22 A-D 
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Adjusting for age, sex, tumor grade, MMR status and T-stage, multivariate analysis showed 
that OS remained significant for patients with pushing/mixed tumor border configuration 
tumors and for ones with high CD8+ scores (see Table 14). This was the case even for 
patients with stage II tumors (TBC: HR=1.96, 95% CI: 1.24-3.09, p=0.004; CD8+: 
HR0.61, 95% CI:0.44-0.86, p=0.005) but not for ones with stage III tumors. Tumor 
budding and CD3+ scores did not remain significant in multivariate analysis. 
 
Table 14. Univariate and Multivariate Analyses for Overall Survival using Cox Proportional 
Hazards Model 
Characteristic  Univariate Analysis 
OS 
Multivariate Analysis 
OS 
Events/ 
patients 
HR (95% CI) p-value HR (95% CI)a p-value 
TBC: 
pushing/mixed vs. 
infiltrative 
 
110/286 
113/192 
 
1 
1.79 (1.37-2.32) 
 
 
<0.001 
 
1 
1.62 (1.21-2.16) 
 
 
0.001 
Tumor budding: 
Low vs.  
High 
 
150/346 
73/132 
 
1 
1.41 (1.07-1.87) 
 
 
0.016 
 
1 
1.20 (0.88-1.62) 
 
 
0.247 
CD3 score: 
Low (3-4) 
Intermediate (5-6) 
High (7-12) 
 
59/113 
116/237 
48/128 
 
1 
0.93 (0.68-1.27) 
0.66 (0.45-0.97) 
 
 
 
0.076 
 
1 
1.03 (0.73-1.45) 
0.69 (0.45-1.05) 
 
 
 
0.110 
CD8 score: 
Low (3-4) 
Intermediate (5-6) 
High (7-12) 
 
80/148 
106/222 
37/108 
 
1 
0.81 (0.61-1.08) 
0.56 (0.38-0.82) 
 
 
 
0.013 
 
1 
0.87 (0.64-1.20) 
0.55 (0.36-0.85) 
 
 
 
0.026 
 
ap values from multivariate analysis adjusted for age, sex, tumor grade (G1, G2, G3), Stage (II, III), 
MMR-status (proficient vs. deficient) and T-stage (0-2 vs 3-4). Cases with unknown information on 
differentiation grade and MMR-status were not included in the multivariate model. 
Abbreviations: OS, overall survival; TBC, tumor border configuration; MMR, mismatch. 
 
In the dMMR category, OS analysis with regard to tumor budding, tumor border 
configuration and CD8+ score was not prognostic. In univariate analysis a high CD3+ 
score was associated with a better OS (p=0.027) but not in multivariate analysis. 
In the pMMR category, patients with low-grade tumor budding had a better OS in 
univariate (p=0.021) but not in multivariate analysis while patients with a pushing/mixed 
tumor border configuration had an improved OS in univariate (p<0.001) as well as 
multivariate analysis (p<0.0001). Analysis of CD3+ and CD8+ was not prognostic in this 
category and showed only a tendency to better OS in univariate analysis for patients with 
high CD8+ score tumors (p=0.051). 
The median OS between low versus high CD8+ scores for the patients with dMMR tumors 
was 95 months versus 92 months and for patients with pMMR tumors it was 68,5 months 
versus 83,5 months. 
No significant difference in OS was found between the treatment arms when analyzing 
tumor budding grade, tumor border configuration as well as CD3+ and CD8+ scores. Only 
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a tendency to improved OS was noted for patients in the adjuvant chemotherapy arm and 
high CD8+ score tumors (p=0.075). 
 
Discussion 
The focus of this study was to analyze in stage II-III primary colon cancer whether tumor 
budding, tumor border configuration and T-lymphocyte infiltration with CD3+ and CD8+ 
cells are prognostic factors. 
A main finding in the entire study group of 478 patients and in the stage II group (n=225) 
of patients, was that tumor border configuration as well as the T-lymphocyte CD8+ score 
were independent prognostic factors. High grade tumor budding compared to low grade 
tumor budding was found to be associated with a more advanced stage, a higher N-stage, a 
pMMR-status, an infiltrating tumor border configuration and a lower level of CD3+ and 
CD8+ T-lymphocyte infiltration. Tumor budding was found to be prognostic in univariate 
analysis but not in multivariate analysis. 
As in our study, other studies in stage II-III colon cancer have also found an infiltrative 
tumor border configuration to be prognostic of worse outcome compared to a pushing or 
mixed tumor border configuration [369, 375]. Our study also further confirmed other studies 
findings of a correlation between an infiltrative tumor border configuration and high degree 
tumor budding in colon cancer [309, 358, 447]. 
The use of cytokeratin-staining to better define tumor buds and the cut-off of 10 to define 
low versus high-grade tumor budding was also used in other recent studies [358, 452, 453]. One 
of these studies by Mehta et al 2018 in colon cancer, stage I-IV and using 1-HPF method, 
found as in our study a similar amount of high grade tumor budding in stage II-III (30% 
compared to our 28%) and no significant correlation of tumor budding to OS [452]. The two 
other studies applied the 10-HPF method by Karamitopoulou [340] as we did with the cut-off 
of 10 [358, 453]. In the Koelzer et al study [358], the amount of high grade tumor budding in the 
combined stage II-III CRC prospective cohort (n=215) was similar to our study’s (30.9% 
and 28%, respectively). However, in their retrospective stage II CRC cohort (n=150), they 
had a higher amount of high-grade tumor budding (30.7%) than in our study (18%). This 
could have contributed to their finding of a significant correlation between high grade 
tumor budding and DFS. The Eriksen et al study [453] on stage II colon cancer (n=573), 
found a mean tumor budding of 4.5±3.7 (range 0-25) which is lower compared to ours of 
7.6 and other studies [358]. This could have attributed to the study’s low amount of high-
grade tumor budding (7%) as well as their finding tumor budding to be a non-significant 
prognostic factor. They found as in our study a significant correlation of high-grade tumor 
budding and pMMR-status. 
The better prognosis associated with a dMMR-status or MSI-H status in primary CRC has 
been established by several randomized trials and a meta-analysis [121]. This positive effect 
has been attributed to the association of a dMMR-status with a higher level of T-cell 
infiltration compared to pMMR tumors [72, 243]. The mechanism behind it is believed to be 
the higher mutational load found in dMMR tumors resulting in a neo-antigen increase thus 
triggering the immune response. 
However, studies have also shown that regardless of MMR-status, the peritumoral immune 
infiltrate including T-cell infiltration is prognostic in CRC [418, 454, 455].  
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Assessment of inflammatory infiltration has been done with different methods in studies. 
The Klintrup-Mäkinen method grades the inflammatory reaction in a semi-quantitative 
manner in H&E slides using a 4-point scale ranging from low grade to high grade [415, 416]. 
The validated immunoscore method utilizes as in our study method, staining of CD3+ and 
CD8+ T-cells and semi-quantitatively grades regions within the invasive margin and tumor 
center by using, unlike our study, digital pathology. In the IS method scoring groups range 
from 0 to 4, from lowest density to highest density, where the calculated score for each case 
is placed in the appropriate scoring group [456]. 
This study’s T-cell CD3+ and CD8+ infiltration was assessed according to the method used 
by Dahlin and Ogino [417, 418]. 
A study by Berntsson et al used the same method as ours to analyze T-cell CD3+ and 
CD8+ infiltration in stage I-IV CRC but in TMA rather than whole tissue [457]. Stratifying 
by tumor location, they found high CD8+ density was an independent favorable prognostic 
factor for patients with right-sided colon tumors and high CD3+ cell density for the right 
colon and the rectum. Unlike our study they found a significant prognostic interaction 
between CD8+ and right-sidedness (p=0.031).  
One study by Lugli et al, used as in our study immunostaining to analyze tumor budding 
and the peritumoral immune infiltration of CD8+ T-cells (ref 26) in CRC (stage II-III, 
n=273) [458]. Differing from our study, counting of tumor buds as well as CD8+ cells was 
done in one-HPF with a cut-off, derived by ROC curve analysis, of 16 for tumor budding 
grade and of 40 for high density CD8+. They found a higher amount of high-grade tumor 
budding (stage II-III 33%; stage II 24%; stage III 42%) than our study did (stage II-III 
28%; stage II 18%; stage III 36%). Similar to our study, tumor budding was prognostic in 
univariate analysis but not in multivariate analysis. However, they found that a 
CD8+/tumor buds index was an independent prognostic factor in which a low index was 
associated with worse survival.  
Another study that also studied tumor budding using the method of Lugli et al [458], MMR-
status and the immune infiltration of CD8+ T-cells as well as FOXP3+ (T regs) and CD68+ 
T-cells was done by Zlobec et al 2011 in stage II-III CRC (n=297) [459]. Controlling for 
prognostic factors that included MMR-status, multivariate analyses showed an independent 
correlation of higher numbers of tumor buds with worse outcome and of higher numbers of 
CD8+, FOXP3+ and CD68+ cells to an improved outcome. 
10.5 Limitations (PAPER I-IV) 
With the use of IHC there are pitfalls such as poor internal control, heterogeneous staining 
patterns, overstaining which limits evaluation or results in false positive interpretation and 
weak staining leading to false-negative interpretation. Necrotic tumor areas are problematic 
because they can show false-negative as well as non-specific positive staining. There is 
always a risk of misclassification when dealing with semi-quantitative methods. Our 
application of a standardized defined manner and area of measuring and independent 
observers blinded to clinical data was done to help minimize this. 
Our tumor material derived from the 2224 patients, included 1991-1997 with primary CRC 
included in the adjuvant Nordic trials randomized to surgery alone versus surgery followed 
by 5-FU-based adjuvant chemotherapy [426]. It is important to note that this Nordic trial 
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found no significant survival advantage in the entire study population. A non-significant 
difference of 7% was found in favor of adjuvant chemotherapy for colon cancer stage III. 
This has to be taken into account in analysis of our data, as well as the limitation of few 
lymph nodes (<12) analyzed in the Nordic trials for the majority of the cases with thus a 
risk of understaging. 
Retrospective studies can have an unseen selection bias. 
Tumor material could during prolonged time have a potential loss of antigenicity due to 
oxidation of cut sections.  
Interpreting the results of studies examining the prognostic or the predictive value of TS 
expression in CRC is complicated since there may be publication bias, underpowered 
studies, heterogeneity with methodology including use of different types of antibodies in 
IHC and TS scoring between the studies. Even factors, such as surgically induced 
ischaemia during resection of tumors can possibly have altered TS expression and impact 
the result of TS testing [460]. In our study, a limitation in the TS expression analyses could 
be the time span between the previously analyzed tumor material from 862 patients and the 
analyses done later on with 527 additional patients.  
Tumor budding has not always been found to be an independent prognostic factor in CRC 
studies, most likely due to the studies having varied cohorts, different methods and cut-offs 
to define high-grade budding. In our two tumor budding studies, the 10-HPF method 
adapted from Karamitopoulou et al [340] used in Paper IV combined with the use of digital 
pathology was a more reliable method than the one used in Paper III. 
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11 CONCLUSION 
There is a remaining need for a better risk stratification for Stage II and even Stage III CRC 
patients to improve adjuvant treatment selection. Our studies were done to explore whether 
TS expression, MMR expression, tumor budding, tumor border configuration and T-cell 
infiltration (CD3+, CD8+) could contribute to a better risk stratification for these patients. 
The following conclusions could be made from the studies: 
 
Paper I: 
We demonstrated that TS expression, assessed by IHC, is an independent prognostic factor 
in the group of patients with primary CRC treated with surgery alone as well as showing a 
benefit of adjuvant 5-FU-based chemotherapy in patients with high TS expression. 
 
 
Paper II: 
Considering the heterogeneity of the disease with different subsets within stage III (IIIA, 
IIIB, IIIC) the question arises whether all patients in stage III benefit from 5-FU-based 
adjuvant chemotherapy. In our study we found that a combined analysis of MMR status 
and TS expression can aid in the prediction of response to 5-FU-based-chemotherapy in 
stage III colon cancer.  
 
 
Paper III:  
In our study we found a significantly higher grade of tumor budding in dMMR/met+ CRC. 
Tumor budding can be of prognostic importance in dMMR CRC. 
 
 
Paper IV:  
In our study on primary colon cancer, stage II-III, we found an independent prognostic 
impact of CD8+ lymphocyte infiltration and tumor border configuration and an association 
between them and tumor budding. Our study supports the inclusion of tumor border 
configuration, tumor budding, CD8+ T cell infiltration in the risk assessment for stage II-III 
colon cancer patients. 
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12 FUTURE PERSPECTIVES 
Further research into prognostic and predictive factors is required to help identify patients 
with stage II-III CRC at risk for disease recurrence and to select the most suitable treatment 
for the individual patient. 
To unequivocally establish TS expression in CRC as a prognostic factor, prospective 
studies are needed with homogenous CRC groups analyzed as well as standardized 
unbiased methods and assessment in which investigators are blinded to clinical data. 
Studies on the predictive effect of TS expression on adjuvant 5-FU-based chemotherapy 
should also take into account other enzymes involved in 5-FU metabolism (e.g. DPD, TP). 
A combined marker analysis of MMR status and TS expression can contribute to 
tumor-node-metastasis staging, especially for stage II-III, when making treatment decision 
for these patients. 
Further, primary CRC studies should be done using tumors from a larger patient group, 
to assess tumor budding with an established method and cut-off so as further establish 
whether tumor budding is a negative prognostic factor in CRC, including stage II dMMR 
CRC. 
Varied study cohorts, different tumor budding methods and cut-offs for high grade 
budding has contributed to the inconsistency of tumor budding not always remaining an 
independent prognostic factor in CRC studies. The recently proposed tumor budding 
assessment advocated by ITBCC using H&E slides and the 3-tier scheme can be the 
established method used in future studies and should also ease incorporating 
assessment of tumor budding as a routine in clinical practice. A future goal is to 
establish tumor budding as a prognostic tool for stage I-II-III CRC.  
Tumor budding has also been correlated to KRAS and BRAF mutations and 
independently predicted poor outcome in all CRC stages [461].  
There is an increased awareness of the impact tumor microenvironment in CRC, 
including tumor stroma and tumor-infiltrating lymphocytes (TILS) has on prognosis and 
the response to oncological treatment. Our study, Paper IV, contributes to the evidence in 
primary colon cancer, that the adaptive T-lymphocyte infiltration, especially the cytotoxic 
CD8+ T-lymphocytes, is an independent prognostic factor. Hopefully, prospective studies 
can further determine whether patients with high-risk stage II and stage III colon cancers 
with a high CD8+ score benefit more from adjuvant chemotherapy than patients with a low 
CD8+ score.  
Clinicians have used TNM-staging including stage, risk factors such as vessel 
involvement, perineural involvement, grade of differentiation and MMR-status to 
determine which patients could benefit from adjuvant chemotherapy. There are only three 
biomarkers, MMR-status, RAS-status and BRAF-status that are available for clinical 
routine use to aid in determining the prognosis of a patient and predicting treatment 
therapy.  
There is a high level of heterogeneity, both genomic and transcriptomic, in CRC which 
poses a challenge in finding additional reliable biomarkers. The Consensus Molecular 
Subtypes (CMS) was developed for CRC in an effort to aid in prognostication, to identify 
the patients who would benefit of adjuvant chemotherapy as well as to individualize the 
oncological treatment in all stages [462]. Based on gene expression data, 4 different groups 
are distinguished: CMS1 (MSI immune), CMS2 (Canonical), CMS3 (Metabolic), CMS4 
(Mesenchymal). Tumors in the CMS1 subtype are more often observed in the female 
gender, have a high histological grade and are associated with dMMR-status or MSI-H, 
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BRAF mutation, right-sided colon location and an anti-tumor immune environment. The 
CMS2 subtype is the most heterogeneous one of the four subtypes and the CMS3 subtype 
is associated with KRAS mutations. More advanced stages are observed in the CMS4 
subtype which is characterized as pro-inflammatory and by mesenchymal and stromal gene 
signatures rather than signatures from the cancer cell itself. An increased number of tumor 
buds was observed in CRC classified in the CMS4 subtype versus tumors classified in 
CMS2 and CMS3 subtype [461]. See Table 15 for summary of CMS subtypes. 
 
Table 15. Consensus molecular subtypes of colorectal cancer. (Reprinted, with permission, from 
Guinney et al, Nat Med 2015). 
 
CIMP, CpG island methylator phenotype; MSI, microsatellite instability; SCNA, somatic copy number alterations. 
 
Analyses of the original dataset used to create CMS shows that distributions differ in early 
compared to metastatic disease at diagnosis (early stage: CMS1 16%, CMS2 43%, CMS3 
15%, CMS4 26% versus stage IV: CMS1 8%, CMS2 43%, CMS3 9%, CMS4 40%) [463]. 
There were about 13% of the tumors in the original dataset that did not classify into a 
specific subtype probably due to intra-tumoral heterogeneity. 
The CMS subtype classification in CRC can be useful in the design of new clinical 
trials to identify reliable biomarkers where patients should be stratified in the correct 
clinical context (early stage versus stage IV).  
The future of biomarkers in the CRC adjuvant setting, especially relevant for stage II, 
may be a combination of markers (TS, MMR, tumor budding, CD8+ T cell infiltration) that 
contribute to a prognostic/predictive score which will aid the oncologist in designing the 
patient’s individual treatment plan. 
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